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TNF-α - tumour necrosis factor-alpha 
tPA -  tissue plasmogen activator 
Tregs - regulatory T cells 
tRNA - transfer ribonucleic acid 
TxA2 - thromboxane A2 () 
UKPDS - UK Prospective Diabetes Study 
VCAM-1 - vascular cell adhesion molecule 1 
VEA - vitamin E analogue 
VEGF- vascular endothelial growth factor 
VLDL - very low-density lipoprotein 
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ABSTRACT 
Atherosclerosis is the major cause of morbidity and mortality in the western world. It is 
also responsible, directly or indirectly, for the highest percentage of health costs in most 
European countries. Despite the use of new technologies for the diagnosis of vascular 
disease and regardless of the major advances in treatment, the atherosclerosis-related 
clinical burden is still raising. 
The “lipid theory” of atherogenesis, which identifies dyslipidemia as the primary cause 
of this vascular disease has some important practical implications: it allows the definition of 
simple guidelines and establishes therapeutic targets which can be generally met with 
current pharmacologic intervention. 
The association between atherosclerosis an the immune system (the immune concept) 
has in turn provided new ways of exploring the mechanisms involved in this condition and 
has opened new perspectives in the understanding of the disease. However, it raises obvious 
difficulties when it comes to treatment options. 
Of all the players (biochemical, immunological and anatomical) involved in this matter, 
high-density lipoproteins (HDL) are currently recognised as one of the most important 
factors in atherogenesis. This is based on the recognition of HDL's multiple anti-atherogenic 
properties: anti-oxidant, anti-inflammatory and antithrombotic, as well as its capacity to 
improve endothelial function. Nowadays, it is widely recognized that the anti-atherogenic 
functions of HDL go beyond reverse cholesterol transport (RCT), and the importance of HDL 
is based not just on its ability to reduce atheroma formation but also on its ability to stabilise 
plaques, therefore preventing their rupture and ultimately thrombosis. 
Two main set of events have been recognised as fundamental in atherogenesis: one, 
characterized by lipoprotein metabolism alterations, resulting in pro-inflammatory and pro-
oxidative lipoproteins, which interact with the normal cellular elements of the arterial wall 
leading to atheroma formation; the other, the immune cellular response towards new sets 
of antigens which lead to the production of pro-inflammatory cytokines. 
Given to HDL complexity and multiple functions this lipoprotein has became a potential 
target for an auto-immune response, the consequences of which may explain some of the 
association identified in epidemiological and clinical studies, though the interaction between 
the immune system and HDL has never been thoroughly addressed. 
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Therefore, we hypothesized that under oxidative and pro-inflammatory conditions, the 
increase in the antigen (HDL) would lead to a consequent increase in the production of 
anti-HDL (aHDL) antibodies be responsible for quantitative and/or qualitative changes of 
HDL. The concept that these antibodies may contribute either to the long-term evolution of 
atherosclerosis or to the triggering of clinical events may also explain the heterogeneity 
found in individual patients and in large cohorts regarding risk factors and clinical outcomes. 
Moreover this may be a major breakthrough in understanding why therapeutic interventions 
that increase HDL levels, failed to show the anticipated reduction in vascular risk. 
The overall aims of this thesis were to identified and characterize the humoral response 
towards HDL components and to evaluate the possible mechanisms that may contribute to 
the modifications of the anti-atherogenic properties of HDL. 
To achieve this objective we investigated: 1) the presence of aHDL antibodies in patients 
with systemic lupus erythematosus (SLE) and in patients with atherosclerosis-related clinical 
events, such as coronary artery disease (CAD), ischemic stroke (IS) and type 2 diabetes; 2) 
the association between the titres of aHDL antibodies and different clinical features of these 
diseases; 3) the modifications of the anti-atherogenic properties of HDL; 4) the biologic 
effect of aHDL antibodies isolated from serum of patients on the anti-oxidant and 
anti-inflammatory properties of HDL; 5) the effect of different pharmacologic treatments for 
dyslipidemia on the prevalence and activity of aHDL antibodies. 
The methodologies used in this work included immunologic-related techniques (e.g. 
enzyme-linked immunoabsorbent assay – ELISA, immunoturbidimetric immunoassay and 
immunoaffinity chromatography), biochemical techniques (enzymatic assays with 
quantification by spectrophotometry and luminescence methods), cell culture experiments 
and flow cytometry. 
Our results indicate that: 1) The titres of IgG aHDL, anti-apolipoprotein A-I (aApoA-I) and 
anti-paraoxonase 1 (aPON1) antibodies were higher in patients with SLE, CAD, IS and type 2 
diabetes when compared with age and sex matched healthy controls. 2) The antibodies 
found in these patients were associated with decreased PON1 activity, (the enzyme 
responsible for most of the anti-oxidant effect of HDL), reduced total anti-oxidant capacity 
(TAC) of serum and increased biomarkers of endothelial dysfunction (nitric oxide 
metabolites, adhesion molecules, nitrotyrosine). In patients with SLE the antibody titres 
were associated with an increase in disease-related cardiovascular damage and activity 
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whereas in patients with type 2 diabetes they were directly related with the fasting glucose 
plasma (FGP) levels and the glycosylated haemoglobin (HbA1c). 3) The antibodies isolated 
from serum of our patients, directly inhibited HDL-associated PON1 activity in a dose 
dependent way ranging from 7 to 52%. 4) The anti-inflammatory effect of HDL, measured by 
the percentage of inhibition of the cytokine-induced production of vascular adhesion 
molecules (VCAM-1), was reduced in more than 80% by aHDL antibodies isolated from our 
patients. 5) The HDL-induced angiogenesis by increasing vascular endothelial growth factor 
(VEGF) levels was abrogated in 65% by the antibodies isolated from serum of patients. 6) The 
current available pharmacologic agents for increasing HDL-C concentrations were associated 
with an increase in the titres of IgG aApoA-I antibodies. This increase was higher in the 
extended release niacin when compared to statins probably due to their dampening effect 
on oxidative stress. 
In conclusion, aHDL antibodies are present in different pathologic conditions. aHDL 
antibodies represent a family of self-reacting immunoglobulins, of which ApoA-I and PON1 
might be the most relevant targets. These antibodies are biologically active, interfering with 
the HDL anti-oxidant and anti-inflammatory properties and, consequently, with the 
atherosclerotic process. The pathogenic potential of these antibodies may lead to the 
identification of a new biomarker for vascular disease, whilst presenting itself as a novel 
target for a different treatment approach which may redefine the treatment strategies and 
clinical trials design for HDL interventions in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
 
xxiii 
 
RESUMO  
Aterosclerose é uma das principais causas de morbilidade e mortalidade no mundo 
ocidental. É responsável, direta ou indiretamente, pela maior percentagem de gastos com a 
saúde na maioria dos países europeus. 
A “teoria lipídica” da aterosclerose, que se baseia na dislipidemia como causa primária 
para a doença vascular tem algumas implicações práticas importantes: permite a definição 
de linhas de orientação e protocolos simples e ainda estabelece alvos terapêuticos que 
podem ser atingidos na maior parte dos casos com a atual intervenção farmacológica. 
A associação da aterosclerose com o sistema imunológico (a “teoria imunológica”), 
forneceu por sua vez novas formas de explorar os mecanismos envolvidos e abriu novas 
perspetivas para um conhecimento mais completo da doença. No entanto, levanta 
dificuldades evidentes no que diz respeito às possibilidades terapêuticas. 
De todos os intervenientes no processo aterosclerótico (bioquímicos, imunológicos e 
anatómicos), as lipoproteínas de elevada densidade (HDL) são atualmente reconhecidas 
como um dos fatores mais importantes na aterogénese. Isto é baseado no reconhecimento 
das múltiplas propriedades anti-aterogénicas das HDL como por exemplo: a anti-oxidante, a 
anti-inflamatória e a antitrombótica, bem como o seu importante papel na melhoraria da 
função endotelial. Atualmente, é consensual que as funções anti-aterogénicas das HDL vão 
além do seu papel no transporte reverso do colesterol (RCT) e a importância das HDL no 
processo aterosclerótico baseia-se não apenas no seu papel protetor impedindo a formação 
da placa de ateroma, mas também na estabilização destas, prevenindo a sua ruptura e, 
consequentemente o evento trombótico. 
Como fundamentais no processo aterosclerótico estão reconhecidos dois principais 
conjuntos de eventos: um caracterizado por alterações no metabolismo das lipoproteínas 
que resultam em lipoproteínas pró-inflamatórias e pró-oxidantes que interagem com os 
componentes celulares da parede arterial e que conduzem à formação da placa de ateroma; 
o outro evento é a resposta imunológica desencadeada contra um novo conjunto de 
antigénios que por sua vez leva à produção de citoquinas pró-inflamatórias. 
Dada a complexidade da HDL e das suas múltiplas funções estas lipoproteínas tornaram-
se um potencial alvo para a resposta auto-imune, e cujas consequências podem explicar 
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algumas das associações identificados em estudos clínicos e epidemiológicos. Contudo esta 
interação entre o sistema imunológico e HDL nunca foi exaustivamente estudada. 
Portanto, pomos a hipótese de que em condições oxidativas e pró-inflamatórias, um 
aumento do antigénio (HDL) conduz a um consequente acréscimo na produção de 
anticorpos anti-HDL (aHDL) responsáveis pela alteração quantitativa e / ou qualitativa das 
HDL. O conceito de que estes anticorpos podem contribuir tanto para a evolução a longo 
prazo do processo aterosclerótico, como para o desencadeamento de eventos clínicos pode 
também explicar a heterogeneidade encontrada em cada doente e nos grandes estudos 
clínicos, no que diz respeito aos fatores de risco e outcomes clínicos. Para além disso, a 
confirmação desta hipótese pode permitir explicar porque é que as intervenções 
terapêuticas atualmente em desenvolvimento para aumentar os níveis de HDL, não 
conseguem mostrar a tão esperada redução do risco vascular. 
O objetivo geral desta tese foi identificar e caracterizar a resposta humoral contra os 
componentes da HDL, e avaliar possíveis mecanismos que possam contribuir para a 
modificação das propriedades anti-aterogénicas das HDL. 
Para alcançar este objetivo investigou-se: 1) A presença de anticorpos aHDL em doentes 
com lúpus eritematoso sistémico (SLE) e em doentes com manifestações clínicas de 
aterosclerose, como os doentes com doença arterial coronária (CAD), acidente vascular 
cerebral isquémico (IS) e diabetes tipo 2; 2) Os principais alvos antigénicos dentro do 
complexo das HDL e a associação entre os títulos de anticorpos aHDL e diferentes 
características clínicas destas doenças; 3) As modificações das funções normais associadas às 
HDL, em particular da função anti-oxidante e anti-inflamatória; 4) A atividade biológica dos 
anticorpos aHDL isolados do soro de doentes através de um conjunto de experiências in vitro 
de inibição da atividade da paraoxonase 1 (PON1) e da expressão de moléculas de adesão 
em culturas de células endoteliais. Para tal foi necessário estabelecer um método de 
isolamento dos anticorpos. Os anticorpos aHDL isolados do soro de doentes foram utilizados 
de forma a identificar as potenciais alterações dos sistemas celulares utilizados; 5) O efeito 
de fármacos usados no tratamento das dislipidemias, em particular o ácido nicotínico e as 
estatinas, na variação dos títulos de anticorpos aHDL através de ensaios clínicos 
randomizados, controlados com placebo e em dupla ocultação. 
Os métodos utilizados neste trabalho incluíram: técnicas imunológicas (como por 
exemplo, enzyme-linked immunoabsorbent assay - ELISA, ensaio imunoturbidimetrico e 
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cromatografia de imuno-afinidade) técnicas bioquímicas (tais como a quantificação de 
atividade enzimática por espectrofotometria e por luminescência), experiências com cultura 
de células e citometria de fluxo. 
Os nossos resultados mostram que: 1) A presença de anticorpos aHDL, e mais 
especificamente anticorpos contra alguns do seus principais componentes como a 
apolipoproteína A-I (ApoA-I, principal apolipoproteína presente nas HDL) e a PON1 (o enzima 
que mais contribui para a propriedade anti-oxidante das HDL), quer em doentes com 
doenças auto-imunes, como o SLE, quer em doentes com manifestações clínicas de 
aterosclerose, como CAD, IS e diabetes tipo 2. Os doentes apresentaram títulos de 
anticorpos IgG aHDL, aApoA-I e aPON1 significativamente mais elevados do que controlos 
saudáveis com a mesma idade e sexo. 2) A correlação positiva estatisticamente significativa 
entre os títulos de aHDL e aApoA-I e aPON1 sugere que estes sejam dois dos principais alvos 
antigénicos dentro do complexo das HDL. Os anticorpos encontrados nestes doentes estão 
associados com a diminuição da atividade da PON1 e a uma redução da capacidade 
anti-oxidante total (TAC) do soro, um aumento dos biomarcadores de disfunção endotelial 
(como por exemplo dos metabolitos do óxido nítrico - NO2
- e NO3
-, as moléculas de adesão 
vascular e intracelular - VCAM-1 e ICAM-1 e os níveis de 3-nitrotirosina). Nos doentes com 
SLE os títulos destes estão associados a um aumento do dano cardiovascular e à atividade 
global da doença avaliados pelas escalas SLICC/ACR DI e BILAG score, respetivamente. 
Enquanto que nos doentes com diabetes tipo 2 estes anticorpos estão associados com um 
aumento dos níveis de glicemia em jejum (FGP) e hemoglobina glicada (HbA1c). 3) Após se 
ter estabelecido um método de isolamento dos anticorpos que permite isolar quantidades 
significativas de anticorpos do soro de doentes sem perder a sua especificidade, foi 
identificada a capacidade dos anticorpos isolados do soro de doentes inibirem de uma forma 
dependente da concentração a atividade da PON1 até um máximo de 70% no caso dos 
doentes com SLE e ente 7-52% no caso dos anticorpos isolados de doentes com CAD e IS. 4) 
O efeito anti-inflamatório das HDL na inibição da produção de VCAM-1 induzida por 
citoquinas (como o TNF-) foi revertido em mais de 80% pelos anticorpos aHDL isolados do 
soro de doentes. 5) A angiogenesis induzida por HDL através do aumento do fator de 
crescimento do endotélio vascular (VEGF) foi anulada em 65% pelos anticorpos aHDL 
isolados do soro de doentes. 6) Os atuais agentes farmacológicos disponíveis para aumentar 
as concentrações de HDL-C estão associados a um aumento dos títulos de anticorpos 
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aApoA-I, sugerindo que o aumento da quantidade de HDL-C não se traduz necessariamente 
num aumento das funções de HDL. Este aumento foi maior no estudo clínico com niacina de 
liberação prolongada em comparação com os estudos com as estatinas, provavelmente 
devido ao seu efeito negativo sobre o stress oxidativo. 
Em conclusão os anticorpos contra diversas estruturas do complexo das HDL estão 
presentes em diferentes condições patológicas. Os anticorpos aHDL representam uma 
família de imunoglobulinas, das quais a ApoA-I e a PON1 parecem ser os alvos mais 
relevantes. Estes anticorpos são biologicamente ativos, interferindo com as propriedades 
anti-oxidante e anti-inflamatórias das HDL e, consequentemente, com o processo 
aterosclerótico. A identificação do elevado potencial patogénico destes anticorpos poderá 
permitir a identificação de um novo biomarcador de risco de doença vascular, abrindo 
simultaneamente as portas para novas opções terapêuticas. 
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1.1 Atherosclerosis: a global overview 
Atherosclerosis derives from the Greek words athero (meaning gruel or paste) and 
sclerosis (hardness). It is a general term describing any hardening of medium or large 
arteries with consequent loss of elasticity. 
Atherosclerosis is considered to be the most common cause of cardiovascular morbidity 
and mortality in western societies1,2 and by 2020 atherosclerosis is expected to be the 
leading cause of death worldwide.3 Atherosclerosis begin in the teenage years and 
progresses silently until the age 40 when it may manifest as myocardial infarction (MI) or 
stroke. It was initially perceived as a degenerative disease, an inevitable consequence of 
ageing secondary to the accumulation of lipids in the arterial wall resulting in narrowing of 
the lumen. 
In 1913, Anitschkow and Chalatow showed that feeding cholesterol to rabbits rapidly 
produces an atheromatous disease similar to that found in man,4 giving rise to the “lipid 
theory” of atherosclerosis. 
In 1950 Gofman et al5,6 showed that specific fractions of cholesterol such as low-density 
lipoprotein (LDL) were responsible for the rapid progression of atherosclerosis in human. 
In the early 80s Brown and Goldstein7 showed that circulating LDL underwent some 
structural modification before it became fully pro-atherogenic. In the last three decades of 
the 20th century Ross and Glomset8 proposed the “response to injury hypothesis”, and 
described atherosclerosis as consequence of mechanical, toxins, and free radicals injury to 
the endothelial lining of the arterial wall.9 
The endothelium is an important organ that modulates vasomotor tone, inflammation, 
thrombosis.10-13 Under normal conditions, the endothelial lining has an anti-adhesive and 
antithrombotic phenotype14 but high-levels of native or modified LDL, free radicals, 
microorganisms, shear stress, hypertension and insulin resistance may shift the endothelium 
to a pro-adhesive and pro-thrombotic phenotype. 
The susceptibility to atherosclerosis depends on potentially controllable factors such as 
hypercholesterolemia, diet, impaired glucose metabolism, hypertension, smoking, lack of 
exercise hyperhomocysteinemia, infections and non-modifiable risk factors such as genetic 
factors, age and gender. 
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1.1.1 Hypercholesterolemia 
The concentration of serum cholesterol is determined by genetic and environmental 
factors such as the type and amount of fat in the diet, obesity and physical activity. Based on 
animal studies, epidemiologic data and interventional studies there is a strong evidence for 
an association between hypercholesterolemia and the increased risk of cardiovascular 
diseases (CVD). Familial hypercholesterolemia (FH) is an autosomal dominant disorder 
characterized by elevated plasma of LDL cholesterol (LDL-C) levels. Mutations in the gene 
encoding for LDL receptor, results in a defective LDL clearance and consequent increase risk 
for premature CVD.15 
Several large randomized interventional trials with lipid lowering drugs have 
demonstrated that the decrease of serum total cholesterol particularly of LDL-C levels led to 
slowing or even reversing of the progression of clinical manifestations of atherosclerosis16-18 
Conversely, serum levels of high density lipoprotein cholesterol (HDL-C) are associated with 
a reduction in the risk of atherosclerosis,19 indeed therapies that raise HDL-C reduce the 
morbidity and mortality associated with coronary heart disease (CHD).20,21 
1.1.2 Diet 
The industrial and technological revolutions of the last 200 years has lead to mass 
production of food, switch food-processing techniques that have created the so-called 
Western diet, characterized by high intake of red meat, fat, cereals and refined sugars.22 
Moreover the caloric intake has increased considerably, in face of clinical experimental 
evidences suggesting that caloric restriction may decrease the risk of atherosclerosis.23 
1.1.3 Impaired glucose metabolism 
Although hyperglycaemia is an established CVD risk factor independent of 
hypercholesterolemia, clinical trials, such as the UK Prospective Diabetes Study (UKPDS), 
have not been able to demonstrate definitively that an intensive glucose lowering policy 
reduces CHD events.24-26 Thus, a focus on reducing glycaemia alone does not appear 
sufficient to reduce the excess risk in diabetes, highlighting the need for a comprehensive 
treatment of other risk factors. 
Although type 2 diabetes is primarily a metabolic disorder, it is also a vascular disease27 
and the most important cause of death among these patients is CVD.28-30 The risk of 
cardiovascular events including fatal CHD in diabetic patients is higher than in non-diabetics 
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regardless of the previous vascular history. Furthermore, the risk of cardiovascular events in 
diabetic patients with no previous history of vascular morbidity is similar to that of non-
diabetic patients who have such a history.31-33 
In patients with type 2 diabetes, the risk of developing atherosclerosis at an earlier age 
is three- to five folds greater than in non-diabetics, after controlling for other risk factors.34-36 
Although type 2 diabetes is a state of increased plasma coagulability,37 endothelial 
dysfunction is the most important factor for thrombotic complications. 
1.1.4 Hypertension 
Hypertension, defined as a systolic blood pressure in excess of 140 mmHg or a diastolic 
blood pressure above 90 mmHg has been shown to accelerate atherosclerosis and the risk of 
cardiac and cerebrovascular disease over time.38 The mechanism by which hypertension 
causes atherosclerosis is not completely known, although loss of the nitric oxide (NO•) and 
prostacyclin (PGI2) precede some morphologic alterations of the arterial intima.39,40 
1.1.5 Smoking 
Smoking promotes atherosclerosis by several mechanisms amongst which a higher 
degree of lipid peroxidation41,42 that induces and worsens endothelial damage. Smoking is 
associated with an increased risk of plaque formation and a reduction in plaque stability.42-44 
1.1.6 Lack of exercise 
Physical inactivity is a recognized risk factor for atherosclerosis and there is evidence 
suggesting that regular exercise may decrease blood pressure and cholesterol levels, insulin 
resistance and excessive weight ultimately lowering atherosclerotic risk and its mortality.45 
1.1.7 Hyperhomocysteinemia 
Homocysteine (Hcy) is an amino acid (aa) with a sulphydryl group, formed by 
demethylation of methionine: deficiencies or impaired activity of the enzymes that 
metabolize Hcy as a result of genetic mutations and/or acquired deficiencies of folate, 
vitamin B12 and B6 causes hyperhomocysteinemia.46 This blood levels is associated with lipid 
peroxidation and a pro-inflammatory state leading to endothelial damage that contributes 
to the development ofatherosclerosis.47 
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1.1.8 Infections 
Over the past years several viral and bacterial infections have been  associated with the 
development of atherosclerosis and the clinical complications of unstable angina, myocardial 
infarction, and stroke.48,49  
Some of these mechanisms by which viruses or bacteria increase the risk of 
atherosclerosis include direct infection of the cells of the arterial that in turn triggers  an 
immune response which could initiate an autoimmune process against endothelial cells.48,50  
1.1.9 Genetic factors 
Atherosclerosis is a complex multifactorial disease and it is likely that many genes may 
contribute to both the susceptibility and the pathogenesis of the disease. Advances in 
molecular genetics have revealed that genetic polymorphisms may significantly influence 
susceptibility to atherosclerosis. A large number of candidate genes, genetic polymorphisms 
and susceptibility loci have been identified in recent years and their number is rapidly 
increasing. Two major experimental approaches are being used to identify and understand 
the role of these genes: the first applies genomic and proteomic technology to study the 
expression, functions, and interactions of genes in models of atherosclerosis.51 The second 
approach is to study human populations for genetic variations that correlate with (and may 
determine) differences in rates of atherogenesis.52 Within a population, the heritability of 
atherosclerosis (the fraction of disease explained by genetics) has been high in most studies, 
frequently exceeding 50%.51,53 
Furthermore, genes that predispose to hypertension, type 2 diabetes, endothelial 
dysfunction, cellular proliferation, tissue remodelling and homeostatic defects can all be 
considered relevant genes for atherosclerosis. 
However, there is a lack of consistent results from different studies and population 
groups which creates an ambiguity about the role of genetic variations in the pathogenesis 
of atherosclerosis. Many of the individual genetic variations have only a modest effect on 
the risk of atherosclerotic disorders but their effects are enhanced in synergism with other 
genetic and environmental factors. Moreover, the variations among population groups, such 
as variations in age, sex, ethnicity and sample size as well as differences in clinical end points 
can significantly influence the results of genetic association studies. 
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It has become apparent that the traditional risk factors explain only part of the 
pathogenesis of atherosclerosis. Albeit dyslipidemia is known to be a major cause of 
atherosclerosis that give raise to pro-inflammatory and pro-oxidative lipoproteins it is being 
increasingly recognised that immunologic mechanisms are also present and both innate and 
adaptive immunity are implicated in the pathogenesis of atherosclerosis, 54-56 
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1.2 Lipids and Plasma Lipoproteins in Atherogenesis 
The major plasma lipids are cholesterol, triglycerides (TG) and phospholipids. 
Cholesterol is by far the most abundant sterol in plasma, predominantly synthesized by liver 
and other tissues but also obtained from the diet. Cholesterol is an essential component of 
cell membranes, a precursor of bile acids and of steroid hormones. 
TG are esters formed by a glycerol backbone to which three molecules of fatty acids are 
attached and are stored in adipose cells. 
Phospholipids are comprised of a polar head group attached to two fatty acids. 
Phospholipids are the most important building blocks of cell membranes, made up of 
bilayers of phospholipids with fatty acids oriented toward the interior of the membrane. The 
type of fatty acid attached to membrane phospholipids has a significant effect on membrane 
fluidity. The outer membrane phospholipid is mostly phosphatidylcholine whereas the inner 
one is phosphatidylserine. 
Cholesterol, TG and phospholipids are water insoluble and because of their 
hydrophobicity are carried in plasma or serum on lipoproteins. 
Lipoproteins are composed of lipids and proteins (apolipoproteins) at variable ratios, 
densities and sizes. Their role is to facilitate the transport of water insoluble lipids in the 
blood stream. 
1.2.1 Lipoprotein structure and composition 
In general lipoproteins are composed by a hydrophobic core of neutral lipids, namely 
cholesterol esters (CE) and TG, surrounded by a monolayer amphipathic surface of 
phospholipids with the fatty acids directed toward the core of the particle. Apolipoproteins 
and free cholesterol are embedded within the surface of the phospholipid outer layer. 
The proteins component confers unique functions to each lipoprotein class by directing 
particle assembly, particle interaction with cell surface receptors and may acting as cofactors 
for enzymes involved in the metabolism of lipoproteins.57,58 Apolipoproteins also maintain 
the structure of the lipoproteins by stabilizing their micellar structure.58 
Lipoproteins are highly heterogeneous regarding to size, structure, hydrated densities, 
and immunological properties.59 On the basis of the density at which they float by 
ultracentrifugation, lipoproteins are divided into 5 major classes: the chylomicrons are the 
largest and least dense and in increasing order of density can be found the very low density 
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lipoproteins (VLDL), intermediate density lipoproteins (IDL), LDL and HDL (Table 1 and Figure 
1). 
Table 1. Composition of the major lipoprotein complexes. 
Complex Source 
Density 
(g/mL) 
%Protein %TG %PL %CE %C %FFA 
Chylomicron Intestine <0.95 1-2 85-88 8 3 1 0 
VLDL Liver 0.95-1.006 7-10 50-55 18-20 12-15 8-10 1 
IDL VLDL 1.006-1.019 10-12 25-30 25-27 32-35 8-10 1 
LDL VLDL 1.019-1.063 20-22 10-15 20-28 37-48 8-10 1 
HDL 
Intestine, liver 
(chylomicrons and VLDLs) 
1.063-1.21 33-55 3-15 26-43 15-30 2-10 0 
Abbreviations: TG: triglycerides, PL: Phospholipids, CE: Cholesteryl esters, C: Free cholesterol, FFA: Free 
fatty acids 
Two basic types of lipoproteins have been postulated. These are micellar lipoproteins 
and the pseudomolecular lipoproteins.60 The micellar type contains less than 30 % of 
proteins and includes chylomicrons, VLDL and LDL. These are thought to consist of a 
hydrophobic core of TG and CE surrounded by a hydrophilic coat of protein, phospholipids, 
and free cholesterol. The pseudomolecular type contains more than 30 % of protein and 
includes HDL. 
 
Figure 1. Schematic presentation of the major lipoproteins in normal human plasma. From Olson 1998.
61
 
1.2.2  Lipoprotein metabolism 
Lipoprotein metabolism involves the production, transport and removal of cholesterol 
and TG from the circulation, although the separation of the metabolism of these lipids is 
artificial as both are transported in lipoproteins. Lipid transport describes the “forward” and 
“reverse” transport of cholesterol. Three main pathways are responsible for the generation 
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and transport of lipids within the body. In this case, “forward” transport indicates the arrival 
of cholesterol in the blood from diet (exogenous pathway) and from liver (endogenous 
pathway) and the carriage back to the liver, whereas “reverse” transport (reverse 
cholesterol transport (RCT) pathway) is the movement of cholesterol in the opposite 
direction, the efflux from peripheral tissues back to the liver. They are interdependent 
pathways and disturbances in one will affect the function and products of the other. 
Chylomicrons are the largest lipoproteins and are synthesized, assembled and secreted 
in the intestinal epithelial cells to transport dietary TG and cholesterol from the site of 
absorption to the various cells of the body (Figure 2).62 Therefore, chylomicrons are the 
molecules formed to mobilize dietary lipids (exogenous pathway). The main structural 
apolipoprotein of chylomicrons is ApoB-48 while others may be found in small amounts. 
 
Figure 2. Overview of lipoprotein metabolism: (1) transport of diet lipids (exogenous pathway). Diet lipids 
are secreted from intestinal cells on chylomicrons, a process that requires apolipoprotein B (ApoB). The 
triglyceride (TG) within the chylomicrons is hydrolyzed by lipoprotein lipase (LPL) with apolipoprotein C-II 
(ApoC-II) as cofactor, producing a chylomicron remnant which is taken up by the low-density lipoprotein-like 
receptor protein (LRP) in the liver; (2) endogenous pathway. Very low-density lipoprotein (VLDL) are TG rich 
particles secreted by the liver. After suffers hydrolyses by LPL VLDL are converted in intermediate-density 
lipoprotein (IDL). The liver, via the interaction of ApoE with the LDL receptor, takes up some of the IDL 
particles; others are hydrolyzed by hepatic lipase (HL) to produce CE-rich low-density lipoprotein (LDL). LDL can 
be cleared by the liver via LDL receptor or delivers CE peripheral tissues such as macrophages. From Rader and 
Hobbs, 2008.
63
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The catabolism of chylomicrons occurs at the endothelial surfaces of capillaries in 
adipose tissue and muscle: the TG in the core of the chylomicrons is hydrolyzed into free 
fatty acids and glycerol by the action of lipoprotein lipase (LPL).64 This free fatty acids may be 
then absorbed by the tissues, used as an energy source by various cells or taken up by 
adipocytes and stored as TG. After the action of LPL, chylomicrons shrink in size becoming 
chylomicron remnants with lipid cores, having a relatively high concentration of CE. 
Chylomicron remnants are taken up by liver cells via receptor-mediated endocytosis by 
a process equivalent to the mechanism of uptake of LDL and are further metabolized by 
hepatic lipases (HL) releasing the cholesterol to the endoplasmic reticulum where it becomes 
part of the cellular cholesterol pool.65,66 This cholesterol can be used for bile acid synthesis 
or resterified by acyl coenzyme A : cholesterol transferase (ACAT) and packaged along with 
TG within VLDL particles. 
The endogenous pathway of lipoprotein metabolism refers to hepatic secretion and 
metabolism of VLD, IDL and LDL (Figure 2). 
VLDL are TG rich particles with small amounts of CE, phospholipids, ApoB-100 and 
others apolipoproteins synthesized by the liver.67 ApoB-100 also synthesized by the liver is 
essential for the assembly of VLDL particles and their secretion into the circulation68,69 Like 
chylomicrons, VLDL acquires in the bloodstream ApoCs and ApoE from circulating HDLs. 
Within the plasma compartment, the TG of VLDL are hydrolyzed by LPL to free fatty acids, 
generating a series of smaller, cholesterol-enriched lipoproteins. The free fatty acids may be 
delivered to cardiac or skeletal muscle cells for β-oxidation or to adipose tissue for TG 
resynthesis and storage. The circulating VLDL particles become progressively smaller as their 
core is removed by lipolysis whereas surface materials, including phospholipids, free 
cholesterol, ApoC’s and some ApoE are transferred to HDL. The smaller VLDL remnant are 
released from the endothelial cells surface and become IDL. 
IDL are essentially composed by CE and a small percentage of TG, having ApoB-100 and 
ApoE as their main apolipoproteins. IDL may become further enriched by CE derived from 
HDL by mediation of the cholesterol ester transfer protein (CETP). IDL have two metabolic 
fates following interaction with HL: (1) to be uptake by hepatocytes after binding to the LDL 
receptor in a both ApoB-100 and ApoE mediated process, or (2) are subject to further lipase 
activity continuing to lose TGs and are released into the circulation as LDL.70 In humans this is 
the predominant pathway and ApoE is lost to HDL during both processes. 
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LDL are cholesterol-enriched lipoproteins, essentially CE, phospholipids, small amounts 
of TG, and ApoB-100 (the only protein component of LDL) make up the remainder of the 
particle. In comparison with the originally secreted VLDL, which range from 35 to 80 nm, LDL 
particles are much smaller having an average diameter of 22 nm, which allows them to cross 
the vascular endothelium and enter the tissue fluid delivering the cholesterol to the tissues. 
LDL delivers CE to peripheral (extrahepatic) cells (about 1/3 of LDL that is produced daily) or 
to hepatocytes within the liver (about 2/3 of LDL that is produced daily). 
LDL particles are transferred from circulation to the liver and peripheral tissues via two 
pathways: 1) LDL receptor pathway which is regulated according to the cholesterol 
requirement of each individual cell; 2) non-receptor mediated pathways that depends 
almost entirely on the extracellular concentrations of LDL. 
The LDL receptor is a single-chain transmembrane glycoprotein that is mainly expressed 
by hepatocytes (75 %) but is also present on adrenal and adipose tissue. Although capable of 
binding ApoE-containing lipoproteins, LDL receptor usually binds to the ApoB-100 -
 containing lipoproteins, in particular LDL. After binding the LDL receptor-ligand complex is 
internalised within the cell by endocytosis, where it undergoes lysosomal degradation of LDL 
particles. ApoB is hydrolysed to its constituent aa and the CE is hydrolysed to free 
cholesterol by acid lipase. Free cholesterol is released to the cytoplasm where is re-esterifed 
by ACAT and stored as CE, reused for lipoprotein synthesis or converted into bile acid and 
vitamin D.20 Following that the receptor is recycled back to the cell surface and is again able 
to bind lipoproteins. Expression levels of LDL receptors are regulated by a sensitive feedback 
control through the intracellular cholesterol content of hepatocytes and the need for 
cholesterol. Transcription levels of LDL receptor gene is controlled by promoters with sterol 
regulatory elements, stimulation of this mechanism causes the release of a sterol regulatory 
element binding protein (SREBP) which binds to DNA and switches on the transcription.71 
Excess of cellular cholesterol, for example after high intake of dietary saturated fat and 
cholesterol, down-regulates LDL receptor, which lowers the uptake of LDL and consequently 
results in elevated plasma LDL-C levels and an accumulation of cholesterol in peripheral 
cells. Cholesterol excess also induces suppression of microssomal 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme of 
cholesterol biosynthesis.72 
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Via the non-receptor-mediated pathway, LDL binds to cell membranes at sites other 
than those at which LDL receptors are located and some of it passes through the membrane 
by pinocytosis. HDL is able to compete with LDL for this type of cell-membrane association. 
In addition, LDL may also be removed from the circulation by a number of receptors 
other than the classical LDL receptor, the scavenger receptors (CD36 and SR-A) which are 
responsible for the clearance of only relatively minor amounts of LDL. Since they bind 
modified LDL and are mainly present on the macrophages scavenger receptor have gained 
considerable interest because they may have a central role in atherogenesis. 
Further to the exogenous and endogenous pathways above explained lipid transport 
also has an important third pathway, the RCT. HDL particles have the capacity to mediate 
cellular cholesterol efflux by acting as primary acceptors, thereby facilitating RCT, a process 
in which cholesterol is transferred from peripheral tissues, including from macrophages on 
the arterial wall, to the liver for the excretion into the bile. 73,74 
As HDL particles are the main interest of this dissertation these will be described below 
in more detail, including the RCT pathway since it is considered one of the most important 
mechanisms by which HDL protects against atherosclerosis. 
1.2.3 Lipoproteins and cardiovascular disease (CVD) 
The first significant study that associated lipid abnormalities with CVD risk was the 
Framingham Heart Study, carried out by the National Heart Institute in the small town of 
Framingham, Massachusetts. It begun in 1948 and it is still ongoing to this day.75,76 The 
original cohort of the Framingham Heart Study consisted of 5209 subjects of a random 
sample of 2/3 of the adult population of Framingham with 30 to 62 years of age. 
Measurements were made of most of the potentially relevant risk factors for CVD known at 
the time. These included data on cigarette smoking, blood pressure, total serum cholesterol, 
LDL-C, HDL-C and presence of type 2 diabetes. Since then, the subjects have continued to 
return to the study every two years for a detailed medical history, physical examination, and 
laboratory tests with the last examination being set between May of 2008 and February of 
2010.  
The study provided first solid evidence that individuals with high blood cholesterol levels 
were more likely to have CHD. It also showed that this was true for a number of other risk 
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factors, such as high blood pressure, smoking, obesity, diabetes and physical inactivity, and 
that any combination of these risk factors were at least additive.77 
The results of the study drived the lipid management guidelines that are still focused on 
decreasing LDL-C levels as the primary target for reducing CHD risk. However, despite the 
generalised use of statins, aggressive LDL lowering has only led to 30 % reduction of clinical 
events.78 Therefore, to further reduce atherosclerotic events, increasing attention is now 
focused on HDL as potential target for atherosclerosis management. According to NCEP/ATP 
III the HDL-C goal is ≥60 mg/dL. 
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1.3  High Density Lipoprotein (HDL) 
1.3.1 Structure (heterogeneity) and composition 
Structurally, HDL represents the smallest (Stoke’s diameter of 7–12 nm) and the densest 
(ranging from 1.063 to 1.21 /mL) plasma lipoprotein (Table 1), which is produced by the liver 
and small intestine.79 It is a heterogeneous fraction, comprising a wide range of circulating 
particles that differ in shape, size, density, composition and surface charge/electrophoretic 
mobility.80 
The basic structure of HDL involves a lipid core of CE and TG surrounded by a surface 
containing a phospholipid bilayer, free cholesterol and a number of apolipoproteins. HDL 
proteins constitute more than half of its mass, unlike the others lipoproteins which are 
mainly composed by cholesterol and /or TG. 
Table 2. Proteins detected in high density lipoproteins (HDL) by mass spectrometry. 
PROTEINs 
Albumin Complement C3 
Alfa-1-acid glycoprotein 2 Complement C4 
Alfa-1-antitrypsin Complement C4b 
Alfa-1B-glycoprotein Complement C9 
Alpha-2-antiplasmin Fibrinogen 
Alpha-2-HS-glycoprotein Haptoglobin-related protein 
Alpha-2-macroglobulin Haptoglobin 
Alpha-amylase (salivary) Inter-alpha-trypsin inhibitor chain H4 
Angiotensinogen Kininogen-1 
Apo(a) Lipopolysaccharide-binding protein 
ApoA-I LCAT 
ApoA-II PAF-AH (LpPLA2) 
ApoA-IV Platelet basic protein 
ApoB PLTP 
ApoC-I PON1 
ApoC-II PON3 
ApoD Prenylcysteine oxidise 
ApoE Prothrombin 
ApoF Retinol-binding protein 
ApoH SAA 1/2 
ApoJ SAA 4 
ApoL-I Serpin F1 
ApoM Transferrin 
Bikunin Transthyreitin 
C4b binding protein Vitamin D-binding globulin 
CETP Vitronectin 
 
HDL proteins have traditionally been divided into four major subgroups: 
apolipoproteins, enzymes, lipid transfer proteins and minor proteins. However, the recent 
development of proteomic technologies have  enhanced the sensitivity of protein detection, 
revealing that the protein burden of HDL is much more diverse than previously realized. 81-85 
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Studies have allowed the identification of more than 50 proteins in human HDL (Table 2). In 
addition to the apolipoproteins and enzymes, numerous proteins involved in acute-phase 
response were found in HDL as well as proteins involved in complement regulation and 
protease inhibition,86,87 raising the possibility that HDL may play a previously unsuspected 
role in host defence mechanisms and inflammation. It is important to keep in mind, 
however, that the content of all these proteins in HDL is much lower than that of major HDL 
apolipoproteins, i. e., ApoA-I and ApoA-II (70% and 20%, respectively). 
1.3.1.1 HDL subpopulations 
On the basis of shape most of the HDL are spherical particles, although there is also a 
minor subpopulation of discoidal HDL (Figure 3 a). Discoid HDL are small ( 8 nm) particles 
and represent a nascent form of HDL, being lipid-poor and presenting two or three ApoA-I 
molecules arranged around a phospholipid bilayer. These relatively unstable and short-lived 
particles will be converted into mature spherical HDL. Spherical HDL particles are larger ( 
8 nm) and contain a hydrophobic core of esterified cholesterol and TG surrounded by an 
outer part composed by two or more ApoA-I molecules, with or without ApoA-II, 
phospholipids and free cholesterol.80 
On the basis of isopycnic ultracentrifugation density HDL may be classified into three 
subfractions: HDL1 (mean density (d) 1.05 g/mL), HDL2 (1.063 < d < 1.125 g/mL) and HDL3 
(1.125 < d < 1.21 g/mL). HDL2 and HDL3 subfractions are spherical and mature particles. The 
composition of the HDL3 particle is a monolayer of phospholipids, mainly 
phosphatidylcholine, and a small amount of free cholesterol, ApoA-I and ApoA-II and a core 
containing esterified cholesterol. HDL3 collects cholesterol to form the larger HDL2 particles 
without ApoA-II, which can exchange both cholesterol and TG with LDL and VLDL particles. 
On the basis of immunoaffinity chromatography HDL may also be separated into two 
major subpopulations according to their apolipoprotein composition using (Figure 3 b). One 
subpopulation comprises HDL containing ApoA-I but no ApoA-II (LpA-I), while the other 
comprises particles containing both ApoA-I and ApoA-II (LpA-I/A-II).88 ApoA-I is divided 
equally between LpA-I and LpA-I/A-II in most subjects, while virtually all of the ApoA-II 
resides in LpA-I/A-II. A small proportion of the ApoA-I exists in a lipid-poor form. LpA-I/A-II 
tend to be smaller and more dense than LpA-I, and prevail in the HDL3 subfraction. LpA-I are 
mostly found in the HDL2 subfraction. 
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Figure 3. High density lipoproteins (HDL) heterogeneity. The HDL in human plasma consist of several 
subpopulations of particles which differ in shape (a), apolipoprotein composition (b), density and size (c) and 
surface charge in electrophoretic mobility (d). Modified from Rye KA et al 2009
89 
and Tabet F & Rye KA 2009.
90 
On the basis of electrophoresis HDL can exhibit alpha (α), pre-beta () or gamma () 
mobility (Figure 3 d). The α –electrophoretic mobility (faster) particles are spherical 
lipoproteins that include both the HDL2 and HDL3 subfractions as well as the LpA-I and 
LpA-I/A-II subpopulations and account for the major proportion of HDL in human plasma. 
Pre- migrating (slower) HDL are either lipid-poor ApoA-I particles, with a single molecule of 
ApoA-I as a free molecule or in association with a few molecules of sphingomyelin and 
phosphatidylcholine, or nascent discoidal particles consisting of one or two molecules of 
ApoA-I complexed with phospholipids and possibly a small amount of unesterified 
cholesterol. In addition,  migrating HDL are lipid-poor particles containing ApoE or 
ApoA-IV.91,92 
The nomenclature of the HDL subpopulations varies depending on the separation 
technique used (Figure 4) and have generated some confusion and inconsistency when 
comparing different studies. 
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Figure 4. Nomenclature of the high density lipoproteins (HDL) subclasses determined by different 
methods. From Asztlos et al, 2011.
93
 
Due to the increasing need to understand, validate, and quantify the diverse roles of 
HDL particles in the atherosclerotic process several investigators initiated an effort to 
uniform the nomenclature for HDL subpopulations. Recently, they proposed the 
development of a new classification system that defines five HDL subclasses on the basis of 
physical and chemical properties that includes very large HDL particles (VL-HDL), large HDL 
particles (L-HDL), medium HDL particles (M-HDL), small HDL particles (S-HDL), and very small 
HDL particles (VS-HDL). The very small HDL subclass includes pre-β-1, discoidal, or nascent 
HDL (Table 3).94 
Table 3. Classification of high density lipoproteins (HDL) by physical properties. From Rosenson et al. 
2011.
94
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1.3.1.2 Major components 
1.3.1.2.1 Apolipoprotein A-I (ApoA-I) 
Human ApoA-I circulates in plasma primarily as a component of HDL (70 % of total HDL 
protein). It is also found in chylomicrons and VLDL.95 ApoA-I has two major sites of synthesis: 
the intestine and the liver. The intestinal derived ApoA-I enters the circulation associated 
with chylomicrons but is rapidly transferred to HDL particles during lipase hydrolysis of 
chylomicrons. Hepatic ApoA-I enters the circulation associated with nascent HDL particles 
and is the major contributor to the plasma ApoA-I pool. 
ApoA-I is a 28 kDa single polypeptide synthesized as a prepropeptide (267 aa residues) 
and is cleaved to release 24 aa residues. Mature, circulating ApoA-I consisting of 243 aa 
residues is encoded by exon 3 (residues 1–43) and exon 4 (residues 44–243) of a gene 
located on the long arm of chromosome 11. Analysis of its aa sequence reveals that with the 
exception of the 44 aa that form the (N)-terminal region, the protein is organized into eight 
α-helical amphipathic domains of 22 aa with two repeats of 11 aa that are frequently 
separated by proline residues. These α-helices contain the lipid-binding carboxyl (C)-terminal 
domain that confers ApoA-I the capacity of avidly binding to lipids and also to move between 
lipoproteins.95-97 ApoA-I does not undergo post-translational modifications such as 
glycosylation, phosphorylation98 and has no disulfide linkages. 
ApoA-I is polymorphic in plasma and is composed of a series of isoforms of similar 
molecular weights but different isoelectric points (pI). The protein is made up of one major 
isoform ApoA-I1 (pI 5.6) and two minor isoforms ApoA-I2 and ApoA-I3 (pI 5.53 and 5.46).
99,100 
The concentration of ApoA-I in plasma is about 100-150 mg/dL58 and has a plasma 
half-life of about 4 days.101 
ApoA-I exists in plasma in three general forms: lipid poor ApoA-I, nascent discoidal HDL 
particles and mature spherical HDL forms. 95,102,103 
In 1999 Segrest et al104 proposed the “double-belt model” for discoidal HDL that consists 
of two ring-shaped ApoA-I molecules wrapped around a leaflet of a disk-like patch of lipid 
bilayer in an anti-parallel orientation. Despite some debate on details of certain regions of 
ApoA-I in the discs, the majority of the most recent theoretical and experimental data 
supports the general features of the “double belt model” 105-107 
In 1997, Borhani et al108 hypothesized a “Faberge Egg model” for spherical HDL, 
suggesting that the intermolecular contacts found in the crystal structure (and in the 
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“double-belt model” in discs) are also present in HDL spheres. However, one model recently 
presented, using cross-linking chemistry and mass spectrometry , indicates that the “double-
belt model” is a common organizational motif for ApoA-I in both discs and spheres.109 These 
authors also showed that particles with a diameter superior to 93 Å (which is comparable 
with human HDL3) present one extra molecule of ApoA-I, but the cross-linking patterns in 
reconstituted spheres were highly similar to those in the discs, regardless of whether they 
contained three molecules of ApoA-I in each particle or only two. The most promising model 
seems the “trefoil model” where the phospholipids in the sphere surface are broken into 
three equal slices with angles of 120○.109  
The understanding of the ApoA-I spatial arrangement in both discs and spheres is critical 
because it offers insights into how the ApoA-I structure modulates the metabolism and 
function of HDL. In fact, Apo A-I is essential for the correct assembly, overall stability of HDL 
and the regulation of HDL metabolism. 
1.3.1.2.2 Apolipoprotein A-II (ApoA-II) 
ApoA-II is the second most important HDL apolipoprotein and represents approximately 
15-20 % of total HDL protein. About half of the HDL particles may contain ApoA-II. ApoA-II 
circulates as a 17 kDa protein and its synthesis takes place mainly in liver.110 Like ApoA-I it is 
also synthesized as a propeptide (100 aa residues) from a gene on chromosome 1 and is 
posterior cleaved to release 23 aa residues.111 ApoA-II transcription is upregulated by 
nuclear receptors such as peroxisomal proliferative-activated receptor-alfa (PPAR-), 
retinoid X receptor (RXR) and SREBP-2.112,113 
ApoA-II circulates as a homodimer of two identical polypeptide chains, each containing 
77 aa and linked by a single disulfide bond.111 The presence of a cysteine residue allows 
ApoA-II to form heterodimers with other cysteine containing apolipoproteins, such as ApoE 
and ApoD. Although it has amphipathic properties, ApoA-II is more hydrophobic than 
ApoA-I. 
Functionally, ApoA-II can both increase HDL particle stability and cause conformational 
changes in ApoA-I on HDL particles by displacing ApoA-I competitively from the HDL surface 
and thereby reducing lecithin:cholesterol acyltransferase (LCAT) activation.114,115 Despite the 
relative abundance of ApoA-II, its role in HDL metabolism and whether it is an anti-
atherogenic or pro-atherogenic protein is not completely clear. 
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1.3.1.2.3 Others apolipoprotein from HDL 
The remainder apolipoproteins of HDL comprises the minor peptides ApoA-IV, V, C-I, 
C-II, C-III, D, E, F, H, J, L-1 and M, which have structural and functional roles as modulators of 
enzyme activities. 
ApoA-IV is a glycoprotein synthesized primarily in the enterocytes of the small intestine 
during fat absorption and is secreted into circulation on the surface of newly formed 
chylomicron particles. The in vitro and in vivo properties of ApoA-IV include a role in the 
protective functions against inflammatory diseases116 and atherosclerosis.117-119 
ApoA-V is predominantly located in TG-rich particles, chylomicrons and VLDL, but also 
on HDL, and its functions are activation of LPL, inhibition of hepatic production and secretion 
of TG.120 
ApoC-I is associated with both HDL and VLDL and can readily exchange between them. 
ApoC-I is involved in the accumulation of cholesterol ester in nascent HDL via inhibition of 
CETP and potential activation of LCAT.121,122 In addition, ApoC-I modulates the interaction of 
ApoE with VLDL and inhibits the binding of VLDL to the LDL receptor.123 
In plasma, ApoC-II and C-III are associated with HDL and VLDL and can exchange 
between their surfaces. Excess ApoC-II has been associated with the increase of TG-rich 
lipoproteins and modifications in the HDL particle distribution, factors that may boost the 
risk of CVD.124,125 
ApoD is mainly associated with HDL. Unlike others, ApoD does not possess a typical 
apolipoprotein structure and belongs to the lipocalin family, which is a multifunctional family 
of carrier proteins.126,127 ApoD has been described in association with various neurological 
disorders, including Alzheimer’s disease, Parkinson’s disease and stroke.126,128  
The major fraction of circulating ApoE is carried by TG-rich lipoproteins in which ApoE 
mediates their receptor binding, internalization and catabolism. Interestingly, ApoE is the 
evolutionary precursor of mammalian ApoA-I. Human ApoE exists as three major isoforms, 
ApoE2, ApoE3 and ApoE4, which differ by aa substitutions at positions 130 and 176. Human 
ApoE3 preferentially binds to HDL, while ApoE4 preferentially binds to VLDL.129 ApoE 
isoforms are associated with different levels of disease’s risk, most notably for 
atherosclerosis130 and Alzheimer’s disease.131 
ApoF is present in human HDL and LDL, being also known as lipid transfer inhibitor 
protein due to its ability to inhibit CETP-mediated lipid transfer between 
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lipoproteins.132Human and mouse ApoF overexpression reduce HDL-C levels, improve the 
clearance of HDL-CE from the plasma and result in HDL particles that are more efficient 
acceptors of macrophage-derived cholesterol.133 
ApoH, also known as beta-2-glycoprotein I (2GPI) is a multifunctional phospholipid 
binding protein, which binds particularly cardiolipin but also various types of negative 
charged substances such as heparin. ApoH may prevent activation of the intrinsic blood 
coagulation cascade by binding to phospholipid on the surface of damaged cells. It also 
regulates platelet aggregation by inhibiting the generation of factor Xa or XI134 and activating 
both factor XIIa and protein C. ApoH has other physiological roles, that include apoptotic cell 
clearance,135 binding to oxidized low-density lipoprotein (oxLDL),136 and has been found to 
be the most relevant antigen target in the subset of antibodies towards oxLDL.137,138 
ApoJ, also called clusterin, presents a structure that allows binding to a wide spectrum 
of hydrophobic molecules and to specific cell-surface receptors. ApoJ was classified as a 
functional homologue of the small Heat Shock Proteins (HSP)139 in many age-related diseases 
including neurodegeneration, vascular damage, diabetes and tumorigenesis.140 
ApoL-I is a key functional element of the trypanosome lytic factor of human serum and 
is associated with HDL.141 Lack of this protein from mutations in both APOL1 alleles leads to 
trypanosome infection in humans.142 
ApoM, first identified and characterized in 1999, is the latest addition to the 
apolipoprotein family.143 ApoM is selectively expressed in hepatocytes and in kidney cells. It 
is mainly found in HDL, but also in VLDL and LDL. Data from knockout (KO) mice shows that 
ApoM is critical for the formation of HDL, notably pre- HLD (lipid-poor ApoA-I).144 
Overexpression of ApoM in LDL-receptor-deficient cholesterol fed mice protects against the 
development of atherosclerosis through a not yet clarified mechanism.144 
1.3.1.2.4 Paraoxonase 1 and 3 (PON1 and 3) 
Human paraoxonases are calcium dependent lactonases and consist in three members 
PON1, PON2 and PON3. The three PON genes are aligned on the long arm of chromosome 
7q21.3-22.1 and are well conserved in mammals sharing 79-95% aa identity and 81-95% 
identity at the nucleotide level between different species.145 
The name “PON” reflects the ability of PON1, the first enzyme discovered of the family 
to catalyze the hydrolysis of the active metabolite of the organophosphate (OP) insecticide 
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parathion, the paraxon, which is the substrate commonly used to measure paraoxonase 
activity (EC 3.1.8.1, aryldialkylphosphatase). PON1 is capable of hydrolyzing a broad 
spectrum of toxic oxon metabolites of OP insecticides, nerve gases as well as a number of 
aromatic carboxylic acid esters.146 PON1 also hydrolyzes phenylacetate which corresponds to 
the arylesterase activity. Although its esterase activity has been known for long, only more 
recently the natural and /or endogenous subtract for PON1 was found. PON1 is primarily a 
lactonase147,148 capable of hydrolyzing a variety of lactones, including certain drugs (e.g. 
spironolactone, mevastatin, lovastatin, simvastatin and prulifloxacin), endogenous 
compounds (e.g. lactone metabolites of arachidonic acid, or hcy-thiolactone) and acyl-
homoserine lactones, which are quorum sensing signals of pathogenic bacteria.148,149 
Phylogenetic analysis shows that PON2 is the oldest member of the family followed by 
PON3 and PON1.150 Human PON1 is synthesized mainly in the liver and circulates in the 
bloodstream associated to HDL. Similarly, PON3 is expressed typically by the liver and at low 
levels by the kidney and is also associated with HDL in circulation albeit at much lower levels 
than PON1.151 In contrast PON2 is not detectable in serum associated with HDL although it is 
ubiquitous expressed and found in many tissues and cells including macrophages, heart, 
brain, liver, kidney, lung, placenta, small intestine, spleen, stomach and testis.152 
Current findings suggest that the name PON is in fact a misnomer, as the capacity of 
hydrolase OP (paraoxonase activity) is almost exclusive of PON1. All three PONs have 
arylesterase activity, although very low activity with the exception of PON1. Nevertheless 
PON1, PON2, and PON3 share the lactonase activity with overlapping but also distinct 
substrate specificity.153 Dihydrocoumarin, long chain fatty acid lactones and acyl-homoserine 
are hydrolyzed by all three PONs and likely represent their natural subtracts.154 The three 
members of the family seem to have an important role in the maintenance of a low 
oxidative state in plasma by protecting against or reversing HDL and LDL oxidation.155 
Despite a growing interest on PON2 and PON3, PON1 still by far the best studied member of 
the family. 
PON1 gene sequence identified almost 200 polymorphic sites on the coding and 
promoter regions. The two most studied and common coding polymorphisms are at position 
192 leading to a glutamine – arginine substitution (Q192R) and at position 55 the leucine to 
methionine substitution (L55M). These polymorphism exhibits an exogenous substrate-
dependent effect on enzyme activity. For instance, subjects with the RR genotype have 
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significantly higher paraoxonase activity towards paraoxon than subjects with QQ genotype, 
but hydrolyze diazoxon, soman, and sarin less rapidly.156,157 Both isoforms of the enzyme 
hydrolyze phenyl acetate at approximately the same rate and do not affect PON1 protein 
concentration.148 Regarding the other polymorphism at position 55 it seems to affect 
enzyme quantity, rather than specific activity or substrate preference although this is not yet 
fully clarified.158 The binding affinity and stability of PON1 on HDL is affected by the PON1 
polymorphisms.159 
The association between PON1 polymorphisms and CHD remains controversial, few 
studies showed a positive association between PON1 192 RR genotype and CHD whereas 
many others failed to confirm this. Recently was performed a meta-analysis on the relation 
between PON1 polymorphism and CHD which included 88 studies published before August 
2010, with a total of 24,702 CHD cases and 38,232 controls.160 This study reported a weak 
overall association with the PONQ192R with a doubtful relevance since there was no 
significant association amongst the larger studies included in the analysis, thereby 
replicating the results of past.161-163 However low PON1 activity seems to be associated with 
atherosclerosis independently of the PON1 polymorphism and appears to be a better 
predictor of CVD development than the PON1 genotype.157,164,165 
PON1 activity and/or level of expression are regulated by several exogenous factors 
such as life –style, dietary factors and age.166,167 PON1 activity increases with the intake of 
lipid lowering drugs, antidiabetic and hormone-replacement drugs.168 
Some of recent studies regarding the PON1 lactonase activity are focused in its capacity 
to hydrolyse Hcy - thiolactones. Elevated blood levels of Hcy (an intermediate metabolite in 
methionine biosynthesis) is a known risk factor for atherosclerosis and is associated with a 
moderately risk of CVD.169 The metabolic conversion of Hcy to Hcy - thiolactone is a mistake 
reaction of the methionyl-tRNA synthetase which by an editing error selected Hcy instead of 
methionine.170 The Hcy-thiolactone formed is a reactive metabolite that has the ability to 
establish isopeptide bonds with protein lysine residues that cause protein N-
homocysteinylation171 which has detrimental effects on protein structure and function 
leading to severe pathophysiological consequences including activation of the immune 
response172 and enhanced thrombosis.173 
Several studies show that Hcy-thiolactonase activity of PON1 inhibits the Hcy-
thiolactone formation and consequently N-homocysteinylation of proteins,147,174,175 so in 
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addition to the anti-oxidant and anti-inflammatory functions of peroxidase and esterase 
activity of PON1, the thiolactonase activity also contributes significantly for its 
cardioprotective function. 
1.3.1.2.5 Lecithin-cholesterol acyltransferase (LCAT) 
LCAT (EC 2.3.1.43) catalyzes the esterification of cholesterol to CE by transferring the 
fatty acid from the second position on the glycerol backbone of lecithin or 
phosphatidylethanolamine to the free hydroxyl group on the first ring of cholesterol.176 The 
generated CE is very hydrophobic molecules that migrate into the inner core of the particle, 
creating a pool of so-called “neutral lipid,” which is completely encapsulated by a surface 
coat of phospholipid, free cholesterol, and apolipoprotein. Cholesterol esterification by LCAT 
occurs predominantly in HDL, but can also take place in ApoB containing particles. 
LCAT plays an important role in RCT as the majority of tissue-derived cholesterol is 
delivered to the liver as CE and only a small amount as free cholesterol. CE trapped in the 
HDL core cannot be spontaneously exchanged with other lipid molecules until it is removed 
from the circulation by the liver.177 In parallel, LCAT promotes cholesterol efflux from 
peripheral cells, acting via the elevation of the concentration gradient for unesterified 
cholesterol between cell membranes and HDL. 
LCAT is a 63 kDa protein synthesized mainly in the liver and, to a lesser extent, in the 
brain and testes. Mature LCAT contains 416 aa residues and is heavily glycosylated. 
In plasma LCAT is closely associated with ApoD. ApoA-I mediates the binding of LCAT to 
HDL and its activation. Others apolipoproteins, including ApoA-IV, C-I, E, are also capable of 
activating LCAT, although less potently compared to ApoA-I. 
LCAT has been shown to directly hydrolyse oxidized polar phospholipids and also 
prevent the accumulation of oxidized lipids in LDL.178,179 However aldehydes that are 
generated during lipid peroxidation can modify HDL structure and inhibit LCAT activity.180,181 
LCAT activity is also decreased in HDL isolated from diabetic subjects (and in in vitro glycated 
HDL), due to the glycation of lysine residues in ApoA-I.182,183 Furthermore, the displacement 
of ApoA-I by serum amyloid A (SAA) during acute phase reaction inhibits LCAT activity.184 
1.3.1.2.6 Cholesterol ester transfer protein (CETP) 
CETP is a plasma lipid transfer protein, primarily expressed by the liver and adipose 
tissue. The mature CETP contains 476 aa residues and multiple glycosylation sites. In 
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circulation, this hydrophobic 74 kDa glycoprotein facilitates the bidirectional transfer of CE 
and TG between mature spherical HDL and ApoB containing lipoproteins. Specifically, CETP 
transfers CE from HDL to ApoB containing lipoproteins, such as VLDL, IDL and LDL, in 
exchange for TG (Figure 5).185 
Its substrate specificity is regulated by lipid transfer inhibitor protein (or ApoF).132 These 
processes deplete the HDL core of CE and enrich them with TG. Therefore CETP promotes 
HDL-mediated cholesterol efflux from peripheral cells via elevation of the concentration 
gradient for unesterified cholesterol between cell membranes and HDL. HDL-derived CE that 
accumulate in ApoB containing lipoproteins can be subsequently delivered to the liver 
through the hepatic LDL receptor, as described before (sub-chapter 1.2.2). Thus, in addition 
to the important role in RCT, CETP actions are equally implicated in the intravascular 
remodelling of lipoproteins, which favours HDL particle recycling and thus the formation of 
lipid-free/lipid-poor ApoA-I, thereby leading to enhanced cellular free cholesterol efflux and 
plasma LCAT activity. 
 
Figure 5. Cholesterol ester transfer protein (CETP)-mediated lipid exchange between lipoproteins. From 
Nicholls et al, 2011.
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Such actions are synonymous to an anti-atherogenic role of CETP. A second major CETP 
mediated pro-atherogenic pathway takes place in states of moderate to marked 
hypertriglyceridaemia, in which CETP drives an enhanced transfer of TG from VLDL to HDL, 
leading to TG enrichment of HDL with anomalous intravascular metabolism involving HL 
mediated hydrolysis of HDL phospholipids and TG, with a consequent reduction of particle 
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size, formation of small dense HDL and dissociation of lipid-poor ApoA-I. This lipid-poor 
ApoA-I instead of acting as an acceptor of cholesterol from pheriferic tissues can be removed 
and lost irreversibly from plasma due to accelerated renal catabolism.187-189 Therefore CETP 
may exert both pro-atherogenic and anti-atherogenic actions, the balance between them 
clearly depending primarily on the metabolic context. 
The importance of CETP in HDL metabolism is demonstrated by the discovery of 
individuals who have loss-of-function mutations in both alleles of the CETP gene. These 
subjects, found almost exclusively in Japan, have extremely elevated levels of HDL-C.190,191 In 
addition, their HDL is exceptionally large, and the turnover of ApoA-I is substantially 
reduced.192 
1.3.1.2.7 Other HDL components 
Platelet activating factor acetylhydrolase (PAF-AH, EC 3.1.1.47) whose plasma form is 
known as lipoprotein-associated phospholipase A2 (Lp-PLA2), is a calcium-independent 
enzyme that degrades the short sn-2 residue of PAF to the biologically inactive lyso-PAF, as 
well as pro-inflammatory oxidized short-chain phospholipids and esterified isoprostanes.193 
This action of Lp-PLA2 indicates that it may be a potent anti-inflammatory enzyme. However, 
Lp-PLA2 also generates lysophosphatidylcholine and bioactive oxidized non-esterified fatty 
acids, two key pro-inflammatory mediators implicated in atherosclerosis.194 Thus, Lp-PLA2 
could play both pro-atherogenic and anti-atherogenic role depending on which lipoprotein 
the enzyme is associated in plasma.195 
Other minor constituent of HDL are: 1) the glutathione peroxidases isoenzyme 3 (GPx3) 
that may reduce the oxidative damage by catalyzing the glutathione dependent reduction of 
lipid hydroperoxides to their corresponding alcohols and hydrogen peroxide to water.196 2) 
the phospholipid transfer protein (PLTP) that aids in the transfer of phospholipids between 
HDL and VLDL, as well as between different HDL particles.197 3) the sphingosine-1-phosphate 
(S1P) that is a bioactive lipid involved in various cellular processes such as cell proliferation, 
motility, apoptosis, angiogenesis, wound healing and immune response.198 
1.3.2 Atheroprotective functions of HDL 
Recently, the interest in HDL has spiked, with the recognition of its multiple anti-
atherogenic properties. The best known anti-atherogenic function of HDL is the capacity to 
promote cellular cholesterol efflux from peripheral cells and deliver cholesterol to the liver 
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for excretion, thereby playing a key role in RCT. However the anti-atherogenic roles of HDL 
goes beyond RCT and involve anti-oxidant, anti-inflammatory and antithrombotic properties, 
as well as cytoprotective, vasodilatory, anti-infectious and antidiabetic activities (Figure 6).199 
It is believed that the varied physiological functions of HDL reflect, the wide variety of 
proteins carried by HDL and the heterogeneity of HDL complexes; indeed, specific HDL 
associated functions appear to be mediated by one or more distinct proteins potentially 
acting synergistically. Nearly all HDL subpopulation display multiple atheroprotective 
functions, many of these activities are particularly effective in small, dense, protein-rich 
HDL.200 Not only the protein content of HDL may influence its functions, the lipid 
composition of HDL may interfere with the association of the different proteins at the HDL 
surface. 
 
Figure 6. Summary of the key anti-atherogenic properties attributed to high density lipoprotein (HDL). 
From  Yamashita et al, 2010.
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1.3.2.1 Reverse cholesterol transport (RCT) 
Promotion of cholesterol efflux from macrophages on the arterial wall for excretion into 
bile constituents, completing the RCT pathway is thought to be one of the most important 
mechanisms by which HDL protects against atherosclerosis (Figure 7). 
ApoA-I is synthesized by the liver and released into the plasma as relatively free from 
lipid, known as nascent HDL. Small nascent HDL are unstable and rapidly receives free 
cholesterol and phospholipids from tissues by a unidirectional active transport process that 
is mediated by a family of transmembrane adenosine triphosphate-binding cassette proteins 
(ATP-binding proteins). The best characterized member of this family, is adenosine 
triphosphate-binding cassette transporter A1 (ABCA1) which preferentially efflux cholesterol 
to lipid deplete or free forms of ApoA-I producing discoid HDL particles. Such particles 
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further acquire cellular lipids via pathways mediated by ABCA1 and others ATP-binding 
proteins as the ABCG1 and ABCG4 which preferentially binds to mature spherical HDL 
particles.201 
 
Figure 7. HDL metabolism and reverse cholesterol transport (RCT). The liver secretes lipid-poor 
apolipoprotein A-I (ApoA-I), which quickly acquires cholesterol via the hepatocytes ATP-binding cassette sub-
family member 1 transporter (ABCA1). Lipid-poor ApoA-I also promotes the efflux of free cholesterol from 
macrophages via ABCA1. Lecithin cholesterol acyltransferase (LCAT) esterifies free cholesterol to cholesteryl 
esters (CE) to form mature HDL, which promotes cholesterol efflux from macrophages via the ABCG1 
transporter, as well as from other peripheral tissues by processes not fully defined. Mature HDL can transfer its 
cholesterol to the liver directly via scavenger receptor class B type I (SR-BI) or indirectly via cholesterol ester 
transfer protein (CETP) mediated transfer to ApoB-containing lipoproteins, with subsequent uptake by the liver 
via the LDL receptor. Hepatic cholesterol can be excreted directly into the bile as cholesterol or after 
conversion to bile acids and, unless reabsorbed by the intestine, is ultimately excreted in the faeces. HDL can 
be remodelled by lipases such as hepatic lipase (HL) and endothelial lipase (EL), which hydrolyze HDL 
triglycerides and phospholipids, respectively. From Duffy et al, 2009.
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Excess of cholesterol can also be removed from cells by scavenger receptor class B type I 
(SR-BI) that promotes an ATP-independent bidirectional cholesterol flux between cellular 
membranes and large HDL particles according to concentration gradients.203 
Within the HDL particle, unesterified cholesterol can be esterified to CE by the addition 
of fatty acid to the cholesterol molecule through the action of the HDL associated LCAT, 
hereafter this newly formed CE migrates into the hydrophobic core of immature discodial 
HDL turning it into a mature and spherical HDL.204 Since the particles on the surface remains 
relatively deplete of cholesterol the gradient driving efflux from cells to the HDL particle is 
maintained. 
Ultimately, HDL must deliver the cholesterol acquired via transporters to the liver for 
bile excretion as free-cholesterol or bile acids. Cholesterol transported by HDL can arrive to 
the hepatocyte by several ways. Perhaps the most common is via SR-BI expressed in the 
hepatocytes. Unlike what happens with LDL when it binds to its receptor the binding of HDL 
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to SR-BI does not result in the internalization of the complex formed. In this case the SR-BI 
mediates the selective translocation of the CE of HDL, but not protein, by forming a 
hydrophobic channel through the plasma membrane designate caveolae while the HDL and 
SR-BI remain on the plasma membrane.205 Thus, HDL particles are quickly recycled and 
returned to the cell surface as a smaller particle (lipid-poor ApoA-I) ready to acquire more 
free cholesterol and continue the loading process to larger particles.206 
HDL particles can also be removed from the circulation by holoparticle HDL receptors. 
Both liver and kidney can rapidly take up holo-HDL particles, including ApoA-I, by 
endocytosis and can be subsequently transferred to multivesicular bodies and, to a minor 
degree to lysosomes for degradation.207 In the last thirty years have been identified several 
potentially candidates leading to HDL holoparticle or ApoA-I uptake and degradation, 
including cubilin, megalin, ApoA-I binding protein (AI-BP), two other membrane proteins 
named HB1 and HB2, also high density lipoprotein binding protein (HBP) and more recently 
the ectopic -chain of ATP synthase.73 
Alternatively, an indirect pathway can occur and CE from HDL is transferred to ApoB 
containing lipoproteins such VLDL, IDL and LDL in exchange for TG through the action of 
CETP.208 PLTP can transfer phospholipids from ApoB containing lipoproteins to HDL.197 
Following transfer to ApoB containing lipoproteins CE are either taken up by the liver via LDL 
receptor or delivered to cells in the periphery. In healthy, normolipidemic individuals such 
indirect RCT pathway to delivery CE to the liver accounts for 70 % of CE removal from 
peripheral tissues.209 
1.3.2.2 Anti-oxidant function of HDL 
Oxidative stress has a key role in initiation and propagation of atherosclerosis and its 
associated complications.210 Oxidative stress results from an imbalance between increased 
generation of intracellular reactive oxygen species (ROS) and the decreased ability of 
endogenous antioxidant systems to scavenge them. Molecules generated during oxidative 
stress may damage the normal structure / functions of proteins, lipids, carbohydrates, 
nucleic acids and thus affect diverse cellular processes like membrane function, enzyme 
activity and DNA replication. Enhanced production of ROS has been attributed to increased 
activation of enzymes such as myeloperoxidase (MPO), nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, xanthine oxidase, lipoxygenase and cyclooxygenase (COX), as 
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well as dysfunction of the mitochondrial respiratory chain. ROS may oxidize phospholipids 
within LDL. OxLDL is a powerful chemoattractant for monocytes, and the phagocytosis of 
oxLDL by monocytes is a critical step for transformation of monocytes into foam cells.211  
The anti-oxidant functions of HDL are explained by its content of anti-oxidants, ApoA-I 
and several enzymes such as PON, PAF-AH and GPx3 which directly or indirectly prevent LDL 
oxidation.212-216 Furthermore, HDL is cytoprotective against apoptosis of vascular cells 
elicited by oxLDL.217 
The importance of PON’s anti-oxidant effect has been demonstrated in several studies: 
PON1 was highly effective in preventing LDL oxidation,218,219 moreover PON1 inhibits 
macrophage cholesterol biosynthesis by attenuating oxLDL uptake by macrophages220 and 
also stimulates HDL-mediated cholesterol efflux from macrophages.221 Anti-inflammatory 
actions of PON1 has also been reported as it decrease monocyte chemotaxis and adhesion 
to endothelial cells222 Furthermore, transgenic animals deficient in PON1 were more 
susceptible to atherosclerosis development,223 while those that overexpressed PON1 had 
less atherosclerosis.224 
With the finding that the major activity of PON’s is a calcium dependent lactonase and 
that the affinity of PON1 for lipid hydroperoxides is several orders of magnitude lower than 
its affinity for lactones, the established anti-atherosclerotic properties of PON1 may also 
involve its major activity as lactonase. In particular, by hydrolyzing Hcy-thiolactones and 
protecting against the pro-atherogenic modifications of proteins caused by them.225 
In addition to ApoA-I, other HDL apolipoproteins display antioxidative activity such as 
ApoE226, ApoJ227 and ApoA-IV228. ApoE possesses distinct antioxidative properties and can 
promote regression of atherosclerosis independently of the reduction in plasma cholesterol 
levels.229 Moreover, HDL particles also contain small amounts of lipophilic anti-oxidants, 
mainly tocopherols, which may supply a minor input to antioxidative properties of HDL.230 
1.3.2.3 Anti-inflammatory function of HDL 
HDL display multiple anti-inflammatory properties which together may significantly 
contribute to its anti-atherosclerotic properties.231-233 
HDL decreases the cytokine-induced adhesion molecule expression on endothelial cells 
and inhibits monocyte adhesion to the endothelium. In vitro HDL particles potently inhibit 
the expression of VCAM-1, intercellular adhesion molecule-1 (ICAM-1) and E-selectin 
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induced in endothelial cells by tumor necrosis factor-alpha (TNF-), interleukin -1 (IL-1), 
endotoxin or C-reactive protein (CRP) .213, 234-236 
These affects may be accomplished by HDL inhibition of factor nuclear kappa B (NF-B) 
activation induced by oxLDL and TNF- .214 
Furthermore HDL can inhibit monocyte activation via reducing the expression of  
chemokine C-C motif ligand 2 (CCL2), CCL5 and chemokine C-X3-C motif ligand 1 (CX3CR1), as 
well as chemokine receptors like C-C chemokine receptor type 2 (CCR2) and CX3CR1.237 
In vivo, infusions of reconstituted HDL (rHDL) inhibit adhesion molecules expression 
across arterial endothelium in a rabbit model of acute arterial inflammation.238 Intravenous 
infusions of rHDL (ApoA-I/phosphatidylcholine) decreases VCAM-1 expression in 
atherosclerotic plaques obtained from patients with peripheral vascular disease in a 
placebo-controlled trial.236,239 
HDL-associated ApoA-I displays inhibitory activity towards contact-mediated activation 
of human monocytes by stimulated T-lymphocytes.240 As direct cell-cell contact with 
stimulated T lymphocytes is a strong inducer of cytokine production in monocytes, HDL 
specifically inhibits the production of some pro-inflammatory cytokines and chemokines 
(TNF-, IL-1, IL-6, IL-8, CCL3 and CCL4) induced by T-cell contact.241 
In addition ApoA-I inhibits oxLDL-induced monocyte chemotaxis and significantly 
decreases lipopolysaccharide (LPS)-mediated monocyte chemotactic protein-1 (MCP-1), 
sL-selectin, sICAM-1 and sVCAM-1 release from THP-1 cells.242 
Apart from turning into foam cells a significant proportion of blood monocytes 
differentiated into migratory dendritic cells (DCs). These monocyte-derived DCs may migrate 
via the afferent lymph and have a considerable role in the removal of dying cells from 
atherosclerotic lesions, which could be a solution to solve the local inflammation. 
Nevertheless, this emigratory process is impaired in atherosclerosis243 as a consequence of 
inhibitory signals generated by PAF or oxLDL that acts as a PAF mimetic. 244 
These multiple anti-inflammatory properties of HDL suggest that several action 
mechanisms may be operative at one time: the cellular lipid efflux mediated by ABCA1 and 
ABCG1 is a mechanistic basis that explains the capacity of HDL to decrease adhesion 
molecule expression and to inhibit monocyte and neutrophil activation, probably due to the 
rapid depletion of cholesterol from cell membranes.245,246 The removal of cellular cholesterol 
by HDL also results in changes in the expression of genes involved in the regulation of the 
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inflammatory response, as the down-regulation the inflammatory phenotype of macrophage 
with consequent attenuation of signalling via toll-like receptor (TLR) 4.247 
On the other hand the ability of HDL to inhibit adhesion molecule expression may be 
related to the presence of several protein and lipid components, which include ApoA-I, 
ApoA-II, ApoA-IV and HDL-associated lysosphingolipids, such as S1P.119,235,248 
Transforming growth factor beta (TGF-) possesses several anti-inflammatory properties 
and stabilizes the atherosclerotic plaque.249 HDL induces TGF-2 expression in vitro and in 
vivo via phosphoinositide 3-kinase (PI3K)/Akt activation, running as another important 
mechanism by which HDL may exert protective effects on endothelial cells and vascular 
wall.250 
Modulation of ILs can be equally involved in the effects of HDL on inflammatory 
cascade. In fact, HDL attenuates the expression of pro-inflammatory cytokine, such as IL-1 
and IL-6,239,251 but increases the production of anti-inflammatory cytokines as IL-10.252 
1.3.2.4 Vasodilatory function of HDL 
One major indicator of endothelial dysfunction in the development, progression, and 
clinical complications of atherosclerosis is the decreased endothelial NO• production and 
bioavailability, as result of enhanced inactivation of NO• by superoxide anion (O2
•-) 253,254 This 
leads to increased neutrophil adherence to the endothelium, enhanced smooth muscle cells 
(SMCs) proliferation and platelet aggregation and adhesion. 
HDL particles display potent vasodilatory activity, which reflects their capacity to modify 
endothelial nitric oxide synthase (eNOS) expression as well as its activity and the stimulation 
of endothelial NO• production in vitro and in vivo.255,256 
Moreover, administration of rHDL has been shown to improve endothelial function in 
subjects with hypercholesterolemia and in subjects with isolated low HDL due to 
heterozygous loss-of-function mutations in the ABCA1 gene locus.257,258 
Several different mechanisms have been proposed to account for the endothelial NO• 
stimulating capacity of HDL (Figure 8). 
Endothelial NOS is localized in caveolae, specialized microdomains prevalent on the 
plasma membrane of endothelial cells that contain cholesterol, sphingomyelin, 
glycosphingolipids, phospholipids and membrane proteins. The structure of caveolae 
depends on the type and amount of cholesterol associated with the domain and a sufficient 
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level of cholesterol is required to maintain the invaginated structure of the caveolae and its 
association with eNOS. Lipoproteins may modulate eNOS activity by interacting with the 
receptors found in caveolae such as SR-BI, CD36 and the caveolae protein, caveolin-1. It is 
known for long that oxLDL depletes caveolae of cholesterol, via binding to CD36 leading to 
the intracellular translocation of eNOS and a reduction in the capacity to activate eNOS.259 
On the contrary, HDL binding to SR-BI maintain the concentration of caveola-associated 
cholesterol by promoting the uptake of CE. Therefore oxLDL-induced depletion of caveola 
cholesterol is prevented and the subcellular location of eNOS is mantained.260 
 
Figure 8. Major pathways involved in vasodilatory activity of HDL. HDL enhances nitric oxide (NO
•
) 
production by endothelial NO synthase (eNOS) phosphorylation at serine residue 1177 via binding of ApoA-I to 
SR-BI and binding of HDL-associated lysophospholipids to the S1P3 receptor. Also, HDL mediated efflux of 7-
oxysterols through endothelial ABCG1 has been observed to inhibit the interaction between eNOS and 
caveolin, and to prevent the loss of eNOS dimerization induced by ROS in the endothelium. From Besler C et al, 
2012.
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Yuhanna et al262 have shown that HDL directly stimulate eNOS mediated NO• production 
through the biding of ApoA-I to SR-BI in endothelial cells. 
Mechanistically, the binding of HDL to SR-BI leads to a tyrosine kinase Src-mediated 
activation of PI3K, which in turn activates Akt and the mitogen-activated protein kinases 
(MAPK) /extracellular signal-regulated kinase pathway.255,263 This activation of endothelial 
Akt has been shown to stimulate phosphorylation of eNOS at serine residue 1177, 
recognized as an key regulatory mechanism that leads to eNOS activation.264 
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In contrast, the mechanism through which the MAPK/extracellular signal-regulated 
kinase pathway activates eNOS in endothelial cells stimulated with HDL remains poorly 
understood. Nevertheless, several lysophospholipids found in HDL (i.e. 
sphingosylphosphorylcholine, S1P, lysosulfatide) can via Akt-mediated activation of eNOS 
independently release NO• through binding of lysophospholipid receptor S1P3 that is 
expressed in endothelial cells.263 
Another pathway whereby HDL may maintain endothelial cell NO• production and 
availability is mediated by ABCG1 and involves cholesterol efflux.265 Studies with cholesterol-
fed mice suggested that HDL-mediated efflux of cholesterol and 7-oxysterols (a dietary 
oxysterol) via endothelial ABCG1 improving the formation of active eNOS dimers and results 
in decreased ROS production.265 In support of these data, vascular deficiency of ABCG1 
impairs eNOS-mediated relaxation and accelarates atherosclerosis in LDL receptor-deficient 
mice.266 Furthermore, HDL-mediated cholesterol efflux via ABCG1 reduced the inhibitory 
interaction of eNOS with caveolin-1 induced by cholesterol loading resulting in increased 
eNOS activity.267 
Recently, Besler et al256 suggested that inhibition of PON1 in HDL from healthy subjects 
impaired the capacity of HDL to stimulate Akt/eNOS phosphorylation, endothelial NO• 
production and NO•-dependent vasodilatation. Consistent with these findings, HDL isolated 
from PON1-deficient mice failed to stimulate endothelial NO• production. These data 
suggest a role of HDL-associated PON1 activity in maintaining the endothelial 
atheroprotective effects of HDL, at least in part by preventing formation of the lipid 
peroxidation product malondialdehyde (MDA) rather than directly degrading MDA. 
Furthermore, inhibition of PON1 prevented the protective effects of HDL from healthy 
subjects on TNF-α–stimulated endothelial VCAM-1 expression, endothelial monocyte 
adhesion and endothelial repair, suggesting that the capacity of HDL to stimulate endothelial 
NO• production is important for the vasodilatory and anti-inflammatory effects of HDL. 
HDL can also stimulate the production of PGI2, which possesses potent vasorelaxing 
activity and therefore being able to modify thrombosis as well as other intravascular 
events.268,269 Furthermore, PGI2 acts synergistically with NO• to induce vascular smooth 
muscle relaxation, inhibit platelet activation and adhesion and diminish the release of 
growth factors that stimulate the local proliferation of vascular SMCs. 
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The effect of HDL on prostacyclin production in the endothelium occurs both by the 
provision of arachidonate268,270 and upregulation of COX-2 expression.271,269 Several different 
mechanisms have been proposed to account for the HDL mediated COX-2 expression and 
PGI2 release. HDL induces the phosphorylation of p38 MAPK, which is implicated in the 
activation of cAMP response element-binding protein (CREB) in endothelium269 and mimics 
the mechanism that occurs in vascular smooth muscle.272 Moreover, the SR-B1 mediated 
PI3K–Akt–eNOS signalling pathway plays a role in HDL induced PGI2 and COX-2 production in 
endothelial cells.273 Also, oxidized steroids may increase COX-2 expression through the PI3K–
Akt–eNOS pathway in human umbilical vein endothelial cells (HUVECs).274 
In addition, HDL has a beneficial effect not only on endothelium, but also on endothelial 
progenitor cells (EPCs).275-276 EPCs mainly reside in bone marrow are mobilized into 
circulation in response to various stimuli of angiogenesis. In the circulation, EPCs express 
surface CD34, CD133 and KDR (VEGFR-2) and may go to the site of injured endothelial cells 
and differentiate into mature and healthy endothelial cells to maintain the integrity of the 
endothelial monolayer.277 Numerical and functional impairment of EPCs contribute to 
endothelial dysfunction and the associated increase in cardiovascular risk.278 A direct link 
between HDL and EPCs was demonstrated with rHDL infusions in ApoE deficient mice which 
nearly doubled the number of EPCs, effectively promoted the EPCs-mediated repair of 
damaged endothelium275 and enhanced ischemia-induced angiogenesis279in vivo through the 
stimulation of differentiation of EPCs. Infusions of rHDL also increased circulating EPCs in 
patients with type 2 diabetes.276 HDL prevents the apoptosis of EPCs by activating eNOS and 
inhibiting caspase 3 in vitro.280 Both ApoA-I, possibly through interaction with SR-BI,281 and 
S1P through S1P3 receptor282 have the ability to stimulate EPCs and promote 
neovascularization. More recently, was demonstrated that PI3K/Akt-dependent cyclin D1 
activation plays an essential role in HDL-induced EPCs proliferation, migration and 
angiogenesis.283 
1.3.2.5 Antithrombotic function of HDL 
Platelets are implicated in the initiation, progression and rupture of atherosclerotic 
lesions (Figure 9).284 Arterial thrombus formation is determined by the balance between 
prothrombotic mediators, like tissue factor (TF) and plasmogen activator inhibitor-1 (PAI-1), 
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and antithrombotic such as tissue factor pathway inhibitor (TFPI) and tissue plasmogen 
activator (tPA).285 
Dyslipidemia is frequently associated with increased platelet reactivity and 
thrombogenic potential.286 
 
Figure 9. Contribution of platelets to the initiation and the progression of atherosclerosis. From Nofer et 
al 2010 
284
 
HDL exerts multiple antithrombotic effects and thereby counteracts the development of 
atherothrombotic vascular disease.284 In fact, infusion of rHDL particles significantly 
mitigates ex vivo platelet aggregation response to multiple agonists activation, in subjects 
with type 2 diabetes characterized by enhanced platelet aggregation.287 The in vitro 
antithrombotic activities of HDL on platelets involves a dose-dependent inhibitory action by 
glycoprotein IIb/IIIa on agonist-stimulated platelet aggregation (such as thrombin, collagen, 
ADP, adrenaline, oxLDL and arachidonic acid) 288,289 and on thrombin-induced binding of 
fibrinogen, which is a pre-requisite of platelet aggregation.290 In addition, HDL-mediates 
inhibition of thrombin- and ADP-stimulated secretion of alpha- and dense granules as well as 
the liberation of thromboxane A2 (TxA2) and 12-hydroxyeicosatetraenoic acid (12-HETE). 
Furthermore, HDL can decrease platelet aggregation as a result of enhanced production of 
NO•.284 
Blood coagulation involves a series of intrinsic or extrinsic pathways that occurs through 
the formation of enzymatic protein complexes that assemble on the surface of anionic 
phospholipids. Although these pathways are initiated by distinct mechanisms, the two 
converge on a common pathway that leads to fibrin clot formation. HDL inhibits factors that 
promote blood coagulation, including tissue factors and factors X, Va and VIIIa.291,292 HDL 
also has been shown to contain a TFPI,293 which would turn HDL less thrombogenic, and 
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thrombin that is generated on the surface of HDL might be 20 times less efficient than when 
formed on the surface of TG-rich lipoproteins. 
Moreover, ApoA-I neutralize the procoagulant properties of anionic phospholipids, 
which lose their capacity to mediate activation of prothrombin by factor Xa in the presence 
of factor Va and unable to support binding of factor Va.294 
 
Figure 10. Intracellular signalling cascate triggered by the interaction of HDL with the platelet receptors 
SR-B1 and ApoER2. SR-B1-mediated interaction prompts the activation of protein kinase C (PKC), which leads to 
cytoplasmic alkalization and inhibits activity of phosphatidylinositol specific phospholipase C (PI-PLC). ApoER2-
mediated interaction induces activation of nitric oxide synthase (NOS) and generation of nitric oxide (NO
•
), 
which subsequently stimulates the production of cyclic GMP (cGMP). ApoER2 may also induce a signalling 
cascade encompassing protein kinases MKK3/6 and mitogen activated protein kinase p38 (p38MAPK) as well as 
phospholipase A2 (PLA2), arachidonic acid (AA), and thromboxane A2 (TxA2). From Nofer et al 2010.
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1.3.2.6 Anti-apoptotic function of HDL 
In addition to the functions already described HDL also protects macrophages and 
endothelial cells from apoptosis215 and from the cytotoxic effects of numerous agents, such 
as oxLDL,295 chylomicron remants,296 TNF-297 and protein of complement system.298 
The most important intracellular mechanisms underlying the anti-apoptotic actions of HDL 
include: (i) cellular efflux of oxidized cholesterol, mainly of 7-ketocholesterol, mediated by 
ABCG1;299 (ii) decreased intracellular generation of ROS,297 suggesting that cytoprotection 
can be related to the intracellular anti-oxidant properties of HDL; (iii) preservation of 
mitochondrial integrity resulting in the inhibition of release of cytochrome c and apotosis-
inducing factor from mitochondria followed by the abrogation of caspase cascade 
activation;215 (iv) stimulation of NO• synthesis by HDL via interaction with SR-BI and 
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stimulation of Akt pathway in a PI3K-dependent manner,255 which is essential for the 
vasodilatory effect of HDL and (v) stimulation of endothelial cell migration by induction of 
intracellular signalling via S1P receptors.300 
1.3.2.7 Other functions of HDL 
Furthermore, HDL also has mitogenic activity301 and can potentiate the beneficial effects 
of growth factor (EGFR, PDGF, EGF, IGF). HDL induced proliferation of SMCs can strengthen 
the fibrous cap of the atherosclerotic plaque and improve plaque stability. 
The cytoprotective capacity of HDL is not limited to arterial wall cells and appears to 
represent a broad physiologic phenomenon. HDL modulates the survival of both human and 
murine β-cells in isolated islets by decreasing basal as well as IL-1β and glucose-induced 
apoptosis.302 This study shown that inducible NOS (iNOS), which mediates the pro-apoptotic 
effects of glucose and cytokines and the death receptor Fas is down-regulated by HDL. 
Recent data, suggest that low HDL-C may play a causative role in the development of 
insulin resistance.303 It has been shown that HDL may improve glucose metabolism by 
multiple mechanisms which include enhanced insulin secretion by -cells as a result of 
improved cellular cholesterol homeostasis (Figure 11).303-305 
 
Figure 11. HDL and glucose homeostasis. HDL might regulate the insulin secretion (1), increasing glucose 
uptake into skeletal muscle (and presumably other peripheral tissues) through non-insulin-dependent 
mechanisms (for example by AMPK phosphorylation and activation) (2) and increasing peripheral insulin 
sensitivity via HDL anti-inflammatory actions within the tissues themselves (for example, adipose tissue, 
muscle, liver) (3) and macrophages (4). The actions of HDL in metabolic tissues and macrophages might result 
from direct signalling events and via lipid removal through reverse cholesterol transport, with subsequent 
improvement of inflammation. From Drew et al, 2012.
306 
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Indeed, infusions of rHDL particles reduced plasma glucose, increased insulin secretion 
and improves the homeostatic model assessment (HOMA) index compared with placebo.307 
Based on this study and on cell culture experiments (skeletal muscle cells), those authors 
suggested the infusions of rHDL increases skeletal muscle glucose uptake via activation of 
AMPK pathway, this effect involves the binding of ABCA1, maintenance of cholesterol 
homeostasis in pancreatic -cells and stimulation of insulin secretion.305,307 
The beneficial effect of HDL and ApoA-I on glucose metabolism and insulin resistant 
states are not limited to their actions on -cells, skeletal muscle cells and monocyte but may 
be also target adipocyte. Thus, both over-expression of ApoA-I and treatment with ApoA-I 
mimetic peptide D-4F, reduces white fat mass, improve insulin resistance and diabetes in 
mice who develop obesity upon feeding on a high fat diet.308 HDL-induced 5' AMP-activated 
protein kinase (AMPK) activation in adipose tissue may led to the inhibition of fatty acid 
lipolysis and oxidation as observed in patients with type 2 diabetes infused with rHDL.309 
 
1.3.3 Functionally defective HDL 
HDL particles progressively lose their normal biological functions and acquire altered 
properties as a result of modification in HDL composition, structure and metabolism that 
occur in the context of high cardiovascular risk.310 Such altered HDL particles have been 
termed “dysfunctional HDL”,311 and HDL has been proposed to possess “chameleon-like 
properties” (Figure 12).216,312,313 
Compared with normal fully functional HDL, the composition of both the protein and 
lipid components of HDL can be modified in metabolic conditions associated with 
accelerated atherogenesis and enhanced cardiovascular risk. In such diseases states, HDLs 
become depleted in ApoA-I, CE, PON1 and LCAT and enriched in ApoE, ApoC-I, ApoC-III, free 
cholesterol, free fatty acids, lysophosphatidylcholine, isoprostanes, sphingolipids, TG, 
complement C3, C9 and SAA, during the acute phase, displaying covalent modifications as a 
result of oxidation and/or glycation (Figure 12).310,314 
The diminution in HDL ApoA-I levels in inflammatory states is associated to both 
decreased hepatic ApoA-I synthesis and to its replacement in HDL particles by SAA, which 
may become the major HDL apolipoprotein during the acute phase.312,314 
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In addition, ApoA-I can undergo other modifications in the circulation, it aa residues like 
tyrosine, metionine, cysteine and lysine can be selectively modified under the action of pro-
oxidants secreted by arterial cells.315-318 
 
Figure 12. Proposed model for generating dysfunctional HDL. From Otocka-Kmiecik et al, 2012.
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MPO is an enzyme released during degranulation of neutrophils and monocytes, that 
uses hydrogen peroxide to generate chlorinating and nitrating oxidants which play an 
essential role in killing microorganisms. However, these reactive species can also modify 
host proteins and lipids. MPO is a major source of chlorinating and nitrating oxidants in the 
arterial wall and is enriched in human atheroma.320 It has been shown to alter the function 
of HDL, in particular binds to ApoA-I in vitro and in vivo and produces similar patterns of 
oxidized aa residues.315,320,321 In fact, the modified ApoA-I are unable to interact with the 
ABCA1 which also leads to impairment of other functions such as the ability to bind lipids.315 
Such modifications of ApoA-I display altered immune properties an can be quantitatively 
detected by specific antibodies.322,323 Besides, ApoA-I oxidation may lead to its 
fragmentation, as well as oligomerization, as take place in aging.324 
In addition to the oxidative modification, ApoA-I can be non-enzymatically glycated 
under conditions of chronic hyperglycemia, as in diabetic patients325 or in aged patients.326 
Non-enzymatic glycation of proteins is a post-translational modification produced by a 
reaction between reducing sugars and amino groups located in lysine and arginine residues 
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or in the N-terminal position. Highly reactive glucose-derived dicarbonyl compounds, such as 
methylglyoxal, may account for the formation of glycated ApoA-I.327 Glycation ApoA-I may 
result in severe structural changes associated with lower binding affinity to phospholipid, 
building discoid HDL with decreased -helical content.328 Furthermore, it may adversely 
affect RCT due loss of ApoA-I ability to activate LCAT,183 and also the anti-inflammatory 
properties via a reduced capacity to inhibit NF-κB activation and ROS formation.327,329 
HDL-associated enzymes, including PAFAH, PON1, and LCAT can become dysfunctional 
and/or depleted under inflammatory conditions,227,330-332 in metabolic diseases involving low 
HDL levels (type 2 diabetes, metabolic syndrome).333,334 
During the acute phase response there is a reduction of PON1 activity, probably as result 
of displacement and replacement of PON1 by SAA.335 Moreover decreased PON1 activity 
may be caused by enzyme inactivation as a consequence of oxidation,336-340 glycation341,342 
and /or homocysteinylation.343,344 
The activity of both HDL-associated enzymes LCAT and PAF-AH may be also diminished 
under conditions such as dyslipidemia, insulin resistance, inflammation, infection and 
autoimmune disease.345-349 
Even though apolipoproteins and enzymes are the most important determinants of 
altered HDL function, it may considerably be influenced by changes in HDL lipid composition. 
Enrichment in TG with depletion of CE in HDL core is the most frequent abnormality of HDL 
lipid composition.314,346,350 Furthermore, the acute-phase HDL also contain high levels of 
nonesterified fatty acids, lysophosphatidylcholines and isoprostanes compared with normal 
HDL.314 Also HDL lipids can also suffers modification and being oxidized in vivo with 
formation of biologically active compounds. 
Even HDL formation itself may be also modified since it occurs a reduction of hepatic 
production of ApoA-I and defective ApoA-I lipidation upon interaction with ABCA1. Thus the 
defective formation of large HDL increases renal clearance of ApoA-I and subnormal HDL-C 
levels, and can also be caused by diminished cholesterol esterification by LCAT. 
All of the previously described anti-atherogenic properties of HDL, such as cholesterol 
efflux capacity, anti-oxidant, anti-inflammatory, vasodilatory, antithrombotic and 
cytoprotective activity can become impaired under conditions favouring the accelerated 
atherogenesis and enhanced CVD risk. 
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The degree of loss of normal HDL function (i.e., defective function) compared with the 
absence of this function (i.e., dysfunction) depends on the assay used to characterize HDL 
functionality. In fact, HDL can be dysfunctional (complete loss of the capacity of HDL to 
perform normal anti-atherogenic function) in cell-based or cell-free assays aimed at 
measuring anti-inflammatory activity311,351 and vasodilatory funtions.352 In contrast, 
measurements of antioxidative activity330-334 or cholesterol efflux capacity346,353 demonstrate 
a diminished levels of the HDL normal anti-atherogenic functionality rather than a complete 
dysfunction. 
 
1.3.4 Epidemiology of cardiovascular risk in relation to low HDL-C  
The Framingham Heart Study conclusively demonstrated that low HDL-C is a risk factor 
for CAD independently of LDL-C (Figure 13): at any level of LDL-C, a decrease in HDL-C 
increases the risk of CAD . 354 
 
Figure 13. Coronary artery disease (CAD) risk predicted by high density lipoprotein cholesterol (HDL-C) 
and low density lipoprotein cholesterol (LDL-C) in the Framingham Heart Study. Modified from Gordon et al, 
1977.
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Subsequent studies of large populations provide even more evidence to support the role 
of low HDL-C as a CVD risk factor. Thus, simultaneous analysis of four American prospective 
studies (Framingham Heart Study, Lipid Research Clinics Prevalence Mortality Follow-Up 
Study, Coronary Primary Prevention Trial Placebo Group and Multiple Risk Factor 
Intervention Trial) has indicated that a 1 mg/dL increase in HDL-C was associated with a 
significant reduction in CAD risk of 2% in men and of 3% in women.355 
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Plasma HDL-C levels were also found to be an important predictor of event rates in 
clinical trials using statins.356,357 Although the evidence for the utility of HDL-C as a risk 
marker in patients treated with lipid-altering therapy has been conflicting depending on the 
extent of covariate adjustments. 
Large multivariable analyses using the Systematic Coronary Risk Evaluation (SCORE) 
dataset containing HDL-C levels of 104961 individuals (45% women) without pre-existing 
CHD from 7 pooled European prospective studies, confirmed the inverse, independent, 
strong and graded relationship between HDL-C and both CVD and CHD mortality.358 
Of 58 prospective studies that providing multivariate assessments of the associations 
between low HDL-C and cardiovascular risk, 31 found a significant inverse association for all 
cardiovascular outcomes and subpopulations studied, whereas 17 found a significant 
association for some cardiovascular outcomes and/or subpopulations assessed.359 Another 
large-scale epidemiologic study in which HDL-C was evaluated as a risk marker on 302430 
individuals without initial vascular disease, from 68 long-term prospective studies, mostly in 
Europe and North America confirmed in multivariate models adjusted for both nonlipid and 
lipid (TG and non-HDL-C) risk factors that HDL-C was inversely associated with CHD events. 
For every 15 mg/dL increase in HDL-C concentration, the risk of a CHD event was reduced by 
22% (95% CI, 18%–26%).360 
These data leave no doubt regarding the role of low HDL-C as major cardiovascular risk 
factor. Thus, HDL-C has become an important component of algorithms to assess the global 
cardiovascular risk of patients such as the Framingham risk prediction tool, the PROCAM 
score and the SCORE approach.361,362 Furthermore HDL is also a target for therapeutic 
intervention and for the definition of treatment goals. 
 
1.3.5 Pharmacologic modulation of HDL-C 
Lipid management guidelines are still focused on decreasing LDL-C levels using statins, 
which inhibit HMG-CoA reductase (a key enzyme in cholesterol biosynthesis), as the primary 
target for reducing CHD risk. However, despite the generalized use of statins aggressive 
LDL-C lowering resulted only in a reduction of 30% to 40% of the clinical events and high 
residual cardiovascular risk (approximately 60-70%) continue to persist (Figure 14).78,363-365 
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Therefore, to further reduce atherosclerotic cardiovascular events, increasing attention is 
now focused on HDL as a potential target for atherosclerosis management. 
 
Figure 14. Residual cardiovascular risk despite statin treatment. 4S=Scandinavian Simvastatin Survival 
Study; HPS=Heart Protection Study; CARE=Cholesterol and Recurrent Events; WOSCOPS=West of Scotland 
Coronary Prevention Study; LIPID=Long-termIntervention with Pravastatin in Ischemic Disease; 
PROSPER=Prospective Study of Pravastatin in Elderly at Risk; CARDS=Collaborative Atorvastatin Diabetes Study; 
ASCOT=Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-lowering Arm; AFCAPS=Air Force/Texas Coronary 
Atherosclerosis Prevention Study; JUPITER=Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin. Fom Chapman et al, 2010.
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1.3.5.1 Current available therapies for increasing HDL-C concentrations 
The current pharmacologic options available for raising HDL-C levees include statins, 
fibrates and niacin. 
1.3.5.1.1 Statins 
Statins are competitive antagonist of HMG-CoA reductase, the enzyme that catalyzes 
the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol 
biosynthesis. Statins, therefore by competing directly with the endogenous substrate for the 
active site of the enzyme effectively reduce serum cholesterol levels. In addition they reduce 
serum cholesterol levels by upregulating hepatic receptor-mediated LDL-C clearance. 
The major effect of statin is to effectively diminish plasma levels of ApoB-containing 
lipoproteins, principally LDL (20-60%) (Figure 15), but also IDL, VLDL and quilomicrons. The 
lowering of intracellular cholesterol levels leads to the activation of SREBP transcription 
factors, which activate the transcription of a number of genes involved in the clearance of 
LDL particles from plasma, such as the LDL receptor.367 Statins also lower plasma TG due to a 
diminished VLDL production, probably as a consequence of less availability of cholesterol for 
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VLDL and quilomicrons assembly.368,369 In addition, they may lower TG due to a strong 
induction of receptor-mediated remnant clearance. 
 
Figure 15. Percentage reductions in serum LDL cholesterol levels according to statin and daily dose. 
Summary estimates from 164 randomised placebo controlled trials. Adapted from Law et al, 2003.
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Statins only modestly raise HDL-C levels (by 3% to 15%) 199, 371-373. Individual statin are 
not identical in their potency to increase HDL-C (Figure 16) with rosuvastatin an pitavastatin 
being the most potent compounds.199 
 
Figure 16. Effect of each statin on HDL-C levels. From Yamashita et al 2010.
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The differential effects of individual statins on HDL are further highlighted by the finding 
that increases in HDL-C is positively related to statin dose with rosuvastatin and simvastatin 
but inversely related to dose with atorvastatin, at least within the dose range of 20 to 
80 mg/day.373-375 
It has been difficult to clinically dissociate the benefits of the increased HDL-C from 
LDL-C lowering since the studies were designed to address LDL-C as the principal mechanism 
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of action of the statins. However the effects of statins on HDL-C levels may be attributed in 
part to inhibition of Rho-signalling pathways with activation of PPAR-α and consequent 
stimulation of ApoA-I production (Figure 17).372,376 Statins also reduced circulating levels of 
CETP, and also importantly the rate of CETP-mediated CE transfer from HDL to VLDL 
secondary to reduction in the latter.377,378 Statins, however, are not known to be direct 
inhibitors of CETP. 
 
Figure 17. Mechanism of up-regulation of ApoA-I production by statins and effect on ABCA1. From 
Yamashita et al 2010.
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Importantly, statins exert multiple pleiotropic effects, as they inhibit the prenylation of 
proteins, such as Ras and Rho that activate the MAPK cascade or NF-κB pathway, that 
include anti-inflammatory, antiproliferative and antithrombotic effects (Figure 18) (For 
review see379). 
Furthermore, statins seems to improve anti-oxidant actions of HDL by increasing the 
activity of HDL-associated enzymes as demonstrated for PON1. The increased PON1 activity 
was clinically confirmed with the administration of fluvastatin,380 simvastatin,381,382 
atorvastatin383,384 and rosuvastatin.385 Statin effect on PON1 activity seems to be 
independent of HDL elevation. 
In vitro studies showed that pitavastatin induces PON1 expression through the 
activation of the p44/42 MAPK signalling cascade in hepatoma cells, suggesting a beneficial 
effect on HDL funcionality.386 
Previously , Deakin et al382 observed that simvastatin was able to modulate in vitro the 
expression of PON1 regulated by SREBP-2 and increase serum PON1 concentration and 
activity in human hepatic HepG2 cells. 
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Statins are generally well tolerated;  the most common adverse effects involve muscle 
problems such as myophathy and/or myositis with potential for rhabdomyolysis, raised liver 
enzymes (alanine transaminase ALT and aspartate transaminase AST), central nervous 
system effects, and the appearance of diabetes.387 
 
Figure 18. Cholesterol biosynthetic pathway. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase by statins decreases the synthesis of isoprenoids and cholesterol. PP pyrophosphate; BMP-2: 
bone morphogenetic protein-2; eNOS: endothelial nitric oxide synthase; t-PA: tissuetype plasminogen 
activator; ET-1: endothelin-1; PAI-1: plasminogen activator inhibitor-1. From Liao et al, 2005.
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1.3.5.1.2 Fibrates 
The fibrates are  effective agents for managing dyslipidemia in particular elevated 
concentrations of TG-rich lipoproteins and low levels of HDL-C  typically associated  type 2 
diabetes and the metabolic syndrome.388 
Fibrates are PPARα agonists of moderate affinity that exert multiple effects on lipid and 
fatty acid metbolism.389 
Fibrates bind to PPARα expressed in hepatocytes, endothelial and smooth muscle cells, 
monocytes, macrophages and the heart, and heterodimerizes with the RXR. The 
heterodimer PPARα/RXR binds to peroxisome proliferator response elements in the 
promoter regions of specific genes, activating the expression of these genes and thereby 
increasing protein expression (Figure 19).390 Activation of PPAR by fibrates mediates 
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several effects such as the modulation of lipoprotein metabolism, coagulation, haemostasis 
and attenuation of inflammation.391 
The primary effect of fibrates on plasma lipoprotein lipids involves a 30–50% reduction 
in TG levels and in general increase levels of HDL-C by 5–15%, depending on lipid phenotype 
and baseline concentration.388,392 Fibrates may also reduce LDL-C potentially by up to 
15-20% although the effect is variable, depending on the fibrate in question and on baseline 
lipid profile.388,393 
 
Figure 19. Mechanism of action of fibrates. From Chapmam 2006.
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Fibrates decrease circulating TG levels by increasing catabolism of VLDL (and 
chylomicrons) via induction of LPL and ApoA-V expression, and simultaneously, LPL action is 
potentiated due to attenuated hepatic ApoC-III expression, a well-known inhibitor of LPL. In 
addition they stimulate cellular fatty acid uptake and transformation to acyl-CoA derivatives, 
and by raising peroxisomal and mitochondrial β-oxidation, thereby leading to attenuated 
synthesis of fatty acids and TGs that results in a decrease in VLDL production.390 
Fibrates increase HDL independently of TG reduction by direct up-regulation of the 
transcription of APOA1 and APOA2 genes, leading to increased synthesis of ApoA-I and 
ApoA-II, thereby enhancing the formation of new HDL particles.394 
Another main aspect of the action of fibrates on HDL metabolism involves enhanced 
expression of ABCA1, a major regulator of HDL biogenesis in hepatocytes, and known to be 
up-regulated by the transcription factor liver X receptor (LXR), especially LXRα, which 
expression is further enhanced by activation of the PPARs.395 
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Studies in primary hepatocytes from mice have shown a down-regulation of hepatic 
SR-BI protein levels on treatment with fibrates.396 Down-regulation of this receptor in the 
liver leads to decreased HDL clearance and would provide another mechanism by which 
fibrates could increase plasma HDL levels. 
Interestingly the indirect inhibitory action of PPARα agonists on plasma CETP activity as 
resulted of reduced TG levels, can be, partly counteracted by enhanced CETP expression, as 
showed by effect of fenofibrate in increasing CETP mRNA, protein and activity in human 
CETP transgenic animal model.397 Consistent with this result, fenofibrate increases 
circulating CETP levels in dyslipidemic humans.398 
In addition, fibrates increased PON1 concentration and activity399 and are involved in 
the redistribution of PAF-AH from ApoB containing lipoproteins to HDL in dyslipidemia 
patients, thereby lowering the pro-inflammatory potential of the enzyme.400,401 
Despite such significant anti-atherogenic actions, clinical trials of cardiovascular risk 
reduction by fibrates have provide mixed results, some revealed beneficial effects (Helsinki 
Heart Study, VA-HIT and WHO trial),402 whereas in contrast others (BIP and FIELD trial) are 
controversial.402,403 
Disappointingly, HDL-C increase by fibrates is markedly attenuated by type 2 diabetes 
and typically does not exceed 5% .366,403 The relatively weak HDL-C-raising effect of fibrates 
in this group of patients may, in part, reflect the increase of atherogenic Hcy plasma levees 
and thus down-regulating hepatic synthesis of ApoA-I.404 In the FIELD trial PPAR agonists 
thus increase plasma Hcy levels and this were negatively correlated with increases in HDL-C 
and ApoA-I, but positively correlated with elevation in ApoA-II levels.403,404 In fact, PPAR 
agonists that have more robust effect on HDL-C and ApoA-I and do not raise Hcy would 
therefore be desirable. 
PPARα agonists can also attenuate the production of pro-inflammatory stimuli such as 
TNFα, interferon gamma (IFN-γ), IL-6 and IL-1, as well as the acute phase proteins, including 
fibrinogen and CRP.405 PPARα activation decrease the expression of adhesion molecules to 
the endothelium, due to the reduction cytokine-induced VCAM-1 expression, leading to 
decreased leukocyte recruitment into the arterial wall.406 Furthermore PPAR  activators 
inhibit thrombin-induced endothelin-1 production and consequently decreases the 
proliferation of smooth muscle cells.407 
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In general, fibrate therapy is well tolerated, but may induce  hyperhomocysteinemia 
with concomitant increase of the creatinine levels, a marker of renal dysfunction.408,409 
Association of some fibrates with statin may produce a increase in the risk of myopathy and 
rhabdomyolysis, due to interferes with statin glucuronidation that could lead to elevation in 
statin plasma concentrations.410-412 
1.3.5.1.3 Niacin 
Niacin (nicotinic acid), vitamin of the complex B3, has been used as a pharmacologic 
agent to regulate abnormalities in plasma lipid and lipoprotein metabolism since 1955.413 
Niacin is presently the most effective commercial available lipid-regulating agent to increase 
HDL-C levels. The HDL-C raising effect of niacin may reach to 35% of increase at a 2g/day 
dose, as well as substantially lowering TGs (20-40%), LDL-C (15-30%) and  lipoprotein(a) 
(Lp(a)) (15-35%).414-416 
The primary action of niacin is to transiently suppress the TG lipolysis in adipose 
tissue.417,418 Nicotinic acid has been identified as a ligand for the human G-protein-coupled 
receptors GPR109A and GPR109B that signal through Gi-mediated inhibition of adenylyl 
cyclase (AC), resulting in a decrease in intracellular cyclic adenosine monophosphate (cAMP) 
levels.419 This cyclic nucleotide is the principal mediator of adipocyte lipolysis (Figure 20) 
Lipolysis is increased when cAMP levels are elevated due to increased AC activity, for 
example, by -adrenergic receptor activation or by decreased phosphodiesterase-mediated 
cAMP degradation.420 Thus, the nicotinic acid-induced, GPR109A-mediated AC inhibition 
suppressing the prolipolytic effects of elevated intracellular cAMP levels and stimulation of 
protein kinase A (PKA), which phosphorylates a number of proteins, most notably hormone-
sensitive lipase (HSL), which are required for TG hydrolysis.416 
Another important lipase in this process is the adipose triacylglycerol lipase (ATGL), 
which hydrolyzes the TGs into FFA and glycerol. Thus, the antilipolytic action of nicotinic acid 
is likely mediated by activation of the Gi-coupled nicotinic acid receptor, impeding the 
cAMP/PKA signalling cascade thereby decreasing lipolysis and the subsequent release of FFA 
into the circulation. The flux of FFA to the liver constitutes the main substrate for hepatic TG 
synthesis, such TG may be either integrated into nascent VLDL particles and secreted into 
the circulation, or may alternatively be stored in the form of intracellular lipid droplets in the 
hepatocyte. Furthermore niacin inhibit the diacylglycerol acyltransferase 2, a key enzyme of 
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TG synthesis in human hepatocytes.421 The inhibition of TG synthesis by niacin potentially 
results in the accelerated intracellular hepatic degradation of ApoB and subsequent 
decreased secretion of VLDL/LDL particles. 
 
Figure 20. Mechanisms of nicotinic acid-induced changes in lipolysis of triacylglycerol (TG) on adipocytes 
and reduction hepatic very low density lipoprotein (VLDL) production. ATGL, adipocyte-triacylglycerol-lipase; 
CETP, cholesterol ester transfer protein; FFA, free fatty acid; HSL, hormone-sensitive lipase; PKA, protein kinase 
A; TG, triacylglycerol; AC, adenylyl cyclase; -AR, -adrenergic receptor. From Gille et al, 2008.
422 
The mechanism of the nicotinic acid–mediated increase in HDL-C levels is less clear. 
Most likely, the decrease in TG levels in ApoB-containing lipoproteins (LDL/VLDL) results in a 
decreased exchange between CE carried by HDL particles and TG in VLDL and LDL particles 
via CETP, resulting in an increase in HDL-C plasma concentrations. In parallel niacin may also 
promotes hepatic ApoA-I production and slows hepatic clearance of ApoA-I.422,424 
Furthermore, another potential mechanism of niacin raising HDL-C involves the 
induction of cholesterol efflux via ABCA1 and ABCG1 from peripheral cells to HDL acceptors. 
In fact, niacin enhances transcription of ABC transporters via nuclear PPAR-dependent 
pathway425 and may promote cholesterol efflux from adipocytes to ApoA-I via ABCA1 
mediated by LXR- dependent mechanism.426 
There is emerging interest in several potentially beneficial non-lipid mediated effects of 
niacin e.g. anti-inflammatory, anti-oxidant, antithrombotic and cytoprotective effects. 
Niacin administration has been shown to inhibit TNF-α induced inflammatory response 
in cultured human endothelial cell by decreasing NF-B activation, VCAM-1 and ICAM-1 
expression and MCP-1 secretion.427-429 
Furthermore, niacin also decreases CRP levels,430 improves endothelial 
dysfunction,431,432 improves the endothelial and leukocyte redox state in vitro, which 
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protected against ROS-induced endothelial dysfunction,427,433 enhances plaque stability and 
reduces thrombosis.434 
Niacin increases adiponectin, an adipokine with insulin sensitizing, anti-atherogenic, and 
anti-inflammatory properties.435-437 
Recently, it has been reported that niacin inhibits vascular inflammation via mechanisms 
independent of its lipid-modifying effects.433,437 Therefore in addition to its lipid modulation 
role these athero-protective qualities seem contribute to the improved cardiovascular 
outcomes demonstrated in patients treated with niacin. 
However, the therapeutic potential of niacin has been limited by its adverse effects; 
cutaneous flushing phenomenon that occurs in 70–80% of the patients.  
Niacin has also been criticized for dysregulation of glycaemia control,438,439 elevation of 
liver enzymes440 and uric acid level441. 
 
1.3.5.2 Emerging therapies for reducing CVD risk via HDL 
The magnitude of the HDL-C elevations achieved by either lifestyle or any of the 
currently available pharmacologic options is small relative to the LDL-C reductions achieved 
by statins and the high residual cardiovascular risk (approximately 60-70%) continue to 
persist. Therefore, development and testing of new therapies that exploit the vascular 
protective effects of HDL constitutes a rational and complementary approach. 
In recent years, a number of promising HDL-based therapies have emerged from 
intensive research (Figure 21). 
 
Figure 21. Emerging HDL-based therapies. From Shah 2007.
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This has led to several new drugs that are currently in various stages of development 
and testing (Phase I–III clinical trials). It is hoped that one or more of these new HDL-based 
therapies, if proven effective and safe, will become a part of the therapeutic option for 
management of dyslipidemia and against cardiovascular disease. These therapeutic 
approaches to raise HDL-C levels can target one or more of several mechanisms involved in 
HDL metabolism, including the production of ApoA-I or modification of intravascular 
remodelling of HDL particles. 
For the purpose of this work I have included only the ones that consist in the 
administration of HDL components as they may have a direct association with the 
production of antibodies towards HDL complex. 
1.3.5.2.1 Apo A-I/Reconstituted HDL (rHDL) Infusions 
Despite intensive research, small molecules that could increasing endogenous ApoA-I 
expression without the multiple side effects of the above-mentioned substances remain 
elusive, an alternate strategy has been to directly infuse ApoA-I or rHDL into the circulation 
that might act as cholesterol acceptors. 
ApoA-I Milano has been known for years to be a variant of the ApoA-I protein backbone 
of HDL particles that enhances the ability of to transport cholesterol out of the body. People 
from a small village in Italy who have this genetic variant have lower CHD events and longer. 
Recombinant form of ApoA-I Milano in a phospholipid complex (ETC-216) is being developed 
as an infusion product. 
Infusions of wild-type ApoA-I/HDL and ApoA-I Milano were tested in animal models and 
were associated with attenuation, and even regression, of atherosclerosis in rabbit 
models.443-446 
This effect has also been demonstrated in humans as shown in Table 4 which 
summarizes the clinical evidence of infusion of Apo-AI Milano and wild-type Apo-AI 
remarkable decrease of atheromatous burden.239,447-449 
Besides this effect on acute plaque regression the ApoA-I/HDL infusions seems to exerts 
anti-inflammatory effects.239,446 
Bringing this compound to clinical practice will require further large trials that evaluate 
its impact on cardiovascular events. However, due to its complexity the protein is difficult 
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and very expensive to produce and its use via the intravenous route limits its trial application 
compared to oral medication. 
Table 4. Clinical evidence for ApoA-I/ HDL infusion. Adapted fom Redondo et al, 2011.450 
Study Patients Administration Results 
Nissen et 
al, 2003
447
 
123 post-acute coronary events 
(randomized) 
Intravenous 
ApoA-I Milano 
4.2% decrease of atheromatous 
plaque volume (measured by 
ultrasound) 
Nicholls 
et al, 
2006
448
 
47 post-acute coronary events 
(randomized) 
Intravenous 
ApoA-I Milano 
4.6% decrease of internal elastic 
lamin (measured by ultrasound) 
Tardif et 
al, 2007
449
 
183 patients on coronariography 
(randomized) 
Intravenous 
reconstituted 
wild-type HDL 
3.4% decrease of plaque volume 
(measured by ultrasound) at follow 
up (not difference at baseline) 
Shaw et 
al, 2008
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20 patients with claudication who 
underwent femoral 
endarterectomy (randomized) 
Intravenous 
reconstituted 
wild-type HDL 
Decreased expression of vascular 
cell adhesion molecule-1 and 
decreased lipid content 
 
1.3.5.2.2 Synthetic Apo A-I mimetic peptides 
ApoA-I mimetic peptides are short synthetic amphipathic peptides of 18–22 aa, which 
mimic the lipid-binding domain of ApoA-I and retain functional properties of ApoA-I, such as 
the ability to form complexes with lipids, promote cell cholesterol efflux, and activate 
LCAT.451,452 They have the advantage of being relatively easy and cheap to synthesize 
compared with the full-length ApoA-I  
The most promising ApoA-I mimetic peptide seem to be D4F, an orally active peptide 
with D-amino acids (which are resistant to gastric hydrolysis unlike L-amino acids) and 4 
phenylalanine substitutions, has been shown to enhance the anti-oxidant and 
anti-inflammatory function of HDL and improve its cholesterol efflux ability without 
increasing plasma HDL-C levels in mouse models.453 
The D4F peptide is also the only apolipoprotein mimetic peptide reported so far to 
undergo testing in human subjects. In a Phase I study of 50 patients with coronary heart 
disease received a single a single dose of 30, 100, 300, or 500 mg of unformulated D-4F. Even 
though no apparent toxicity was observed from this trial, there has been apprehension 
about whether long term use of D4F.454 
Therefore the early optimism regarding the therapeutic potential of these mimetic 
peptides has been attenuated by the inability of any of these peptides to move to an 
advanced stage of clinical development. 
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An alternative therapeutic option may be to turn on endogenous ApoA-I synthesis. Such 
an approach would generate nascent HDL particles, which should carry out normal 
physiological functions. Nevertheless, the capacity to identify agents that selectively increase 
ApoA-I synthesis has proven to be a major challenge. 
RVX-208 is a first-in-class, orally active, small-molecule that acts via an epigenetic 
mechanism leading to enhanced activity of the APOAI gene resulting in upregulation hepatic 
expression of ApoA-I and to increase systemic cholesterol efflux capacity in in vitro and in 
vivo models and in phase I/II clinical trials.455-457 
Currently there is great expectation for the results of two Phase IIb trials with this 
ApoA-I stimulator the SUSTAIN (the Study of Quantitative Serial Trends in Lipids with 
Apolipoprotein A-I Stimulation) study that aims to evaluate the lipid efficacy, safety and 
tolerability of RVX-208, and the ASSURE (the ApoA-I Synthesis Stimulation and Intravascular 
Ultrasound for Coronary Atheroma Regression Evaluation) study that aims to evaluate the 
effect of RVX-208 on plaque burden.458 
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1.4 Immunity in Atherogenesis 
1.4.1 Overview 
Once considered a feature of the long and relentless aging process, atherosclerosis is 
regarded now as a chronic inflammatory and auto-immune disease in which all branches of 
the immune system are involved at each stage of the atherosclerotic process. 54-56 
Some of the most remarkable data in support of a link between immune response and 
atherosclerosis came from epidemiologic studies of patients with auto-immune diseases. 
Patients with rheumatoid arthritis (RA) have a 2- to 5-fold increase in cardiovascular 
morbidity and mortality,459 and patients with SLE have a 9 to 50-fold risk of developing 
atherosclerotic CHD than the normal population.460 Interestingly, patients with SLE, RA and 
other inflammatory syndromes share several auto-immune phenomena with atherosclerotic 
patients, such as immune dysfunction, inflammation and endothelial activation as a 
consequence of chronic therapies.461-463 
The study of immunity in atherogenesis was boosted with the creation of animal models 
of atherosclerosis. Hypercholesterolaemic mice deficient in specific components of the 
innate and adaptive immunity show that the net effect of both systems is pro-
atherogenic.464-466 These findings may explain why atherosclerosis has such a major impact 
in systemic auto-immune diseases as they are characterized by a dysregulated and 
hyperactive immune system. However, immune activation and hyperesponse can still be a 
major player in atherogenesis event outside the context of auto-immune diseases. 
Therefore, these particular diseases might constitute a logical model for the study of the 
complex mechanisms of atherogenesis. 
1.4.2 General innate immune response 
The innate immune system is the first line of defence against bacteria, viruses, and 
substances that appear foreign and harmful. Innate immunity is mediated by leucocytes, 
mast cells, natural killer (NK) cells and antigen presenting cells (APCs), such as macrophages 
and DCs. 
Inflammation in physiological conditions is a self-limiting ancient protective mechanism 
that defends the host from invading pathogens. However it has become apparent that the 
innate arm of the immune inflammatory response does not involve only specific responses 
and phagocytosis. It relies on a set of pattern-recognition receptors (PRRs) that include 
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scavenger receptors (SRs) and TLRs that are able to sense highly conserved pathogen 
associated molecular patterns (PAMPs) and endogenous products of tissue injury and 
inflammation, with a greater degree of specificity than previously believed and has the 
ability to discriminate self versus foreign pathogens.467,468 
TLRs expression is not constitutive and may be regulated by multiple factors including 
cell differentiation and the presence of their cognate ligands. Once activated, the TLR 
recruits adaptor proteins, being the myeloid differentiation factor 88 (MyD88) common to 
all TLR signalling pathways (with the exception of TLR3), that triggers the activation of pro-
inflammatory transcription factors (NF-kB, AP1, CREB, c/EBP, and IRF), resulting in 
stimulation of the expression of various inflammatory molecules, such as IL-6, TNF-α, and 
IL-1β, chemokines, proteases, free oxygen radicals, ecosanoids (leukotriene B4, LTB4) and 
costimulatory molecules. 
In the circulation, these pro-inflammatory mediators induced by SRs and TLRs 
stimulation may subsequently activate hepatic (low grade) acute phase responses. For 
instance, systemic IL-6 can induce expression of the acute phase proteins such as CRP and 
SAA, whose elevated levels are associated with increased cardiovascular risk.469 
Furthermore, recent evidence indicates that activation of the innate immunity is 
necessary to stimulate complete maturation of DCs and is essential to the induction of 
adaptive immune responses. 
TLR-induced DCs maturation is characterized functionally by increased potency of DCs as 
APCs which results from the upregulation of major histocompatibility complex (MHC) class II 
and costimulatory molecules (CD40, CD80, CD86), as well as by cytokine production which 
leads to an efficient T cell activation (Figure 22).470,471 
1.4.3 General adaptative immune response 
The adaptive immune response, evolved later than the innate immune response, is 
composed of specialized antigen-specific lymphocytes T and B cells that require presentation 
of antigens, costimulators and particular cytokines from innate immune cells to become 
activated. Adaptive responses occur following recognition of an antigen by T-cell receptors 
(TCRs) on T cells and B cell antigen receptor (BCRs) on B cells. Once the adaptive immune 
cells have been activated, memory cells will be generated to rapidly respond in case of a new 
infection by the same pathogen.472,473 
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Figure 22. Interaction between innate and adaptative immunity. Dendritic cell (DCs) maturation and 
consequent T cell activation. Activation of toll-like receptors (TLRs) by recognition of pathogen associated 
molecular patterns (PAMPs) in DCs results in the stimulation of the expression of various inflammatory 
cytokine and costimulatory molecules and upregulation of major histocompatibility complex (MHC) class II, 
which are all necessary for the DCs antigen presentation and efficient T cell activation. From Akira, 2009.
471
 
Adaptive immune responses are carried out by lymphocytes that mediate two types of 
response: a cellular immunity (cell-mediated immune responses) and a humoral immunity 
(antibody responses) that are carried out by T cells and B cells, respectively. 
T cells can be divided into subsets based on their cell surface antigens, i.e. into CD4+ T 
cells, also called T helper (Th) cells, regulatory T cells and cytotoxic CD8+ T cells. Both CD4+ 
and CD8+ T cells are activated by mature antigen presenting DCs, however CD8+ T cells are 
activated by peptide-antigens presented on MHC class I molecules and also requires 
costimulation via CD28 (on the T cell) and CD80 or CD86 (on the APC) and secretion of 
cytokines from CD4+ T cells.474 
CD4+ T cells are key players in orchestrating immune responses by differentiation into 
specific Th subtypes with distinct and adequate immune responses. In addition, Th cells 
participate in humoral immune responses, by “helping” B cell isotype switch, resulting in the 
generation of antigen specific antibody production. 
Once an antigen is recognized by the BCRs on B cells it transmits signals directly to the 
cell's interior and triggers a receptor-mediated endocytosis which allows the antigen to be 
processed and displayed as peptide fragments bound to MHC class II molecules at the B cell 
surface. B cell can then be recognized by antigen-specific armed Th cells, leading to the 
expression of the B cell stimulatory molecule CD40 ligand (CD40L) on the Th cell surface and 
to the secretion of the B cell stimulatory cytokines IL-4, IL-5, and IL-6, which drive the 
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proliferation and differentiation of the B cell into antibody-secreting plasma cells (plasma B 
cells) and memory B cells (Figure 23).475 
In addition to producing antibodies, B cells play an important role in T cell responses via 
antigen presentation476 and cytokine production.477 
 
Figure 23. T cell-dependent B cell activation. Once a B cell encounters its cognate antigen, the B cell 
receptor (BCR) delivers the antigen to intracellular sites where it is degraded and returned to the B-cell surface 
as peptides bound to MHC class II molecules. The peptide:MHC class II complex can be recognized by antigen-
specific armed helper T (Th) cells, leading them to make B cell stimulatory molecule CD40 ligand (CD40L) and 
cytokines such as IL-4 that cause the B cell to proliferate and differentiate into antibody-secreting plasma cells 
(plasma B cells) and memory B cells. Adapted from Avci et al, 2011.
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1.4.4 The immune response in atherogenesis 
1.4.4.1 Innate immune response in atherogenesis 
Activation of the innate immune mechanisms are implicated early in atherogenesis and 
in the inflammatory response.479 The most abundant cell types within the atherosclerotic 
plaque are innate immune cells, such monocytes-macrophages, DCs and endothelial cells 
that can express a large repertoire of SRs classes and TLRs types.467,480 These recognize and 
internalize a broad range of molecules and particles such as bacterial endotoxins, stress 
proteins, apoptotic cell fragments, DNA motifs, modified lipoprotein as oxLDL, HSP60 (Table 
5).481 Although other antigens may also be important, recent data suggests that major 
atherosclerosis-relevant antigens consist of neoepitopes generated as a consequence of 
oxidative reactions, as occur when oxLDL is formed or when cells undergo apoptosis.482 
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Table 5. Several ligands for the different pattern-recognition receptors (PRRs), scavenger receptors (SRs) 
and toll-like receptors (TLRs). From Hansson et al, 2002.
54
 
 
Intracellular cholesterol that accumulates after SRs –mediated uptake of modified LDL 
might activate cytoplasmic caspase-1-activating protein complexes (inflammasomes), being 
the most studied NLRP3, that promote maturation and secretion of the pro-inflammatory 
cytokines IL-1β and IL-18 (Figure 24).483 
TLRs also recognise modified LDL triggering the intracellular signalling cascade described 
previously that culminate with the expression of several pro-inflammatory molecules such as 
cytokines, chemokines, eicosanoids, proteinases, oxidases and costimulatory molecules 
(Figure 24). 
 
Figure 24. Activation of innate immune response in atherosclerotic lesion Uptake of modified LDL 
particles such as oxLDL through scavenger receptors (SRs) leads to the intracellular increase of cholesterol that 
can trigger the inflammasome, inducing the secretion of IL-1β. Toll-like receptors (TLRs) also recognise 
components of modified LDL, triggering an intracellular signaling cascade that leads to the expression of a 
series of genes encoding pro-inflammatory molecules, including cytokines, chemokines, eicosanoids, 
proteinases, oxidases and costimulatory molecules. From Hansson and Hermansson, 2011.
484
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In addition to stimulate complete maturation of DCs, activation of monocytes-
macrophages are also a crucial link between the innate and adaptive arms of the immune 
response either on presenting foreign antigen to T cells as by subsequently responding to 
cytokines produced by activated T cells, promoting inflammatory responses, stimulation of 
lesion progression, and increase the risk of plaque rupture.485 
1.4.4.2 Adaptative immune response in atherogenesis 
1.4.4.2.1 Cellular immunity 
Several studies have shown an accumulation of activated T lymphocytes in 
atherosclerotic plaques strongly suggesting that they influence disease progression.486-488 
APCs within the atherosclerotic plaque trigger a predominantly Th1 cell response 
characterized by secretion of IFN-γ489-491 which activates monocytes-macrophages, DCs, 
improves the efficiency of antigen production and promotes further Th1 polarizatin.484 
Furthermore, IFN-γ induces the expression of the SRs in macrophages increasing the oxLDL 
uptake, and inhibits the ABC transporters leading a defective cholesterol efflux, thus 
contributing to the formation of foam cells.492 In addition to IFN-γ activated monocytes-
macrophages and DCs produce others inflammatory cytokines such as IL-1, IL-12, IL-15, IL-18, 
and TNF-α and release proteases that reduce the stability of plaque by degrading the 
extracellular matrix and induce migration of SMCs from the media. These cells may also 
produce prothrombotic and procoagulant factors that directly precipitate the formation of 
thrombus at the site of plaque rupture (Figure 25 and Figure 26). 
The role of Th2 cells in atherogenesis is poorly understood and data are inconsistent 
depending on the stage and ⁄ or site of the lesion, as well as on the experimental model 
(Figure 26). The Th2 cytokine IL-4 has been reported to be pro-atherogenic493 or have no 
effect.494 On the other hand, IL-13 was reported to be atheroprotective,495as was IL-5.496 
The third distinct lineage of Th cells are the Th17, characterized by the production of the 
inflammatory cytokine IL-17,497 and several other pro-inflammatory cytokines (IL-22 and IL-
23) and are differentiated from activated naive T cells in the presence of TGF-β and pro-
inflammatory cytokines, such as IL-6. 
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Figure 25. Activation of T cells in atherosclerotic lesions. It is characterized by a type 1 helper T (Th1) 
effector cells response that secrete interferon-gamma (IFN-γ) which improves the efficiency of antigen 
presentation and stimulates synthesis of inflammatory cytokines. Various cytokines and mediators produced by 
macrophages and T lymphocytes reduce the stability of plaque and induce migration of SMCs from the media 
and their proliferation and extracellular matrix production. They may also increase prothrombotic and 
procoagulant factors that directly accelerate the formation of thrombus at the site of plaque rupture. From 
Andersson et al, 2010.
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Th17 cells are involved in the promotion of inflammatory auto-immune diseases.498 
Nevertheless the effects of Th17 cells or IL-17 in human atherosclerosis are inconsistent, 
likely reflecting poorly understood relationships between Th1 and Th17.499 Although 
accumulation of Th17 cells and IL-17 has been observed in murine500,501and human502,503 
atherosclerotic lesions, conflicting results with pro-503,504 and anti-atherogenic (Figure 
26).505,506 
The discrepancies in the data may be relate to the existence of IL-17–producing T cells 
that also produce IFN-γ,502,507 or to plasticity of Th17 cells, which can redifferentiate into Th1 
cells.508,509 
While overall T effector cells aggravate atherosclerosis, certain subsets of T cells within 
certain contexts can limit inflammation and counteract plaque complication. Regulatory T 
cells (Tregs), which actively maintain immunological tolerance to self and nonself antigens, 
are powerful inhibitors of atherogenic process by secreting anti-inflammatory cytokines such 
as IL-10, TGF-β, and IL-35 (Figure 25 and Figure 26).510 
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Figure 26. Naive T-cell differentiation into specific T helper (Th) substes involved in atherosclerosis and its 
complex interactions. From Ait-Oufella et al, 2009.
511  
The atheroprotective role for Tregs in animal models of atherosclerosis has been 
supported by studies in which Tregs depletion,511,513 ablation514 or genetic 
inactivation/blockade of Tregs, principal effector cytokines IL-10 and TGF-β510,515 
significantly, aggravates atherosclerosis. On the other hand injection or induction of the 
Tregs leads to diminished disease.511,516,517 
Recently, the importance of Tregs in atherosclerosis development was further showed 
by the Tregs-mediated suppression on monocytes-macrophages foam-cell formation though 
inhibiting the uptake of oxLDL.518 In addition Treg can also directly regulate endothelial cell 
activation and leukocyte recruitment, independent of their suppressive functions on effector 
T-cells.519 Moreover, prolonged hypercholesterolemia resulted in reduction of peripheral and 
plaque Treg numbers, increased Treg apoptosis and diminished Treg lesional infiltration, but 
reversal of hypercholesterolemia can restored Treg numbers and stopped lesion growth.520 
Nevertheless the human atherosclerotic lesions contain only limited Treg numbers (1–
5% of all T-cells) given the pro-inflammatory lesion microenvironment, the survival and 
maintenance of Treg cells would be compromised compared with pathogenic T cells 
suggesting that protection mediated by Treg is hampered in atherosclerosis. 
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1.4.4.2.2 Humoral immunity 
Despite the complexity of the interactions between the immune and vascular systems, 
most of the research so far has targeted the cellular aspects of the immune response. 
Nevertheless, the development of atherosclerosis is also associated with B cell activation 
suggesting that the humoral immune response might also play a relevant role in this process. 
B cells have been found in atherosclerotic lesions in mice521 and in humans.522 Moreover 
it has been shown that patients with atherosclerosis produce antibodies against many 
antigens, the best characterized are HSP and oxLDL. 
HSP are a group of more than 20 molecules categorized in five families according to 
molecular weight.523 They are present in all living organisms and represent one of the most 
conserved protein structures in evolution. HSP have a dual function: inside the cells they 
help in the assembling and translocation of newly formed proteins as well as in repairing or 
clearing proteins which have become unstable,524 and outside the cells they act as stress 
markers in order to allow the recognition of stressed cells by the immune system.525  
HSP have been widely associated with atherosclerosis. In the early 1990’s, anti-HSP65 
antibodies were associated with atherosclerosis.50 Later, this data would be confirmed in 
another prospective population-based survey which showed that the same type of 
antibodies was elevated in subjects with carotid atherosclerosis when compared to those 
without lesions.526 More recently, these results have been complemented with the finding of 
an association between the risk of development of premature atherosclerosis in young 
males and the level of reactivity of T lymphocytes to human HSP60.527 Eventually, clinical 
(cardiovascular) events would also be associated with the presence of these antibodies along 
with an already known presence of diffuse atherosclerosis.528 These findings have been 
thoroughly tested and confirmed in different animal models (e.g. the presence of anti-HSP 
antibodies in general and anti-HSP60/65 in particular was associated with endothelium 
injury in rabbits fed with cholesterol-rich diets.529 Different hypotheses were put forward to 
explain this association, one of the most popular being the one based on the concept of 
“molecular mimicry”. An immune response against HSP would represent a cross-reaction 
between HSP produced by endothelial cells subjected to oxidative or other pro-atherogenic 
stress factors and HSP produced as a response to eventual bacterial and viral infections that 
happened in the past. In this way, HSP60 expressed by the endothelial cells in response to 
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any biochemical or haemodinamic stress would become a target of an immune system that 
has already been sensitized to it on previous infectious events. 
However, other possibilities have been put forward to explain such a consistent 
association of atherosclerosis and anti-HSP antibodies: the protein could become 
immunogenic due to oxidation or metabolic-induced alterations, other antigens (foreign or 
self) could interact with HSP60 hence forming a immunogenic complex, the lack of 
recognition of soluble HSP as a self protein could be due to the fact that it is in most cases an 
intracellular molecule, and finally the possibility of genetic variations that would keep the 
immune response active.530 
These hypotheses are directly or indirectly based on the concept of HSP as an interface 
between infection and atherosclerosis. In fact, numerous studies have shown a relationship 
between chronic infection-associated bacteria or viruses and vascular disease. The classic 
example is the long term infections by Chlamydia pneumoniae and Chlamydia trachomatis 
which have been associated with an increased rate of atheroma formation and even the 
sites of infection for the latter (the eye and the fallopian tubes) show fibrosis with the 
presence of lymphocytes and macrophages in a surprisingly similar way to the development 
of the atherogenic plaque.531 Further evidence has been provided in relation to other micro-
organisms including Helicobacter pylori, Cytomegalovirus, Epstein-Barr virus amongst 
others.532 
The atherosclerotic lesion starts when LDL molecules are trapped in the arterial wall, in 
the subendothelial extracellular matrix.56 At this stage, lymphocytic T cells are already 
present in this lesion, and it was shown that these cells recognize as antigens the oxidized 
molecules of LDL.487 
OxLDL are the product of a variety of modifications of both the lipid and protein 
components of LDL due to the increased concentration of ROS at the subendothelial level. 
The resulting oxidized phospholipids and aldehyde-modified breakdown fragments of ApoB-
100 are not only pro-inflammatory but also are recognized as foreign by the immune system 
and therefore are highly immunogenic.533 
In 1989 antibodies to oxLDL (anti-oxLDL) were detected in atherosclerotic patients, 
experimental animals and in atherosclerotic lesions.534 Experimental models whereby 
atherosclerosis suppression was achieved by immunization of hypercholesterolaemic 
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rabbits535 or apolipoprotein E-deficient mice,536 with oxLDL, reinforces the concept that an 
immune response to oxLDL may modulate atherogenesis. 
Both IgM and IgG auto-antibodies to oxLDL are common in humans but their association 
with cardiovascular disease remains controversially. Although IgG type anti-oxLDL antibodies 
were positively associated with vascular risk, circulating levels of IgM type anti-oxLDL 
antibodies have been more frequently linked with reduced vascular risk in humans.537-539 
Moreover, high levels of IgG anti-oxLDL were associated with lipid-rich, fibrous poor plaques 
(characteristic of vulnerable, rupture-prone plaques), whilst high levels of IgM anti-oxLDL 
were related with fibrous, lipid-poor plaques containing less macrophages and more 
extracellular matrix (characteristic of stable plaques with little risk of clinical events).540 
Further studies are needed to clarify whether oxLDL auto-antibodies are markers of CVD 
and/or have an active role in either the progression of or protection against the 
atherogenesis. 
In addition to this two main auto-antigens others have been identified, such as 2GP1 
and cardiolipins, predominantly in the context of autoimmune diseases. 
2GP1 is a phospholipid-binding protein that is present on platelets, endothelial cells 
and in human atherosclerotic plaques.541 Auto-antibodies against 2GP1 have been found in 
patients with inflammatory disorders, including atherosclerosis, SLE, and antiphospholipid 
syndrome (APS). 
OxLDL interact with this endogenous anti-atherogenic plasma protein to form 
complexes (oxLDL 2GP1), preventing its uptake by macrophages.136 OxLDL 2GP1 
complexes are found in primary and secondary APS, SLE136 and chronic nephritis.542 
The binding of auto-antibodies to these complexes at endothelial level has been 
reported to be responsible for the endothelial activation and the immune-mediated 
inflammation.543 In fact, these immune complexes (antibody towards oxLDL 2GP1) are 
phagocytised by macrophages much faster, leading to an increased rate of foam cell 
formation and enhanced atherogenesis.137 IgG antibodies towards oxLDL 2GP1 are 
associated with arterial thrombosis in SLE related APS.543 Ames et al,544 described a direct 
association of IgG anti-oxLDL 2GP1 complexes with intima-media thickness (IMT) in primary 
APS (PAPS), suggesting a potential atherogenic role of these antibodies. 
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Another aspect is that oxLDL 2GP1 complex binds CRP.545 Previous studies have 
revealed that CRP binds phosphorylcholine moieties on oxLDL in what appears a very 
primitive form of innate immunity.546 In vitro data demonstrated that CRP can bind 
oxLDL 2GP1 in a ternary complex (CRP-oxLDL 2GP1).547 This ternary complex was specific 
for PAPS and predicted by increased IgG-2GP1, suggesting that an enhanced level of oxLDL 
might require buffering from both 2GP1 and CRP.548 
Reason why these complexes and their related auto-antibodies exist as well as their 
function role remains unclarified. 
Anti-cardiolipin (aCL) antibodies are auto-antibodies directed against negatively charged 
phospholipids and plasma proteins such 2GP1.549 The aCL antibodies are considered the 
hallmark of primary APS,550 a distinct clinical entity characterized by the occurrence of 
arterial and/or venous thrombosis and recurrent miscarriages. These antibodies have also 
been detected in the sera of patients with SLE551 and it has been proposed that they may 
play a pathogenic role in the accelerated atherosclerosis that afflicts these diseases.552 The 
atherogenic mechanism of these antibodies seems to involve the formation of pro-
inflammatory IgG- oxLDL 2GP1 complexes.553 
In immunized mice, aCL and 2GP1 antibodies were detected and associated with the 
development of atherosclerosis.554 aCL antibody titres independently predicted IMT of 
carotid arteries, an acceptable and reliable surrogate marker of sub-clinical atherosclerosis, 
in subjects with PAPS.555 In addition, these titres were inversely correlated with the PON1, 
contributing to the overall increase oxidation found in these patients.556 
Since the beginning of the 2000´s several others studies support the hypothesis that 
humoral immunity protects against atherosclerosis. Caligiuri et al,557reported that 
splenectomy increases atherosclerotic lesion development in ApoE(-/-) mice, whereas B-cell 
transfer ameliorates atherosclerosis. Likewise, using bone marrow transplantation strategy 
demonstrated that mice lacking B cells increased lesion growth in Ldlr(-/-) mice.558 These 
observations contribute to the acceptance of a paradigm that, in contrast to other immune-
mediated diseases, i.e., RA and SLE, B cells have been assigned a protective role in 
atherosclerosis. 
Introduction 
 
69 
 
However, in a major paradigm shift, the two recent studies demonstrated that depletion 
of B cells in ApoE(-/-) and Ldlr(-/-) mice by anti-CD20 monoclonal antibody ameliorated the 
Western diet-induced atherosclerosis.559,560 
The atherogenic role of B cells was confirmed in 2012 in studies using 
hypercholesterolemic B cell activating factor (BAFF) receptor deficient ApoE(−/−) mice, which 
reported that atherosclerosis and arterial inflammation was markedly reduced in these 
animal models.561,562 
The exact role of B cells in atherosclerosis is not yet fully understood, partly due to 
incomplete characterization of B cell subsets in humans. B cell subsets have been well 
recognized in mice, however surface markers that identify B cell subsets differ between mice 
and humans. While CD5 is a marker of B1 cells in mice, it does not reliably discriminate 
between B1 and B2 cells in humans.563,564 In mice both B1 and B2 cells have been shown to 
play significant roles in atherosclerosis. B1 cells represent a small percentage of B 
lymphocytes and their major role is in innate immune responses, where they are responsible 
for the production of the bulk of serum IgM.565 While B2 cells are predominant population of 
B cells in spleen and lymph nodes and are the main producers of adaptive IgG antibody after 
activation by specific antigens and differentiation into plasma cells.559-561 
Overall, these data contribute to the hypothesis that natural IgM is playing a protective 
role in atherosclerosis whereas the adaptative IgG response is pro-atherogenic. However the 
concept of a third subpopulation of B cells with regulatory properties (Breg) was only 
recently introduced.566 This B-cell subsets seems to act as immune regulators via IL-10 
production, which inhibits pro-inflammatory cytokines and supports regulatory T cell 
differentiation, although the role of Bregs in atherosclerosis is not yet determined. 
 
1.4.5 Immune response in atherogenesis and HDL 
In addition to the multiple anti-atherogenic properties of HDL previously described 
accumulating evidence also suggests that HDL possesses important function in both innate 
and adaptive immunity. 
Perhaps the interaction between HDL and the immune system longest known is their 
ability to protection from sepsis caused by the LPS, the endotoxin from gram-negative 
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bacteria that binds preferentially to HDL preventing LPS to interact with TLRs hence 
preventing macrophages to release massive amounts of inflammatory cytokines.567,568 
ApoA-I seems to be a key component responsible for LPS neutralization.569 Infusion of 
ApoA-I mimetic peptides into animals with experimental sepsis improves survival preventing 
defects in vascular function.570 
Furthermore, HDL also plays a protective role in parasitic infections. The lysis of 
trypanosomes is mediated by HDL particles that contain ApoL-I and haptoglobin-related 
protein.142 
The proteomic analysis of HDL composition identified proteins involved in complement 
regulation, including C3, C4a, C4b, C9, suggesting that HDL may regulate complement 
activation and consequently have a role in host defence mechanisms.86 
In addition to anti-inflammatory properties ApoA-I appears to play an important role in 
modulating innate immune response. ApoA-I inhibits DCs differentiation from monocytes 
with a decreased expression of surface costimulatory molecules such as CD1a, CD80, CD86 
and increased production of PGE2 and LI-10 (which are known to be DC differentiation 
inhibitors and/or modulators of DC function).571 Moreover DCs differentiated in the 
presence of ApoA-I stimulate T cells to a lesser extent, suggesting that ApoA-I exerts a 
protective mechanism against the differentiation and activation of DCs. 
Likewise, ABC transporter-deficient macrophages resulted in impaired cholesterol efflux 
to HDL or ApoA-I, leading to accumulate excess free cholesterol in plasma membrane and 
improvement of lipid rafts formation, which increased TLRs cell surface concentration and 
enhanced inflammatory responses.247,572 These studies suggest that HDL and ApoA-I by 
exerting anti-inflammatory effects by promoting cholesterol efflux via ABCG1 and ABCA1 
attenuated TLR activation (Figure 27). 
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Figure 27. Role of HDL and ApoA-I in regulating immune responses by promoting cholesterol efflux via 
ATP-binding cassette transporters (ABCG1 and ABCA1) with consequent attenuation of toll like receptor (TLR) 
signaling, which is activated by the increased lipid raft. From Weber et al, 2011.
573 
Besides cholesterol depletion from lipid rafts downregulates signalling pathways in 
several immune cells it also disturb the antigen-presenting capacity.574 
It has been shown that MHC class II molecules are localized in lipid rich microdomains 
on the surface of APCs, the integrity of this lipid rafts are important for the antigen 
presentation to T and B cells.575,576 In fact the number of MHC class II molecules present in 
this lipid rich microdomains are important because it provide a mechanism for localized 
concentration of MHC class II-peptide complexes on the surface of APCs which decrease the 
amount of the antigen required for T or B activation.  
Recently, Wang et al577 showed that HDL and ApoA-I reduced cholesterol and MHC class 
II protein content in lipid rafts, suggesting that cholesterol efflux from APCs to HDL and 
ApoA-I inhibits antigen presentation and consequently T cell activation. 
Despite these significant function of HDL in the immune system, an humoral response 
towards HDL has not been fully explored and only few studies have addressed the 
importance anti-HDL (aHDL) antibodies and its potential pathogenicity.556,578,579 
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1.5 Aims of the thesis 
We hypothesized that antibodies towards HDL and/or its components are associated 
with modifications in the anti-atherogenic functions of HDL and might represent a new 
mechanism of atherogenesis. 
The goals of this thesis are to identify and characterize the humoral response towards 
HDL components and to evaluate the possible mechanism that may contribute to the 
modifications of the anti-atherogenic properties of HDL. 
The specific aims are: 
1) To identify the presence of antibodies towards HDL components in patients with 
vascular diseases. For this purpose we used different cohorts: a) patients with SLE, a disease 
characterised by an enhanced humoral activity with a high prevalence of cardiovascular 
events; b) diseases associated with a higher atherosclerotic burden such as CAD, 
cerebrovascular disease and diabetes. 
2) To determine whether these antibodies have any biologic effect. For this purpose 
aHDL antibodies were isolated from patients and introduced in several experiments design 
to determine if their presence interfered with HDL anti-oxidative and anti-inflammatory 
properties. 
3) To investigate whether drugs acting on plasma lipids and lipoproteins in different 
fashions could alter the antibody profile. 
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The following chapter describes the methods that were used throughout the thesis, 
according to the methodology and the order that they are referred to in the results chapter 
All the information about the subjects in the different studies (healthy controls and patients) 
and the selection criteria for the clinical trials will be described in their respective results 
chapter. 
2.1 Immunologic-related methods 
2.1.1 Enzyme-Linked Immunoabsorbent Assays (ELISAs) 
2.1.1.1 Performance parameters /optimization of assays 
To determine the appropriate assays conditions for the ELISAs assays described in the 
following sections, of each step/component was performed using a check board. This enable 
the optimization of two components simultaneously and the maintenance of all the other 
reagents constant. Optimization of the assays included the determination of the type of 
plate, assay temperature, duration of incubation, coating concentration, blocking buffer, 
standards, controls and serum dilutions (always in triplicates), secondary antibody 
concentration and signal detection. The optimization of the assay was performed using 
negative controls, with high and low analyte concentrations. Optimum concentrations were 
selected based in the maximal desired optical density and minimum background activity e 
ratio. 
All assays were validated by the inclusion of internal quality control samples of known 
activity. Results were expressed as a percentage of the positive control present in each plate 
after subtraction from the background in the uncoated half of the plate. Exceptions are 
mentioned. Inter/intra plate coefficients of variation were always less than 10 %. Sera from 
150 healthy subjects was used for standardisation of the methods for determination of titres 
of the different antibodies. Values >3 standard deviations (SD) above the mean of healthy 
age and sex matched controls were considered to be positive. 
2.1.1.2 Anti-high density lipoproteins (aHDL) IgG and IgM antibodies 
IgG and IgM aHDL antibodies were measured by ELISA using a 96-well microtitre plates 
(Polysorp, Nunc, VWR, Portugal) half-coated with 20 µg/mL (IgG) or 10 µg/mL (IgM) human 
HDL (Sigma-Aldrich, Sintra, Portugal) in 70 % ethanol up to evaporation at 37ºC. The plates 
were then blocked (non-specific binding) with the addition of 100 μL/well of 1 % or 2 % (w/v) 
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of bovine serum albumin (BSA from Sigma-Aldrich) - 10 mM phosphate buffer saline (PBS 
from Sigma-Aldrich) pH 7.4 for IgG or IgM antibodies, respectively, over one hour at 37 ºC. 
The unbound blocking agent was removed by washing the plates four times with PBS. Next, 
positive and negative controls and samples were diluted (1:100) in the respective blocking 
buffer (1 % BSA - 10 mM PBS pH 7.4 for IgG or 2 % BSA - 10 mM PBS pH 7.4 for IgM) and 
added in both halves of the plate for one hour at 37 ºC. The unbound antibodies were 
removed by repeating the washing step. Secondary antibodies (Sigma-Aldrich) alkaline 
phosphatase (AP) conjugated anti-human IgG (1:1000 in blocking buffer) or anti-human IgM 
(1:5000 in blocking buffer) were added for one hour at 37 ºC. Following three washes with 
PBS and three washes with bicarbonate (BIC) buffer pH 9.8 the colorimetric reaction was 
performed by the addition of 100 μL/well p-nitrophenyl phosphate (pNPP from Sigma-
Aldrich) 1:5000 in BIC buffer, an AP substrate and allowed the reaction to proceed for one 
hour at 37 ºC. Absorbance of the resultant yellow colour was measured by Biotrak II plate 
reader (Amersham Biosciences) at 405 nm. 
2.1.1.3 Anti-apolipoprotein A-I (aApoA-I) IgG antibodies 
IgG aApoA-I antibodies were measured by half-coating a 96-well plate (Polysorp) with 
10 μg/mL human ApoA-I (Sigma-Aldrich) in 70 % ethanol up to evaporation at 37ºC. Blocking 
(non-specific binding) was performed using 100 μL/well 1% BSA - 10 mM PBS pH 7.4 for 1 
hour at 37ºC following four washes with PBS. Serum samples, positive and negative controls 
(1:200 in blocking buffer) and standards were added to each half of the plate for 1 hour at 
37ºC. The washing step was repeated and the secondary antibody AP conjugated anti-
human IgG (1:1000 in blocking buffer) added for 1 hour at 37ºC. After washing three times 
with PBS and three times with BIC buffer pH 9.8 the plates were incubated with 100 μl pNPP 
(1:5000 in BIC buffer) for 1 hour at 37 C. Absorbance of the resultant yellow colour was 
measured at 405 nm. 
Initially the titres of aApoA-I antibodies were expressed as the percentage of the 
positive control present in each plate after subtraction from the background in the uncoated 
half of the plate. After chapter 3, section 3.2 the aApoA-I antibody titres were converted in 
g/mL, as determined by the standard curve present in each plate. This curve was prepared 
with six standards of human monoclonal aApoA-I antibody in a concentration range of 
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0.001-0.04 g/mL. In both assays the inter and intra plate coefficients of variation were 
always less than 10%. 
2.1.1.4 Anti-paraoxonase 1 (aPON1) IgG antibodies 
Human PON1 (Abnova, Tebu-bio, Portugal) was adsorbed on half-microtitre plates by 
incubating 100 µL/well at a concentration of 1 µg/mL prepared in 70 % ethanol up to 
evaporation at 37ºC. The plate was blocked with 1 % BSA - 10 mM PBS pH 7.4 for 1 hour at 
37 ºC and washed four times with PBS. Serum samples, positive and negative controls (1:300 
dilutions in blocking buffer) were added in both halves of plate for 1 hour at 37 ºC. After 
repeating the washing step, the secondary antibody AP conjugated anti-human IgG (1:1000 
in blocking buffer) was added for 1 hour at 37 ºC. To remove the unbound conjugate the 
plate was washed three times with PBS and three times with BIC buffer pH 9.8. The plate 
was incubated with 100 μL pNPP (1:5000 in BIC buffer) and after 1 hour the absorbance was 
measured at 405 nm. 
2.1.1.5 Anti-apolipoprotein A-II (aApoA-II) and C-I (aApoC-I) IgG antibodies 
Ninety-six well plates (Polysorp) were half-coated up to evaporation at 37ºC with 
10 µg/mL human Apo A-II (Sigma-Aldrich) or 2 µg/mL human Apo C-I (Sigma-Aldrich) in 70 % 
ethanol. The plates were blocked with 1 % BSA - 10 mM PBS pH 7.4 for 1 hour at 37 ºC. 
Samples and positive control were diluted in blocking buffer (1:100) and added in both 
halves of the plates for 1 hour at 37 ºC. The washing step was repeated and the anti-human 
IgG conjugated with AP (1:1000 in blocking buffer) added to each well for 1 hour at 37ºC. 
Following three washes with PBS and three washes with BIC buffer pH 9.8 the plate was 
incubated with 100 μL pNPP (1:5000 in BIC buffer) for 1 hour at 37  C. Absorbance of the 
resultant yellow colour was measured at 405 nm. 
2.1.1.6 3-Nitrotyrosine (3-NT) 
Serum concentration of 3-NT were determined by ELISA using commercial kits (Oxis 
Research, Foster City CA, USA) in accordance with the manufacturer’s instructions. Standard 
curves were performed in each plate, using samples with known 3-NT concentrations 
included in the kit and the results were expressed as nM. Repeatability and accuracy of the 
assay was ensured by the inclusion of internal quality control sample. 
Methods 
 
78 
 
2.1.1.7 Soluble vascular cell adhesion molecules (VCAM-1) and intracellular cell adhesion 
molecules (ICAM-1) 
Soluble adhesion molecules (VCAM-1 and ICAM-1) levels were measured by ELISA using 
commercial kits (R&D systems, Citomed, Portugal), according to the manufacturer’s 
instructions. Standard curves were performed in each plate, using samples with known 
VCAM-1 or ICAM-1 concentrations, respectively included in each kit and being the results 
expressed as ng/mL. Repeatability and accuracy of the assay was ensured by the inclusion of 
internal quality control sample. 
2.1.1.8 Vascular endothelial growth factor (VEGF) 
Levels of VEGF from supernatant of cell cultures were quantified by ELISA using 
commercial kits (R&D systems, Citomed, Portugal), in accordance with the manufacturer’s 
instructions. Standard curves were performed in each plate, using samples with known VEGF 
concentrations included in the kit and the results expressed as pg/mL. Repeatability and 
accuracy of the assay was ensured by the inclusion of internal quality control sample. 
2.1.1.9 High sensitivity C-reactive protein (hs-CRP) 
Serum concentration of hs-CRP were assessed by ELISA using commercial kits (Biosupply 
Ltd, Bradford, UK), in accordance with the manufacturer’s instructions. Standard curves 
were performed in each plate, using samples with known hs-CRP concentrations included in 
the kit and the results expressed as µg/mL. Repeatability and accuracy of the assay was 
ensured by the inclusion of internal quality control sample. 
2.1.1.10 Serum amyloid A (SAA) 
SAA levels were evaluated by ELISA using commercial kits (Europa Bioproducts, Ely, UK), 
according to the manufacturer’s instructions. Standard curves were performed in each plate, 
using samples with known SAA concentrations included in each kit and being the results 
expressed as µg/mL Repeatability and accuracy of the assay was ensured by the inclusion of 
internal quality control sample. 
2.1.1.11 Oxidised low density lipoprotein-beta 2 glycoprotein-I complex (oxLDL 2GP1) 
oxLDL 2GP1 complex levels were determined by ELISA using commercial kits (Corgenix, 
Bloomfield, Colorado, USA), according to the manufacturer’s instructions. Standard curves 
were performed in each plate, using samples with known oxLDL 2GP1 concentrations 
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included in each kit and being the results expressed as units/mL. Repeatability and accuracy 
of the assay was ensured by the inclusion of internal quality control sample. 
2.1.1.12 Asymmetric dimethylarginine (ADMA) 
Serum concentration of ADMA were quantified measured by ELISA using commercial 
kits (DLD, Diagnostika GmbH, Hamburg, Germany), in accordance with the manufacturer’s 
instructions. Standard curves were perform in each plate, using samples with known ADMA 
concentrations, included in each kit and being the results expressed as μM. Repeatability 
and accuracy of the assay was ensured by the inclusion of internal quality control sample. 
2.1.2 Immunoturbidimetric immunoassay 
2.1.2.1 Apolipoprotein A-I 
Serum concentration of ApoA-I was determined by a immunoturbidimetric 
immunoassay using commercial kits (Randox, Irlandox - Laboratorios Quimica Analitica Lda, 
Porto, Portugal) in accordance with the manufacturer’s instructions. The test is based on the 
reaction of a sample containing ApoA-I (calibrator or serum sample) and specific antiserum 
to form an insoluble complex which can be measured turbidemetrically at 340 nm by RX 
Daytona (Randox). ApoA-I concentration was determined using a WHO/IFCC reference 
standard580 and the results expressed as mg/dL. Repeatability and accuracy of the assay was 
ensured by the inclusion of internal quality control sample. 
2.1.3 Antibody isolation 
2.1.3.1 aHDL and aApoA-I IgG antibodies isolation in a 96-well microtitre as solid phase 
aHDL antibodies were isolated by solid phase adsorption using microtitre plates 
(Polysorb) half-coated overnight at 4 °C with 20 μg/ml human HDL in 70 % ethanol. Blocking 
was performed using 1 % BSA - 10 mM PBS pH 7.4 for 1 hour at 37 ºC. The plate was washed 
four times with PBS. Serum samples positive for IgG aHDL antibodies (1:50 in blocking agent) 
were added in quadruplicate in both half of the plate for 1 hour at 37 ºC. The washing steps 
were repeated and then 250 μL of 100 mM glycine buffer (pH 2.0) were added. The content 
of each quadruplicate well was aspirated to a tube which contained 70 μL of Tris buffer 1 M 
pH 9.0 for neutralization. Afterwards, each fraction was dialyzed against PBS and then 
lyophilised (Christ Alpha 1-Z, B. Braun Biotech International). The procedure for the aApoA-I 
antibody isolation was overall similar the only difference being that the antigen used to coat 
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the plate was 10 μg/mL of human ApoA-I and the serum samples were selected based on 
their highly positive activity for the antigen. In each fraction, the titres of aHDL or aApoA-I 
antibodies were tested by ELISA following the protocol described in sub-chapter 2.1.1.2 and 
2.1.1.3 respectively. 
2.1.3.2 aHDL IgG antibodies isolated by immunoaffinity chromatography 
aHDL antibodies were isolated using an HiTrap NHS- activated HP (1 mL) column. The 
ligand, human HDL (10 mg) was dissolved in coupling buffer (0.2 M NaHCO3, 0.5 M NaCl 
pH 8.3). The column was embedded in isopropanol to preserve the stability of the activated 
medium and immediately prior the coupling of HDL the column was washed with six column 
volumes (6 mL) of 1 mM ice-cold HCl using a syringe of 1 mL at a flow rate of 1 mL/min (1/2 
drop/sec). Following the addiction of the HDL solution, the column was sealed and left to 
stand for 45 minutes at room temperature. To deactivate any excess active groups that had 
not coupled to the ligand and the non-specifically bound ligands, the column was washed 
with 6 mL of 0.5 M ethanolamine, 0.5 M NaCl pH 8.3 (buffer A) following 6mL of 0.1 M 
acetate, 0.5 M NaCl pH 4 (buffer B) and again with the same volume of buffer A. After this, 
the column was sealed and left standing for 30 minutes at room temperature. The washes 
were then restarted using buffer B interspersed with buffer A. In the end of the second wash 
with buffer B the column was washed with 10 mM phosphate buffer NaH2PO4, 2.7 mM KCl, 
137 mM NaCl pH 7.4. After this step the column was ready for use. If it was not used 
immediately, it was stored, after applying a storage buffer consisting of 0.05 M Na2HPO4, 
0.1 % NaN3 pH 7. 
Before applying the samples, the column was conditioned with 10 mL of binding buffer 
(20 mM Tris pH 7.5). Serum samples were diluted in equal volume of the binding buffer and 
filtered through a Millex GV 0.22 μm filter. The diluted serum was then applied into the 
column using a 1 mL syringe and passed over at least six times at room temperature. The 
unbound antibodies were removed by washing the column with 10 mL of 20 mM Tris pH 7.5 
and further 10 mL of 20 mM Tris, 500 mM NaCl pH 7.5. Antibodies retained by the HDL-
column were eluted with 10 mL of 0.1 M glycine pH 2.5 into tubes containing 70 μL of the 
neutralization buffer (Tris 1 M pH 8.8). After elution of the antibodies at low pH, the column 
was washed with 10 mL of 20 mM Tris pH 8.8 and then with 10 mL of 20 mM pH 7.5 to 
reconditioned the column. 
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Absorbance (280 nm) of the collected fractions (1 mL) was measured and the peak 
fractions were dialyzed against PBS and tested for the presence of aHDL antibodies by the 
ELISA procedure described above (sub-chapter 2.1.1.2). The fractions positive for the 
antibodies were pooled, concentrated by evaporation under nitrogen and stored at -4 ºC 
until tested for their biologic activity. 
2.2 Biochemistry-related methods 
2.2.1 Paraoxonase 1 (PON1) activity 
Serum PON1 activity was measured according to Eckerson et al,581 with some 
modifications. Paraoxon (1mM) (Sigma-Aldrich) was freshly prepared in 300 μL of 50 mM 
glycine buffer containing 1 mM CaCl (pH 10.5) and then was incubated at 37 ºC with 10 μL of 
serum for 10 min in 96 well plates (PolySorp). Para-nitrophenol formation was monitored at 
412 nm. Enzyme activity was calculated with a molar extinction coefficient of 18.290 Mcm-1 
and expressed as U/L, which is defined as 1µmol of p-nitrophenol generated per minute per 
litter under assay conditions. All samples were tested in triplicate. Inter/intra plate 
coefficients of variation were always less than 10%. 
2.2.2 Total anti-oxidant capacity (TAC) 
TAC was assessed by measuring the capacity of a sample to scavenge peroxynitrite 
(ONOO-) formed by the reaction between O2
•- and NO• released from a solution of 3-
morpholino-sydnonimine hydrochloride (SIN-1). The assay was performed in a Greiner 96 F 
White plate using an ABEL-41M2 antioxidant test kit (Knight Scientific, Plymouth, UK) which 
uses Pholasin (a photoprotein that produces light in the presence of free radicals and certain 
oxidants), as a probe. The light emission was measured every 54 seconds for 1 hour at 25 ºC 
using an Anthos Zenyth 1100/3100 multimode detector. The antioxidant capacity of the 
sample is defined as the time maximum light was emitted i.e. the time taken to consume the 
available antioxidants. The time to achieve peak luminescence (peak time) was converted 
into Vitamin E analogue (VEA) equivalent units (μM), using six solutions of 6-hydroxy-2,5,7,8-
tetramethyl-chroman-2-carboxylic acid with known concentration to generate a standard 
curve in each plate. 
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2.2.3 Nitric oxide metabolites 
NO• has a short biological half-life (10–20 milliseconds) that cannot be measured 
directly, so must be inferred by indirect methods. Estimation of stable NO• end products, 
nitrite (NO2
-) and nitrate (NO3
-), are widely used as indicators of the effective availability of 
NO•.582 Therefore, these metabolites were determined using a modified Griess reaction, 
following the reduction of nitrate to nitrite using nitrate reductase and NADPH as previously 
reported.583 Briefly, the assay was performed in a standard flat-bottomed 96-well plates half 
divided for simultaneous measurement of NO2
- and NO3
- concentration. Serum was diluted 
one in four with PBS pH 7.4, and 200 µl of this solution was ultra-filtered by centrifugation at 
10000 g for 1 hour, using 10000 kD molecular weight filters (Ultrafree-MC, Millipore, VWR). 
Only clear and colourless filtrates were tested. Fifty µL/well of PBS (blank), standard or 
serum sample were added in duplicate to both halves of the plate. In one of the halves, 4 µL 
of nitrate reductase (Sigma-Aldrich) and 10 µL of NADPH (Sigma-Aldrich) were added for the 
reduction of NO3
- to NO2
-, giving a final concentration of 6.3 U/L and 550 µM respectively. 
Following 2 hours of incubation at room temperature, Griess reaction was initiated by 
adding equal volumes of 2 % sulfanilamide (Sigma-Aldrich) in 5 % H3PO4 and 0.2 % N-(1-
naphthyl)-ethylenediamine dihydrochloride (Sigma-Aldrich) in water, mixed just prior to use. 
After 10 minutes of incubation at room temperature the absorbance was read at 540 nm 
and the levels were expressed as μM. 
2.2.4 Total HDL cholesterol, HDL2 and HDL3 
(This quantifications were made by Firmina Lebre, Técnica Especialista de Análises 
Clínicas of FCM). 
Total HDL cholesterol (HDL-C), HDL2 and HDL3-cholesterol were determined by a 
precipitation assay using the QUANTILOP HDL (HDL2/HDL3) test reagent. The test consists of 
the addition of the precipitation reagents containing polyethylene glycol (PEG) in different 
concentrations and pH to the serum. 
Reagent A precipitates VLDL and LDL fractions, while Reagent B precipitates along with 
VLDL, LDL, HDL2 subclass. Therefore, after centrifugation of the solution precipitated with 
Reagent A the supernatant contains all the HDL subclasses whereas the centrifugation of the 
solution precipitated with Reagent B, creates a supernatant containing only the HDL3 
subclass. The cholesterol content of these supernantants was quantified using the CHOD-
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PAP enzymatic test reagent at 500 nm . The content of HDL2 cholesterol was obtained by 
subtracting the HDL3 to total HDL. 
2.3 Functional assays in vitro 
2.3.1 Inhibition of paraoxonase 1 (PON1) activity by the antibodies isolated from 
patient’s serum 
2.3.1.1 aHDL and aApoA-I IgG antibodies isolated from patients systemic lupus erythematosus 
(SLE) 
Dose dependent inhibition was performed by incubating 50 μL of human HDL as a 
source of PON1 with 50 μL of aHDL or aApoA-I antibodies isolated from patients with SLE 
(descried above in sub-chapter 2.1.3.1) for 1 hour at 37 °C. Irrelevant human IgG (Sigma-
Aldrich) at the same concentration of HDL was used as controls and glycine buffer. After 1 
hour of incubation, PON1 activity was measured as described in sub-chapter 2.2.1. A dose 
dependent inhibition test was performed by incubating doubling dilutions (2, 4, 8 and 16 
fold) of HDL (starting at 200 μg/mL). All experiments were run in triplicate. 
2.3.1.2 aHDL IgG antibodies isolated from patients with atherosclerosis-associated clinical 
events: ischemic stroke (IS) and coronary artery disease (CAD) 
Dose dependent inhibition assays of PON1 activity were performed by incubating 
human HDL (100 μg/mL) with PBS pH 7.4 (basal) or aHDL IgG antibodies isolated from 
patients with IS and CAD (pool) (descried in sub-chapter 2.1.3.2). Irrelevant human IgG was 
used as control at the same concentration of the antibodies tested. After 1 hour of 
incubation, PON1 activity was assessed as described in sub-chapter 2.2.1. All experiments 
were run in triplicate and the results were expressed as a percentage of the effect on PON1 
activity in basal conditions. 
2.3.2 In vitro exposure of human umbilical vein endothelial cells (HUVECs) to aHDL 
antibodies 
Confluent monolayers of HUVECs seeded in 24-well tissue culture plates were incubated 
for 16 hours at 37 °C in 5 % CO2, in different conditions: M199 medium (Sigma-Aldrich) 
supplemented with 1% fetal calf serum (basal); human HDL (1.6 mg/mL) with or without 
aHDL antibodies (50 μg/mL) isolated from serum of patients (descried in sub-chapter 
2.1.3.2), a non-specific human IgG (50 μg/mL), or human nonoclonal aApo A-I antibody 
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(30 μg/mL). HDL and the antibodies were incubated for 1h at 37ºC before cell addiction. 
After washing, the cells were incubated further for 4 hours in the basal or stimulated state 
with 10 ng/mL TNF-. Following three washes with PBS, cells were gently dislodged by brief 
trypsinization (0.025 % trypsin and 2 mM EDTA in PBS) for 3 minutes at room temperature. 
Trypsin was neutralized with PBS and the cells were centrifuged at 12000 rpm for 5 minutes. 
The supernatants were colleted and stored at -20ºC for VEGF quantification as described in 
sub-chapter 2.1.1.8. The cells were stained with a fluorescein-conjugated mouse monoclonal 
anti-human VCAM-1 (R&D system) added for 30 minutes at 4°C and then washed again with 
FACS buffer (PBS containing 0.1% BSA and 0.01% sodium azide) to remove the unreacted 
anti-VCAM-1 reagent. The expression of VCAM-1 was measured as fluorescence intensity in 
a FACSCalibur (Becton Dickinson) flow cytometer. Ten thousand cells were analyzed per 
sample by using Cell Quest Software. Data was expressed as the percentage of basal VCAM-1 
expression positive cells. All experiments were done in triplicate. 
Cell viability was determined by a lactate dehydrogenase release assay and found to be 
>90% in all experiments. 
2.4 Statistical analysis 
Data was expressed as means ± SD, unless otherwise stated. Variation between groups 
was compared by ANOVA, or Kruskal-Wallis test for normal and non-normal distributed 
variables, respectively. Likewise, a t-test or Mann-Whitney test was used to compare 
individual groups depending on variable distribution. Relationships between variables were 
assessed by Spearman correlation. Multiple regression was used to assess independence of 
relationships after log- transformation, when appropriate, to normalise distributions. 
All reported probability values are two-tailed, with values of p < 0.05 being considered 
statistically significant. Statistical analysis and graphical illustration was carried out using the 
GraphPad Prism software, version 5 (GraphPad Software Inc., San Diego, USA). 
Determination of independent predictors was done using the SPSS version 21 (SPSS Inc., 
Chicago, USA) 
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The presence of antibodies against lipoproteins suggests a humoral response against 
some lipoprotein components, independently of a possible underlying auto-imune condition. 
This thesis deals mostly with cross sectional studies, that limit causuality assumption, 
but represents the baseline from which prospective population-based studies may be 
developed. 
To enhance the chance of detecting these antibodies we initially explored their presence 
in SLE a systemic disease characterised on the one hand by an enhanced and pleitropic 
humoral response and on the other by a higher cardiovascular risk identified as increased 
atherogenesis. The confirmation of their presence with a high prevalence and biologic 
activity allowed the obvious extention towards the general population with known, common 
atherosclerosis risk factors but without immune-mediated comorbidities. 
3.1 aHDL and aApoA-I antibodies in systemic lupus erythematosus 
(SLE) 
SLE is a chronic autoimmune systemic disease with a wide spectrum of clinical 
manifestations ranging from skin and mucosal lesions to severe injuries in the central 
nervous system, kidneys and other organs. It is characterized by systemic inflammation and 
by the presence of auto-antibodies against a large variety of auto-antigens.584 
SLE is much more frequent among women than men, with a ratio of approximately 9:1, 
although this ratio can change in different age groups. Additionally, ethnic origins is thought 
to be a major factor in SLE onset, as African-American, Afro-Caribbean, Asian Indian, 
Polynesian and Chinese women are are more likely to develop disease than European 
descents.585,586 
The diagnosis of SLE is based on clinical and laboratory criteria. For the purpose of 
classification the most widely used are the American College of Rheumatology (ACR) criteria, 
proposed in 1971 and revised in 1982 and again in 1997.587,588 
Genetic, hormonal, environmental and infectious factors are involved in the 
pathogenesis of SLE.589 Furthermore multiple immune system defects have been described 
in SLE patients, including B cell hyperactivity and increased auto-antibody production, 
abnormal T cell activation, aberrant cytokine production and enhanced apoptosis.590-592 
Currently, more than one hundred auto-antibodies have been described in SLE, these 
include autoantibodies directed against a multiplicity of nuclear, cytoplasmic, cell 
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membrane, phospholipid-associated, blood cells, endothelial cells, and nervous system 
antigen, plasma proteins, matrix proteins, and miscellaneous antigens.593  
Over the past 50 years, improved patient survival in SLE has allowed the emergence of 
CVD as a major cause of morbidity and mortality.594 However, the traditional cardiovascular 
risk factors does not explain the increased CVD burden in SLE, and therefore it has been 
suggested that disease-specific factors, such as prolonged steroid treatment, chronic 
inflammation and renal disease, could be more relevant.595-597 
Furthermore, an atherogenic lipid profile, characterized by elevated levels of VLDL, TG 
and lower levels of HDL has been reported in SLE.598 Indeed, decreased levels of HDL and its 
main protein component, Apo A-I, have been shown to be an important feature in the 
development of atherosclerosis in SLE.599,600 These findings might be relevant considering 
that HDL is a particular lipoprotein with different atheroprotective functions. 
The occurrence of autoantibodies against plasma lipoproteins and their constituents has 
been addressed in SLE but with major emphasis on anti-LDL and/or its oxidized form, with 
the possibility of cross-reactivity between these autoantibodies and aCL antibodies .601  
Very few studies have addressed the importance of the humoral response towards HDL 
and the potential pathogenesis of these antibodies in SLE.556,578,579 
3.1.1.1 Aim 
This study aimed at confirming the presence of a humoral response towards HDL in SLE 
and to assess whether Apo A-I could be a specific target. We have also explored the 
relationship between aHDL and aApo A-I antibodies and the anti-oxidant and anti-
inflammatory functions of HDL in SLE, to determine a possible association with disease 
activity and damage. 
3.1.1.2 Patients and methods 
Patients 
SLE patients attending the Lupus Outpatients Clinic of University College London, 
London, UK and controls of similar age and sex, recruited amongst healthy staff members 
and students attending the rheumatology department were invited to participate in a study 
assessing the relevance of new markers of atherosclerosis in SLE. Exclusion criteria for SLE 
patients were secondary APS, a positive aCL and/or lupus anticoagulant test even in the 
absence of thrombosis or miscarriage and the use of lipid-lowering drugs. Ninety-eight 
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consecutive patients fulfilling at least four of the ACR revised criteria588 for the classification 
of SLE were considered, of whom 21 were excluded: 16 had at least one of the exclusion 
criteria and 5 declined to participate. 
Exclusion criteria for controls were diabetes, hyperlipidaemia, hypertension, kidney, 
liver, heart or lung disease, and intake of lipid-lowering drugs. A total of 64 healthy subjects 
were invited to participate but 14 were not considered: 8 met one or more of the exclusion 
criteria and 6 were excluded in order to achieve a frequency match by sex and age with the 
study group. 
The study was therefore carried out on 77 SLE patients and 50 controls, after approval 
from the local ethics committees in agreement with the revised Declaration of Helsinki and 
with written consent being given by all participants. 
Data regarding steroid dose, immunosuppressant drugs use and anti-platelet agents 
were available for all SLE patients. Disease-related damage was determined at the time of 
serum sampling using the Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology Damage Index (SLICC/ACR DI).602 The disease activity was assessed 
using the British Isles Lupus Assessment Group (BILAG-2004) index: patients scored Grade A 
or B in any system were categorised as having active disease and patients scored Grade C, D 
or E in all systems were categorised as having inactive disease.603 Serum from patients and 
controls were kept at –80ºC until analysis. Demographics and clinical data of patients and 
controls are shown in Table 6. 
Methods 
Serum IgG aHDL and aApo A-I antibodies titers and levels of soluble VCAM-1 and ICAM-1 
were measured by ELISAs. PON1 activity, TAC and nitric oxide metabolites (NO2
- and NO3
-) 
were tested as described in the methods chapter. Lipid profile (total cholesterol, HDL, LDL 
and TG) were determined by standard enzymatic techniques in the hospital when sample 
was collected. Statistical analysis was performed as described in the previous chapter. 
3.1.1.3 Results 
IgG aHDL and aApo A-I antibodies, PON1 activity and plasma lipids 
Patients with SLE showed lower HDL and higher TG, LDL and total cholesterol than 
controls (Table 6). 
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Table 6. Demographic characteristics and clinical and serological data of healthy controls (CTRL) and 
patients with systemic lupus erythematosus (SLE). Data are presented as mean ± SD. 
 CTRL (n = 50) SLE (n = 77) P value 
Age, years 36.56 ± 13.17 39.61 ± 11.75 0.2 
N. (%) female/male 45 (90) / 5 (10) 68 (88.3) / 9 (11.7) 0.7 
Global score (BILAG) NA 4.5 ± 3.8 - 
Medication    
Steroids, n. (%) NA 52 (67.5) - 
Steroid dosage (mg/day) NA 6.74 ± 3.34 - 
Hydroxycloroquine, n. (%) NA 32 (41.6) - 
On immunosuppressant treatment, n. (%) NA 37 (48.0) - 
Serological data (mg/dL)    
Total cholesterol 139.6 ± 55.9 201.0 ± 41.6 <0.0001 
TG 91.3 ± 58.9 133.7 ± 92.4 0.006 
LDL-C 76.7 ± 35.7 111.3 ± 35.0 <0.0001 
HDL-C 66.6 ± 25.3 57.5 ± 13.3 0.02 
Abbreviations: BILAG:British Isles Lupus Assessment Group; TG: Triglycerides; NA Not applicable. Data 
are presented as mean ± SD. P value represents the statistical comparison between the two groups. 
Mean IgG aHDL and aApo A-I antibodies were higher in SLE patients than healthy 
controls (Figure 28 A and B) and positively correlated (r = 0.64, P<0.0001) in the SLE 
population. The prevalence of positive titres of IgG aHDL antibodies were 59.7% in SLE 
patients and 8% in healthy controls, whilst for aApo A-I antibodies were 50.6% in SLE 
patients and 10% in healthy controls. 
HDL-C levels showed an inverse correlation with IgG aHDL (r = -0.32, p=0.02) and IgG 
aApoA-I (r = -0.41, p=0.001). 
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Figure 28: Levels of IgG aHDL (A) and IgG aApoA-I antibodies (B) in healthy controls (CTRL) and patients 
with systemic lupus erythematosus (SLE) Bars show the means. 
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Mean PON1 activity was lower in SLE than controls (P<0.0001) (Table 7) and negatively 
correlated to IgG aHDL (r = -0.34, P=0.002) and IgG aApo A-I titres (r = -0.31, P=0.006) (Figure 
29 A and B). 
Table 7: Biological variables (oxidation and endothelial dysfunction markers) measured in healthy controls 
(CTRL) and patients with systemic lupus erythematosus (SLE). 
 CTRL (n = 50) SLE (n = 77) P value 
PON1 activity (U/L) 303.60 ± 60.38 185.00 ± 86.37 <0.0001 
TAC (VEA equivalents units M) 6773 ± 1343 5448 ± 2519 0.001 
NO2
-
 (M) 10.97 ± 6.60 20.71 ± 11.81 <0.0001 
NO3
-
 (M) 20.75 ± 13.92 37.94 ± 19.51 <0.0001 
NO2
-
 + NO3
-
 (M) 31.42 ± 15.48 58.52 ± 25.95 <0.0001 
VCAM-1 (ng/mL) 558.00 ± 91.67 816.80 ± 357.90 <0.0001 
ICAM-1 (ng/mL) 280.40 ± 48.27 346.20 ± 106.40 0.0008 
Abbreviations: PON1: paraoxonase 1; TAC: Total antioxidant capacity; NO2
-
: nitrite; NO3
-
: nitrate; 3-NT: 
3-nitrotyrosine; VCAM-1: vascular cell adhesion molecule; ICAM-1: intracellular adhesion molecule. Data 
are presented as mean ± SD. P value represents the statistical comparison between the two groups. 
Current treatment did not affect the titres of IgG aHDL and aApoA-I antibodies or PON1 
activity in the SLE group. 
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Figure 29: Correlation (Spearman’s rank test) between PON1 activity (U/L) and IgG aHDL levels (A) and IgG 
aApoA-I levels (B) in patients with systemic lupus erythematosus (SLE). 
In a regression model including HDL-C or PON1 activity as the dependent variables and 
age, smoking, current steroid dose, current immune suppressor dose, other lipid proflie 
measurements, IgG aHDL, aApoA-I, SLICC/ ACR and BILAG as independent variables, higher 
IgG aApoA-I titre were independently associated with lower levels of HDL-C (t = -3.04, 
p = 0.004) and decrease PON1 activity (t = -2.35, p = 0.02). 
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Total antioxidant capacity (TAC) and nitric oxide metabolites (NO2
- and NO3
-) 
TAC was lower in patients with SLE than in healthy controls (p=0.001) (Table 7) and 
inversely correlated with to the titres of IgG aHDL (r = -0.43, p = 0.0005) and IgG aApoA-I 
(r = -0.47, p = 0.0001). There was a positive association with PON1 activity (r = 0.32, 
p = 0.0009) ( Figure 30). 
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 Figure 30: Correlation (Spearman’s rank test) between the total antioxidant capacity (TAC) expressed in 
Vitamin E analogue (VEA) equivalent units (µM) and IgG aHDL (A), IgG aApoA-I (B) antibodies titres and PON1 
activity (C) in patients with systemic lupus erythematosus (SLE). 
 
As both NO2
- and NO3
- levels were higher in patients with SLE compared to healthy 
controls (p<0.0001) (Table 7) for the association analyses the sum of both metabolites was 
used. In SLE patients, NO2
- + NO3
- levels showed a direct correlation with IgG aHDL (r = 0.33, 
p = 0.009) and IgG aApoA-I (r = 0.42, p = 0.008) antibodies and an inverse correlation with 
PON1 activity (r = 0.32, p = 0.0009). 
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Soluble vascular adhesion molecules (VCAM-1) and soluble intracellular adhesion molecules 
(ICAM-1). 
Mean levels of VCAM-1 and ICAM-1 were higher in patients with SLE compared to 
healthy controls (p<0.0001 and p = 0.0008, respectively (Table 7). In the SLE group, IgG aHDL 
antibody titres independently predicted ICAM-1 (t = 3.51, p = 0.001) whereas IgG aApoA-I 
and NO2
- + NO3
- independently predicted VCAM-1 (t = 3.31, p = 0.002 and t = 2.27, p = 0.02, 
respectively). VCAM-1 (r = -0.39, p = 0.004) and ICAM-1 (r = -0.32, p = 0.02) inversely 
correlated with PON1 activity but no relationship was observed with TAC. 
Relationship between serological and clinical data 
SLE patients with a higher damage index had elevated IgG aHDL and IgG aApoA-I titres 
(Figure 31 A) and lower PON1 activity (Figure 31 A). Patients with active disease (BILAG) 
showed higher titres of IgG aHDL, IgG aApoA-I and lower PON1 activity than patients with 
inactive disease (p= 0.03, p= 0.03 and P= 0.002, respectively) (Figure 31 B). 
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Figure 31. Relationship between the titres of IgG aHDL, aApoA-I antibodies and PON1 activity with 
SLICC/ACR damage index (A) and disease activity (BILAG score) (B) in patients with systemic lupus 
erythematosus (SLE) (Kruskal-Wallis test – Anova). 
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Mean NO2
-+NO3
- was associated with an increase in the SLICC/ACR DI (p = 0.02), but no 
association was found with disease activity (Figure 32 A). 
TAC was not associated with either disease activity or damage. VCAM-1 levels were 
associated with an increased SLICC/ ACR DI (p = 0.006) and disease activity (p = 0.03) (Figure 
32 B and C), but no associations were found between ICAM-1 levels and clinical data. 
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Figure 32. Relationship between the NO2
-
+NO3
-
 (A) and VCAM-1 (B, C) levels with damage (SLICC/ACR DI) 
and disease activity (BILAG score) in patients with systemic lupus erythematosus (SLE) (Kruskal-Wallis test – 
Anova). 
In a regression model including SLICC/ ACR as the dependent variable and age, smoking, 
current steroid dose, current immune suppressor dose, HDL-C, IgG aHDL, aApoA-I, PON1 
activity, NO2
-+NO3
-, VCAM-1, ICAM-1 and BILAG as independent variables, higher IgG aHDL 
antibodies titres and , NO2
-+NO3
- levels were independently associated with high SLICC/ACR 
damage index (t = 2.44, p = 0.02 and t = 2.61, p = 0.01, respectively). 
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3.1.1.4 Discussion 
This study confirms the presence of antibodies towards HDL, and its main protein 
component ApoA-I, in patients with SLE. They are associated with decreased PON1 activity, 
reduced TAC (suggesting a lower resistance to oxidation of the plasma), endothelial 
activation (elevated NO2
- + NO3
-, VCAM-1 and ICAM-1), and with an increase in damage and 
disease activity. Altogether, these findings suggest that IgG aHDL antibodies increase the risk 
of oxidative stress, therefore contributing to the accelerated atherogenesis present in SLE. 
In this cohort, titres of IgG aHDL and aApoA-I antibodies strongly correlate, suggesting 
that ApoA-I might be one of the key antigens for aHDL antibodies. This does not exclude the 
possibility of other potential targets within the HDL complex. 
Patients with SLE have increased levels of TG, LDL-C, and total cholesterol and lower 
HDL-C levels when compared with controls.598 In this patients, IgG aApoA-I antibody titres 
were independently associated with HDL-C levels, suggesting that quantity as well as quality 
of HDL may be influenced by them. 
The presence of IgG aHDL and aApo A-I antibodies may have clinical implications as their 
relationship with the SLICC/ACR DI indicates. This finding is further highlighted by the lower 
PON1 activity in patients with higher disease activity. PON1 is the enzyme that accounts for 
most of the capacity of HDL to prevent oxidation of LDL, and consequent reduction of foam 
cell formation. By interfering with PON1 function, aHDL and aApoA-I may tilt the 
oxidant/anti-oxidant balance towards oxidative stress. The activity of this enzyme has 
already been associated with particular SLE-related features such as lupus nephritis.604 
NO• plays a central role in regulating vascular tone, but its overproduction may 
contribute to tissue injury, by increasing the vascular permeability, generating toxic-free 
radicals such as ONOO-, and inducing cytotoxicity.261 Belmont et al,605 reported 
overexpression of iNOS in periods of active disease. NO• has a short half-life and its 
metabolites, including nitrite and nitrate, are widely used as indicators of the effective 
availability of NO•.606 Our study confirms elevated plasma NO• concentration in patients 
when compared with healthy controls.605,607 
Under normal conditions, NO• inhibits vascular muscle cell proliferation, platelet 
aggregation and monocyte adhesion to the endothelium. However, free radicals such as 
ONOO-, when excessively generated by the reaction of NO• with superoxide, induce 
Results 
 
96 
 
modifications in proteins, lipids and DNA which may increase the immunogenicity of 
intracellular antigens, leading to a break in immune tolerance. 
Furthermore, the overproduction of free radicals and the excess NO• concentration 
primes the vascular endothelium for subsequent injury. Here we report for the first time 
that NO• is in a positive relationships with IgG aHDL and aApoA-I antibodies and in a 
negative one with PON1 activity, highlighting how these changes may reflect clinical damage 
(SLICC/ACR DI). 
Oxidative stress plays a vital role in the pathogenesis of atherosclerosis and its 
complications. TAC reflects the capacity of serum to resist oxidation and has been defined as 
a global measure that takes into account the overall antioxidant defence of serum. 
In the present study, TAC of patients with SLE was significantly lower than the control 
group, and IgG aHDL and aApoA-I antibodies were negatively associated with TAC. Moreover 
the positive correlation between TAC and PON1 activity suggests that IgG aHDL and aApoA-I 
may decrease TAC by an inhibitory effect on PON1. Since PON1 inhibits oxidation of 
phospholipids, thus preventing ONOO--mediated lipid peroxidation, the reduction of PON1 
activity, as seen in SLE patients, would further increase the overall oxidative state showed by 
a reduction in TAC. 
The interaction of leucocytes with the vascular endothelium is pivotal to the 
inflammatory process, and is mediated, amongst others, by adhesion molecules, such as 
VCAM-1 and ICAM-1, which participate in atherogenesis by promoting monocyte adhesion 
to the endothelium and subsequent accumulation in the arterial intima. In the above 
process, HDL inhibits the expression of cell surface adhesion molecules by activated 
endothelial cells.213 Levels of soluble adhesion molecules have been shown to correlate with 
various cardiovascular risk factors including low HDL-C.608 
Our study showed that soluble VCAM-1 levels correlate with low HDL levels and with disease 
activity, being significantly higher during active disease. Soluble ICAM-1 levels did not reflect 
disease activity. Whilst the variations in VCAM-1 are in agreement with previous studies,609-
611 ICAM-1 levels have generated contradictory results, with studies reporting a positive 
correlation between s-ICAM-1 levels and disease activity,612 and others failing to find 
significant differences when compared with healthy controls, or even an association with 
disease activity.609,613 This difference was addressed by Cybulsky et al,614 who showed that 
VCAM-1 deficiency significantly diminishes early foam cell lesion formation in the aorta of 
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mice deficient in the LDL receptor (Ldlr -/-), suggesting that VCAM-1 may play a role in 
preventing the initiation of atherosclerosis. However, ICAM-1 deficiency did not influence 
early foam cell lesion formation, either alone or when combined with VCAM-1 deficiency. 
Despite the up-regulation of both adhesion molecules in atherosclerotic lesions, VCAM-1 
seems to play a more important role in the initiation of atherosclerosis.614 
The association between VCAM-1 and ICAM-1 levels and IgG aHDL and aApoA-I 
antibodies and PON1 activity was demonstrated by the first time in this study. Moreover the 
IgG aHDL and aApoA-I antibodies titres independently predicted higher levels of ICAM-1 a 
VCAM-1 levels, respectively, suggesting that the presence of the antibodies may induce the 
synthesis these molecules by inhibiting HDL. 
In conclusion, by interfering with the anti-atherogenic properties of HDL, IgG aHDL and 
aApoA-I are associated with an enhanced oxidative stress and a higher SLE-related 
atherosclerotic risk. Given the cross-sectional nature of the study, disease activity and 
damage cannot be causally linked with the markers under study: their prognostic value with 
regards to SLE-related vascular disease should be assessed prospectively in further studies. 
At this point we asked ourselves whether this was a SLE-specific phenomenon or was it 
present also in the non autoimmune setting 
 
 
3.2 Anti-HDL and anti-ApoA-I antibodies in non auto-immune 
patients with atherosclerosis-related clinical events 
3.2.1 Coronary artery disease (CAD) and ischemic stroke (IS) 
CAD (or atherosclerotic heart disease) is the end result of the accumulation of 
atheromatous plaques within the walls of the coronary arteries and is one of the most 
relevant clinical features of atherosclerosis. Although without the same strong association IS 
can also be related to an increased atheroma burden in the arteries supplying blood to the 
brain. 
Despite major advances in the understanding of the nature of the atherosclerotic plaque 
and the phenomenon of plaque rupture, together with the proliferation of coronary care 
units, angioplasty and bypass surgery, thrombolysis, pharmacologic treatment for 
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hypercholesterolemia and hypertension (e.g. statin and angiotensin-converting enzyme 
(ACE) inhibitors) and a tremendous emphasis on lifestyle modification, CAD and IS continue 
to be major causes of mortality and morbidity throughout the world.1,2 
Epidemiologic and clinical studies show an inverse correlation between HDL-C and an 
increased incidence of cardiovascular diseases354 and the importance of HDL is now more 
recognised not just for preventing atheroma formation but also for stabilising plaques, 
therefore preventing rupture and ultimately thrombosis.239,447-449 
The existence of a possible humoral response towards the HDL complex was found in 
patients with autoimmune disease like SLE where enhanced atherogenesis and overactive 
immune response are prominent features. 
The suspicion that antibodies against HDL might be present outside the context of 
autoimmune diseases, led us to test this hypothesis in non auto-immune patients with 
atherosclerosis-related clinical events. 
3.2.1.1 Aim 
This study aimed to identify the presence of antibodies towards HDL and/or some of its 
components in patients with atherosclerosis-related clinical events such as CAD and IS and 
to evaluate their association with endothelial dysfunction and with some of the HDL anti-
oxidative properties. 
3.2.1.2 Patients and methods 
Patients 
One-hundred and eleven consecutive patients (56 CAD and 55 IS) with atherosclerosis-
associated clinical events, followed at the Internal Medicine outpatients clinic of Curry 
Cabral Hospital from November 2007 to September 2008 were invited to participate in this 
study. Inclusion criteria were: routine follow up appointment, for patients with at least a 
vascular event confirmed by CT scan (IS) or coronary angiography (CAD) in the last 5 years, 
without evidence of active systemic inflammation (normal erythrocyte sedimentation rate -
 ESR) and hs CRP < 1.0 mg/dL. Exclusion criteria included renal or hepatic dysfunction (serum 
creatinine < 1.2 mg/dL and ALT/AST < 2x reference value), infection, neoplastic disease, 
decompensated cardiac insufficiency and a thrombotic event of any kind in the previous 3 
months. 
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Of the initial cohort, 16 patients with CAD and 15 with IS were excluded: 11 CAD and 12 
IS to match both groups for age (the oldest patients were excluded), 5 did not have CAD 
confirmed and 3 had had a cerebral haematoma and not IS. Forty patients with CAD and 40 
with IS were definitely enrolled in the study. Ten patients with CAD also had an IS and 5 
patients with cerebral events had cardiac insufficiency, but no coronary disease was 
confirmed. Two patients with IS had atrial fibrillation.  
Healthy subjects used as controls were recruited during the same period of time 
amongst family and friends of the patients. Demographic data of patients and controls, 
medical history including current medication and other clinical data are summarized in Table 
8. 
All subjects signed consent forms approved by the ethics committees of the Hospital 
and the study was carried out according to the revised declaration of Helsinki. 
Blood samples were collected after a 12h fast and were centrifuged at 3000 xg at 4ºC for 
10 min to obtain serum. Serum from patients and controls were kept at –80C until assayed. 
Methods 
Serum IgG /IgM aHDL, IgG aApoA-I, IgG aPON1, IgG aApoA-II and aApoC-I antibodies 
titres and levels of soluble VCAM-1, ICAM-1 and 3-NT were measured by ELISAs. PON1 
activity, TAC and nitric oxide metabolites (NO2
- and NO3
-) levels were also tested as 
described in methods chapter. Lipid profile (total cholesterol, HDL-C, LDL-C and TG) were 
determined by standard enzymatic techniques in the hospital when sample was collected. 
Statistical analysis was performed as described in methods. 
3.2.1.3 Results 
Characteristics of the study subjects  
The characteristics of the study subjects are shown in Table 8. Patients groups were 
more likely to present with co-morbidities such hypertension (65-75%), type 2 diabetes (20-
30%) and dyslipidemia (22.5-25%) and to be on medication than controls. 
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Table 8: Demographic characteristics and clinical and serological data of healthy controls (CTRL) and 
patients with atherosclerosis-associated clinical events: coronary artery disease (CAD) and ischemic stroke (IS). 
 
CTRL 
 (N=40) 
CAD   
(N=40) 
IS 
 (N=40) 
P value 
Age (years) 67 ± 12 78 ± 7 69 ± 12 ‡0.0004 
Female sex (%) 50 50 50 0.89 
Medical History, N (%)     
Hypertension 4 (10)  26 (65) 30 (75) <0.0001 
Type 2 diabetes 1 (2.5) 12 (30) 8 (20) 0.004 
Dyslipidemia 2 (5) 10 (25) 9 (22.5) 0.04 
Medication, N (%)     
ACE inhibitors 1 (2.5) 12 (30) 7 (17.5) 0.004 
ARB 0 2 (5) 2 (5) 0.36 
Beta-Blocker 0 7 (17.5) 5 (12.5) 0.01 
Calcium-channel blocker 0 7 (17.5) 4 (10) 0.02 
Diuretics 2 (5) 14 (35) 9 (22.5) 0.004 
Anti-platelet agents 0 13 (32.5) 12 (30) 0.0004 
Statin 0 9 (22.5) 5 (12.5) 0.007 
Lipid levels (mg/dL)     
HDL-C 56.7 ± 22.2 34.9 ± 13.5 37.4 ± 13.3 <0.0001 
LDL-C 82.1 ± 30.9 100.0 ± 36.3 112.3 ± 42.1 0.002 
Total cholesterol 153.4 ± 51.7 140.7 38.1 164.7 ± 57.9 0.11 
Triglycerides 95.2 ± 45.6 110.3 ± 37.6 137.2 ± 65.6 0.003 
Abbreviations: ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker. NA: not 
applicable. Data are presented as mean ± SD. P value represents the statistical comparison between the three 
groups, Kruskall Wallis with Dunn’s post hoc. ‡ Statistical comparison between CTRL and CAD patients 
IgG aHDL, aApoA-I and aPON1 antibodies in patients with CAD and IS 
Mean titres of IgG aHDL, aApoA-I and aPON1 antibodies were higher in both patient 
groups, when compared to healthy controls (Figure 33 A-C; p < 0.0001).  
No differences were observed for the remaining antibodies tested (IgG aApoA-II, aApoC-
I and IgM aHDL) (Table 9). 
Table 9: Antibodies titres measured in healthy controls (CTRL) and in patients with atherosclerosis-
associated clinical events coronary artery disease (CAD) and ischemic stroke (IS). 
 CTRL CAD IS P value 
IgG aHDL (% p. control) 87.5 ± 26.9 184.5 ± 81.3 182.6 ± 115.4.5 <0.0001 
IgM aHDL (% p. control) 43.3 ± 29.6 46.8 ± 65.1 42.3 ± 62.5 0.11 
IgG aApoA-I (μg/mL) 0.49 ± 0.22 1.19 ± 0.74 1.14 ± 0.98 <0.0001 
IgG aApoA-II (% p. control) 154.6 ± 133.3 178.2 ± 119.4 165.2 ± 120.5 0.70 
IgG aApo C-I (% p. control) 334.8 ± 318.7 372.9 ± 353.6 336.4 ± 310.4 0.94 
IgG aPON1 (% p. control) 87.2 ± 57.8 163.5 ± 114.5 211.5 ± 162.9 <0.0001 
Abbreviations: aHDL: anti-high density lipoprotein antibodies; aApo A-I: anti-apolipoprotein A-I antibodies; 
aApo A-II: anti-apolipoprotein A-II antibodies aApo C-I: anti-apolipoprotein C-I antibodies; aPON1: anti-
paraoxonase 1 antibodies; Kruskall Wallis with Dunn’s post hoc. 
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The prevalence of positive titres of IgG aHDL were 97.5% for patients with CAD, 95% for 
patients with IS and 45% in healthy controls, whilst for aApo A-I antibodies were 60% and 
77.5% for patients with CAD and IS, respectively and 25% in healthy controls. The prevalence 
of positive titres of IgG aPON1 in patients with CAD was 40% and 32.5% in patients with IS 
while in healthy controls was 12.5%. 
      A)                B) 
    
0
100
200
300
400
500
600
CTRL CAD IS
***P<0.0001
3SD
Ig
G
 a
H
D
L
 a
n
ti
b
o
d
ie
s 
(%
 p
o
si
ti
v
e
 c
o
n
tr
o
l)
         
0
1
2
3
4
5
CTRL ISCAD
***P<0.0001
3SD
Ig
G
 a
A
p
o
 A
-I
 a
n
ti
b
o
d
ie
s
 (

g
/
m
L
)
 
           C)           
0
100
200
300
400
500
600
700
CTRL ISCAD
***P<0.0001
3SD
Ig
G
 a
P
O
N
1
 a
n
ti
b
o
d
ie
s
 (
%
 p
o
s
it
iv
e
 c
o
n
tr
o
l)
 
Figure 33. Levels of IgG aHDL (A), aApoA-I (B) and aPON1 (C) antibodies in healthy controls (CTRL) 
and patients with atherosclerosis-associated clinical events: coronary artery disease (CAD) and 
ischemic stroke (IS). Bars show the means. Kruskall Wallis test. 
IgG aHDL directly correlated with the IgG aApoA-I titres (p < 0.0001 in CAD and IS) and 
IgG aPON1 titres p < 0.0001 but only patients with CAD (Figure 34 A, B). 
Co-morbidities such hypertension, diabetes melitus and dyslipidemia were not 
associated with differences between antibodies titres in the patients with CAD and IS, or 
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with different treatment modalities. There were also no differences when we compared 
patients with and without hypertension regardless of the groups. 
Although total cholesterol did not differ between patients groups and healthy controls, 
LDL-C and TG levels were higher and HDL-C levels were lower in both patients groups, when 
compared to healthy controls, as expected (Table 8). No correlation was found between 
HDL-C levels the presence of IgG aHDL, aApoA-I or aPON1 antibodies. 
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Figure 34. Relationship between the titres of IgG aHDL and IgG aApo A-I (A) and aPON1 antibodies (B) in 
both group of patients with atherosclerosis-associated clinical events: coronary artery disease (CAD) and 
ischemic stroke (IS). 
PON1 activity and association with antibody titres 
PON1 activity was lower in both groups of patients when compared to healthy controls 
(p<0.0001, Table 10) and negatively correlated with the titres of aApo A-I antibodies (CAD 
p = 0.006 and IS p = 0.01) and aPON1 antibodies (CAD p = 0.007 and IS p = 0.0004) (Figure 35 
A, B). 
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Figure 35. Correlation (Spearman’s rank test) between PON1 activity (U/L) and IgG aApoA-I (A) and aPON1 
antibodies (B) in both groups of patients with atherosclerosis-associated clinical events coronary artery disease 
(CAD) and ischemic stroke (IS). 
No difference was observed in the mean levels of TAC (Table 10) between both groups 
of patients and healthy controls. 
When age, HDL-C, LDL-C, TAC and IgG aHDL, aApoA-I and aPON1 antibodies titres were 
entered as independent variables In a regression model with PON1 activity as the dependent 
variable for the CAD group IgG aApoA-I antibodies titres negatively predicted PON1 activity 
(t = -2.91, p = 0.006); when a similar regression model was applied to the IS group IgG aPON1 
antibodies titres and high HDL-C levels resulted as independent negative (t = -4.65, 
p = 0.0001) and positive (t = 4.16, p = 0.0001) predictors of PON1 activity respectively. 
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Table 10: Biological variables (oxidation and inflammation markers) measured in healthy controls (CTRL) 
and in patients with atherosclerosis-associated clinical events: coronary artery disease (CAD) and ischemic 
stroke (IS). 
 CTRL CAD IS P value 
PON1 activity (U/L) 275.7 ± 76.7 181.2 ± 97.3 190.6 ± 88.0 <0.0001 
TAC (VEA equivalents units M) 8.1 ± 1.6 8.9 ± 2.8 8.0 ± 2.0 0.13 
NO2
-
 (M) 13.4 ± 8.8 8.6 ± 4.2 9.6 ± 6.1 0.006 
NO3
-
 (M) 25.6 ± 15.9 42.8 ± 33.5 16.5 ± 11.4 0.006 
3-NT (nM) 16.2 ± 3.9 21.2 ± 8.3 19.2 ± 5.7 0.002 
VCAM-1 (ng/mL) 589.8 ± 158.2 1534.0 ± 792.5 1057.0 ± 547.6 <0.0001 
ICAM-1 (ng/mL) 297.6 ± 69.1 462.4 ± 156.4 347.6 ± 76.9 <0.0001 
Abbreviations: PON1: paraoxonase 1; TAC: total antioxidant capacity; NO2
-
: nitrite; NO3
-
: nitrate; 3-NT: 3-
nitrotyrosine; VCAM-1: vascular cell adhesion molecule; ICAM-1: intracellular adhesion molecule. Kruskall 
Wallis with Dunn’s post hoc: NO3
-
 (CAD vs IS p<0.001); VCAM-1 (CAD vs IS p <0.001); ICAM-1 (CAD vs IS 
p<0.001). 
Endothelial dysfunction parameters have distinct profiles between patients groups 
Mean NO2
- levels were decreased in both patient groups when compared with controls 
(p = 0.006, Table 10) and with no significant difference between CAD and IS. Mean NO3
- 
levels were higher in CAD patients when compared to IS patients (p < 0.001) and healthy 
controls (p = 0.006, Table 10). Additionally, 3-NT, VCAM-1and ICAM-1 levels were increased 
in both patient groups, when compared to healthy controls (Table 10, p = 0.002, p < 0.0001, 
p < 0.0001, respectively, Table 10). VCAM-1 and ICAM-1 levels were higher in CAD patients 
than in IS patients (p < 0.001). 
In CAD patients the levels of NO3
- were directly correlated with IgG aHDL (p = 0.02), 
aApoA-I (p = 0.006) and aPON1 (p = 0.02) antibodies (Figure 36 A-C) whereas in IS patients 
the levels of NO2
- were inversely correlated with IgG aApoA-I (p = 0.0001) and aPON1 
(p = 0.02) antibodies. 
The levels of 3-NT were directly correlated with IgG aHDL and aApoA-I antibodies 
(r = 0.36, p = 0.02) and NO3
- levels (r = 0.41, p = 0.01) in CAD patients, whereas in IS patients 
3-NT levels were positively correlated with IgG aApoA-I antibodies (r = 0.47, p = 0.003) and 
inversely correlated with NO2
- levels (r = -0.37, p = 0.01). 
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Figure 36. Correlation (Spearman’s rank test) between NO3
-
levels and IgG aHDL (A), aApoA-I (B), aPON1 
(C) antibodies titres in coronary artery disease (CAD) patients. 
VCAM-1 levels showed a direct correlation with IgG aHDL (CAD: p = 0.02, IS: p = 0.04), 
aApo A-I (CAD and IS: p = 0.01) and aPON1 antibodies (CAD and IS: p = 0.03) in both groups 
of patients. In patients with CAD, the ICAM-1 levels showed a direct correlation with IgG 
aHDL (p < 0.0001), aApoA-I (p = 0.0004) and aPON1 antibodies (p < 0.0001). In patients with 
IS, ICAM-1 levels were only positively correlated with IgG aPON1 antibodies (p = 0.02). An 
inverse correlation was found between PON1 activity and VCAM-1 levels (CAD: p = 0.01 and 
IS: p = 0.004) in both groups of patients. ICAM-1 levels were negatively correlated with PON1 
activity only in the IS group (p = 0.009). 
In patients with CAD, NO3
- levels showed a direct correlation with VCAM-1 (p = 0.003) 
and ICAM-1 (p = 0.01) while a positive correlation was observed between 3-NT levels and 
these adhesion molecules in IS patients (VCAM-1 and ICAM-1: p = 0.01). 
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Multivariate analysis entering the endothelial dysfunction markers as dependent 
variables and titters of IgG aHDL, aApoA-I and aPON1 antibodies as independent variables 
demonstrated that IgG aApoA-I titers independently predicted NO3
- levels (t = 2.92, 
p = 0.006) while IgG aPON1 titers independently predicted ICAM-1 levels (t = 3.97, 
p = 0.0001) in patients with CAD. 
3.2.1.4 Discussion 
This study shows for the first time that antibodies towards HDL and two of its major 
components ApoA-I and PON1 are present in patients with IS and CAD. Previously, only 
aApoA-I antibodies had been identified in a cohort of patients with acute coronary syndrome 
and MI.615-617 The lack of a positive titre of IgG aApoA-II and IgG aApoC-I across the two 
study groups rules against ApoA-II and ApoC-I as possible (auto)-antigens within the HDL 
complex, rather the strong correlation between IgG aHDL, aApoA-I and aPON1 titres 
suggests that ApoA-I and PON1 might be key targets. Moreover, the presence of IgG aHDL, 
aApoA-I and aPON1 antibodies in these subset of patients are associated with a decrease in 
PON1 activity and an increase in biomarkers of endothelial dysfunction (NO3
-, 3-NT, VCAM-1 
and ICAM-1), suggesting some biologic activity and potential pathogenicity. 
It is widely accepted that elevated LDL and low HDL are independently related to the 
risk of vascular disease.618 The anti-atherogenic properties of HDL are well established but 
neither the effect of aHDL antibodies on HDL's protective function, nor its relevance in 
patients without an auto-immune background is known. In this study the presence of IgG 
aApoA-I and aPON1 antibodies independently predicted decreases in PON1 activity and an 
increases in serum levels of endothelial dysfunction markers (NO3
-, ICAM-1) indicating that 
the antioxidant/oxidant balance is tilted towards the latter with possible negative effects on 
the endothelial function. 
The two NOS, the constitutive eNOS and the iNOS, convert L-arginine to NO• and 
citrulline at different concentrations according to substrate availability.619 Of the NO• 
metabolites, it is generally accepted that in humans only NO2
- reflects changes in eNOS 
activity and endothelial dysfunction whereas NO3
- reflects mostly the “inflammatory” NO• 
from iNOS.620-622 In keeping with these concepts serum NO2
- was decreased in both patient 
groups whereas NO3
- was markedly higher in CAD than IS. This may be a reflection of a more 
relevant role of inflammation in coronary diseases when compared to the brain-associated 
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injury. Moreover only CAD patients showed that IgG aApoA-I titers independently predicted 
increased NO3
- levels, thus supporting an atherogenic role for IgG aApoA-I antibodies in CAD 
patients and highlight a different pattern of the two groups of patients regarding oxidation. 
Physiological stimulation of the eNOS or iNOS enzyme enhances NO• release which then 
behaves either as a pathogenic mediator or as a cytotoxic molecule.623,624 In the latter case 
NO• reacts with O2
- generating ONOO–,625 a strong oxidant that induces modifications in 
proteins, lipids and DNA by reacting with the tyrosine residues to form 3-NT which may in 
turn increase the immunogenicity of intracellular antigens, leading to a break in immune 
tolerance.626 Nitrotyrosine (3-NT) has been widely used as a biomarker of protein damage 
induced by ONOO– and other reactive nitrogen species. In both groups of patients, 3-NT 
levels were increased when compared with healthy controls, however patients with CAD 
showed a positive relationship between 3-NT and IgG aHDL, aApoA-I antibodies, NO3
-, 
whereas in IS patients 3-NT levels were positively association only with IgG aApoA-I 
antibodies and negative related with NO2
- levels, again suggesting the possibility of different 
mechanisms in patients with cardio and cerebrovascular disease. 
Levels of soluble adhesion molecules have been shown to correlate with various 
cardiovascular risk factors including low HDL-C levels.608 Both groups of patients showed 
increased levels of ICAM-1 and VCAM-1 when compared with healthy subjects. Patients with 
CAD showed greater serum levels of ICAM-1 and VCAM-1 than IS patients though this 
difference was no obvious in previous surveys on cardio-vascular and cerebrovascular 
cohorts.627-629 Although ICAM-1 has a low constitutive expression in a variety of cell types, 
VCAM-1 is not constitutively expressed, though up-regulation of the expression of both may 
be rapidly induced by pro-atherosclerotic conditions in animal models and in humans.630-631 
The clinical relevance of plasma adhesion molecules is not clear. In healthy individuals, an 
increase in ICAM-1 titres is a significant predictor of future CAD events whereas VCAM-1 is a 
significant predictor of future coronary events only in patients with pre-existing CAD.632-636 In 
patients with IS a plasma concentration of VCAM-1 greater than 1350 ng/mL increases 4-fold 
the risk of new cerebrovascular events,637 while iincrease of ICAM-1 is linked to a poor short 
term in acute stroke prognosis.638 
In this study, VCAM-1 levels were positive associated with IgG aHDL, aApoA-I and aPON1 
antibodies in both groups of patients, while ICAM-1 levels were positive associated with IgG 
aHDL, aApoA-I and aPON1 antibodies in CAD patients. In patients with IS, ICAM-1 levels were 
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only positive associated with IgG aPON1 and additionally IgG aPON1 titres independently 
predicted increased ICAM-1 levels in these group of patients. 
This study reports the concurrent presence of IgG aHDL, aApoA-I and aPON1 antibodies 
in non autoimmune patients with atherosclerosis-associated clinical events together with 
markers of oxidation, nitrative stress and endothelial activation/damage. Outside the 
autoimmune disease context, only one group has shown a significant presence of aApoA-I 
antibodies in patients with acute coronary syndrome615 and suggested that these antibodies 
increase atherosclerotic plaque vulnerability617 and could be used as a prognostic marker in 
MI.616 However they could do not found an association of the aApoA-I antibodies with other 
arterial or venous thromboembolic events, such as stroke or acute pulmonary embolism. 
Moreover, our study described for the first time the presence of aPON1 antibodies. The 
associations between antibodies titres and markers of oxidation, nitrative stress and 
endothelial activation/damage were found to be stronger in CAD patients than in IS patients, 
which can be explained by a greater inflammatory drive in CAD patients. Because of its cross 
sectional design, this study cannot explain whether the antibodies are causal to the clinical 
events, nevertheless the antibodies titres seems to be significant predictors of decreased 
HDL anti-atherogenic function and the associations found are consistent with a coherent 
pathogenic explanation. 
 
3.2.2 Type 2 diabetes 
Type 2 diabetes is primarily a metabolic disorder, with a major vascular involvement31 
and is a risk factor for the development of atherosclerosis. In fact the risk of developing 
atherosclerosis at an earlier age in patients with type 2 diabetes is three-to five fold greater 
that of nondiabetics after controlling for other risk factors.32 
Recent findings indicate that HDL improve glucose metabolism by multiple mechanisms 
which include enhanced insulin secretion by -cells as a result of improved cellular 
cholesterol homeostasis, protection of stress-induced apoptosis and islet inflammation303-305 
and may be a causative role in the development of insulin resistance.303  
Infusions of rHDL in patients with type 2 diabetes reduce plasma glucose, increase 
insulin secretion, improve the HOMA index when compared with placebo306 and can inhibit 
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the cellular expression of VCAM-1 and ICAM-1 on stimulated human coronary endothelial 
cells.639 
Dysfunctional HDL has been identified in patients with type 2 diabetes: these show an 
impaired HDL-mediated RCT as well as defaults in the anti-oxidative, anti-inflammatory and 
endothelial-protective features of HDL.640 Dysfunctional HDL can be due to changes in its 
multiple components, but is most frequently associated with ApoA-I glycation.327 
We confirmed the presence of antibodies towards HDL components outside the context 
of autoimmune diseases, in patients with CAD and IS. Due to the potential role of HDL in the 
pathogenesis of type 2 diabetes, together with the known increased atherosclerotic risk of 
these patients, we looked for the presence of aHDL antibodies also in this disease. 
3.2.2.1 Aim 
This study was undertaken to determine the presence of antibodies directed against 
different components of HDL in patients with type 2 diabetes and establish a possible 
relationship between these antibodies and the anti-oxidant and anti-inflammatory 
properties of HDL. 
3.2.2.2 Patients and methods 
Patients 
Seventy four consecutive patients with type 2 diabetes, followed at the Internal 
Medicine outpatients clinic of Curry Cabral Hospital from June 2010 to June 2011, where 
invited to participate in this study. Seventeen declined participation and 57 accepted. 
Inclusion criteria were routine follow up appointment, diagnosis of type 2 diabetes according 
to American Diabetes Association guidelines 2008641: fasting plasma glucose (FPG) 
≥ 126 mg/dL (7.0 mmol/L) or two-hour plasma glucose ≥200 mg/dl (11.1 mmol/L) during an 
glucose tolerance test (OGTT) or classic symptoms of hyperglycaemia such as polyuria, 
polydipsia, and unexplained weight loss. Exclusion criteria included diabetes mellitus other 
than type 2; disease, renal or hepatic (serum creatinine < 1.2 mg/dL and ALT/AST < 2x 
reference value) dysfunction, infection, neoplastic disease, history of alcoholism or drug 
abuse, history of mental illness 
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Of the initial cohort, 7 patients with type 2 diabetes were excluded to match with the 
control group for age (the oldest patients were excluded), fifty patients were definitely 
enrolled in the study. 
Healthy subjects used as controls were recruited during the same period of time from 
healthy blood donors and family and friends of hospital staff. 
Demographic data of patients and controls, medical history (including current 
medication) and other clinical data are summarized in Table 11. 
All subjects signed consent forms approved by the ethics committees of the Hospital 
and the study was carried out according to the revised declaration of Helsinki. 
Blood samples were collected after a 12h fast and were centrifuged at 3000 xg at 4ºC for 
10 min to obtain serum. Serum from patients and controls were kept at –80C until assayed. 
Methods 
Serum IgG aHDL, IgG aApoA-I, IgG aPON1, IgG aApoA-II and aApoC-I antibodies titers 
and levels of soluble VCAM-1, ICAM-1 and 3-NT were measured by ELISAs. PON1 activity and 
nitric oxide metabolites (NO2
- and NO3
-) levels were tested as described in methods. Lipid 
profile (total cholesterol, HDL-C, LDL-C and TG) were determined by standard enzymatic 
techniques in the hospital when samples were collected. ApoA-I levels were determined by 
immunoturbidimetry as described in methods chapter. 
3.2.2.3 Results 
Characteristics of the study subjects 
Type 2 diabetic patients had a greater body mass index than controls and were more 
likely to present with co-morbidities such hypertension (50%) and dyslipidemia (22%) and to 
be on medication (Table 11). 
FPG levels (180.0 ± 95.4 mg/dL) and HbA1c (9.1 ± 4.9 %) have been used as the indices 
of glycaemia as they were measured in all subjects and they were significantly increased in 
patient with diabetes, consistent with uncontrolled diabetes (Table 11). 
HDL-C and ApoA-I were significantly lower in patients with diabetes when compared 
with controls, but other lipid parameters were not significantly different across subject 
groups (Table 11). In patients with diabetes, HDL-C levels were inversely correlated with FPG 
levels (r = -0.41, p = 0.004) and both HDL-C and ApoA-I levels were negatively associated 
with HbA1c (r = -0.42, p = 0.003). 
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Table 11. Demographic characteristics and clinical and serological data of healthy controls (CTRL) and 
patients with type 2 diabetes. 
 
CTRL 
(n = 50) 
Type 2 diabetes 
(n = 50) 
P value 
Age (years)  67 ± 12  71 ± 10  0.06 
Sex: female/male (n)  24 / 26  21 / 29  0.68 
BMI (Kg/m
2
) 28.6 ± 4.0 32.1 ± 5.5 <0.0001 
Medical History, N (%)    
Hypertension 5(10) 25 (50) <0.0001 
Dyslipidemia 2(4) 11 (22) 0.01 
Medication, N (%)    
Sulfonylureias 0 11 (22) 0.0005 
Biguanides 0 16 (32) <0.0001 
Insulins 0 5 (10) 0.05 
Antihypertensives drugs 5(10) 17 (34) 0.007 
Antidyslipidemic drugs 2(4) 9 (18) 0.05 
Serological data    
FPG (mg/dL)  89.5 ± 10.8  180.0 ± 95.4 <0.0001 
HbA1c (%)  5.1 ± 1.3 9.1 ± 4.9 <0.0001 
HDL-C (mg/dL) 55.0 ± 22.7 37.4 ± 12.3 <0.0001 
LDL-C (mg/dL) 89.2 ± 32.7 90.0 ± 35.3 0.76 
Total cholesterol (mg/dL) 163.3 ± 53.3 149.3 ± 45.2. 0.07 
TG (mg/dL) 113.7 ± 51.8 135.7 ± 55.9 0.14 
ApoA-I (mg/dL) 147.6 ± 26.8 121.7 ± 27.2 <0.0001 
Abbreviations: Body mass index (BMI); Fasting plasma glucose (FPG); Glycosylated hemoglobin (HbA1c); 
Triglycerides (TG); Apolipoprotein A-I (ApoA-I). Data are presented as mean ± SD. P value represents the 
statistical comparison between the two groups. Mann Whitney test. 
IgG aHDL, aApoA-I and aPON1 antibodies in patients with type 2 diabetes 
Mean titres of IgG aHDL, aApoA-I and aPON1 antibodies were higher in patients with 
type 2 diabetes than healthy controls (Figure 37 A-C; p < 0.0001, p = 0.0005, p < 0.0001, 
respectively). No other differences were observed for the remaining antibodies 
(IgG aApoA-II, aApoC-I) tested (Table 12). 
The prevalence of positive titres of IgG aHDL antibodies were 66% in patients with type 
2 diabetes and 26% in healthy controls, whilst for aApo A-I antibodies were 48% and 10% for 
patients type 2 diabetes and healthy controls, respectively. The prevalence of positive titres 
of IgG aPON1 antibodies in patients with type 2 diabetes were 64% and in healthy controls 
8%. 
IgG aHDL directly correlates with the IgG aApoA-I titers (r = 0.56, p < 0.0001) and IgG 
aPON1 titers (r = 0.52, p < 0.0001) in patients with type 2 diabetes. 
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Figure 37. Levels of IgG aHDL (A), aApoA-I (B) and aPON1 (C) antibodies in healthy controls (CTRL) and in 
patients with type 2 diabetes. Bars show the means. Mann Whitney test. 
 
Table 12. Antibodies titres measured in healthy controls (CTRL) and in patients with type 2 diabetes. 
 CTRL Type 2 diabetes P value 
IgG aHDL (% p. control) 170.6 ± 61.56 261.5 ± 130.1 <0.0001 
IgM aHDL (% p. control) 35.5 ± 24.6 30.14 ± 22.0 0.48 
IgG aApoA-I (μg/mL) 0.43 ± 0.23 0.96 ± 0.89 0.0008 
IgG aApoA-II (% p. control) 126.8 ± 78.33 153.2 ± 75.5 0.21 
IgG aApo C-I (% p. control) 289.3 ± 158.2 344.1 ± 202.6 0.28 
IgG aPON1 (% p. control) 71.3 ± 45.5 192.0 ± 108.4 <0.0001 
Abbreviations: aHDL: anti-high density lipoprotein antibodies; aApo A-I: anti-apolipoprotein A-I antibodies; 
aApo A-II: anti-apolipoprotein A-II antibodies aApo C-I: anti-apolipoprotein C-I antibodies; aPON1: anti-
paraoxonase 1 antibodies. Mann Whitney test. 
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Patient’s fasting glucose, glycosylated haemoglobin levees and lipid profile association with 
titres of antibodies 
FPG levels of patients with type 2 diabetes were positively correlated with the titres of 
IgG aHDL (r = 0.49, p < 0.0001), aApoA-I (r = 0.36, p = 0.01) and aPON1 (r = 0.78, p < 0.0001) 
antibodies. Levels of HbA1c were also positively correlated with IgG aHDL (p < 0.0001), 
aApoA-I (p = 0.01) and aPON1 (p < 0.0001) antibodies (Figure 38 A-C). 
A)        B) 
0 10 20 30
0
200
400
600 r=0.59 ***p<0.0001
HbA1c (%)
Ig
G
 a
H
D
L
 a
n
ti
b
o
d
ie
s
 (
%
 p
o
s
it
iv
e
 c
o
n
tr
o
l)
       
0 10 20 30
0
1
2
3
4
5
r=0.35 *p=0.01
HbA1c (%)
Ig
G
 a
A
p
o
 A
-I
 a
n
ti
b
o
d
ie
s
 (

g
/
m
L
)
 
    C) 
0 10 20 30
0
100
200
300
400
500 r=0.61 ***p<0.0001
HbA1c (%)
Ig
G
 a
P
O
N
1
 a
n
ti
b
o
d
ie
s
 (
%
 p
o
s
it
iv
e
 c
o
n
tr
o
l)
 
Figure 38. Correlation (Spearman’s rank test) between glycosylated hemoglobin (HbA1c %) and IgG HDL 
(A), aApoA-I (B) and aPON1 (C) antibodies in patients with type 2 diabetes. 
HDL-C levels were negatively correlated with the titres of IgG aHDL (r = -0.47, 
p = 0.0006), aApoA-I (r = -0.38, p = 0.008) and aPON1 ( r = -0.45, p = 0.001) antibodies. Whilst 
ApoA-I levels were only negatively correlated with the presence of IgG aPON1 antibodies 
(r = -0.40, p = 0.004). 
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In a regression model including FGP levels or HbA1c as the dependent variables and age, 
gender, HDL-C, LDL-C, total cholesterol, TG, ApoA-I levels, PON1 activity, IgG aHDL, aApoA-I 
and aPON1 antibodies titres as independent variables, IgG aPON1 antibodies independently 
predicted FGP levels (t = 4.52, p = 0.0001), whilst IgG aHDL antibodies independently 
predicted increased HbA1c (t = 3.49, p = 0.001). 
Moreover a regression model including HDL-C as the dependent variable and age, 
gender, LDL-C, total cholesterol, TG, ApoA-I levels, PON1 activity, IgG aHDL, aApoA-I and 
aPON1 antibodies titres as independent variables, Apo A-I levels were independently 
predicted HDL-C levels (t = 5.53, p = 0.0001), whilst IgG aApoA-I antibodies negatively 
predicted HDL-C levels (t = -3.05, p = 0.006). 
PON1 activity and association with higher titres of antibodies 
PON1 activity was lower in patients when compared to healthy controls (p<0.0001, 
Table 13) and correlated in a negative fashion with the titres of IgG aHDL (p = 0.009), aApoA-
I (p = 0.01) and aPON1 (p = 0.005) antibodies (Figure 39 A-C). Moreover PON1 activity 
directly correlated with ApoA-I levels (r = 0.32, p = 0.04) but was lower when associated with 
FGP levels (r = -0.30, p = 0.04). 
Table 13. Biological variables (oxidation and inflammation markers) measured in healthy controls (CTRL) 
and in patients with type 2 diabetes. 
 CTRL Type 2 diabetes P value 
PON1 activity (U/L) 274.0 ± 78.9 174.0 ± 92.6 <0.0001 
NO2
-
 (M) 13.7 ± 8.7 15.5 ± 10.9 0.67 
NO3
-
 (M) 25.5 ± 17.0 42.3 ± 31.5 0.008 
3-NT (nM) 16.3 ± 6.0 20.7 ± 11.0 0.25 
VCAM-1 (ng/mL) 723.6 ± 342.4 1307.0 ± 635.1 <0.0001 
ICAM-1 (ng/mL) 286.7 ± 90.9 452.5 ± 234.2 0.0002 
Abbreviations: PON1: paraoxonase 1; NO2
-
: nitrite; NO3
-
: nitrate; 3-NT: 3-nitrotyrosine; VCAM-1: 
vascular cell adhesion molecule; ICAM-1: intracellular adhesion molecule. 
In this cohort of patients with type 2 diabetes, IgG aPON1 antibodies titres 
independently predicted PON1 activity (t = -3.68, p = 0.001) in a negative fashion in a 
multivariate analysis. 
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Figure 39. Correlation (Spearman’s rank test) between PON1 activity (U/L) and IgG HDL (A), aApoA-I (B) 
and aPON1 (C) antibodies in patients with type 2 diabetes. 
Endothelial dysfunction parameters and association with higher titres of antibodies 
There were no differences between mean NO2
- levels in healthy control and patients 
with type 2 diabetes, but NO3
- levels were increased when compared with healthy controls 
(p = 0.008) (Table 13). No association were observed between NO3
- and the antibodies titers 
in type 2 diabetes. Also there were no differences regarding 3-NT levels between healthy 
control and patients with type 2 diabetes. 
VCAM-1and ICAM-1 levels were increased in patients with type 2 diabetes, when 
compared to healthy controls, (p < 0.0001, p = 0.0002, respectively) (Table 13). VCAM-1 
levels showed a direct correlation with IgG aApoA-I (p = 0.0001) and aPON1 (p < 0.0001) 
antibodies (Figure 40 A-B). 
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Figure 40. Correlation (Spearman’s rank test) between VCAM-1 (ng/mL) levels and IgG aApoA-I (A) and 
aPON1 (B) antibodies in patients with type 2 diabetes.  
VCAM-1 levels were inversely correlated with HDL-C (r = -0.46, p = 0.001), ApoA-I levels (r = -
0.46, p = 0.002) and PON1 activity (r = -0.39, p = 0.009). ICAM-1 levels were directly 
correlated with IgG aHDL (r = 0.35, p = 0.02), aApoA-I, aPON1 antibodies(r = 0.43, p = 0.006) 
and with FGP levels (r = 0.39, p = 0.01). An inverse correlation was found between ICAM-1 
and ApoA-I (r = -0.52, p = 0.0008) levels and with PON1 activity (r = -0.36, p = 0.02) in 
patients with type 2 diabetes. 
In a regression model including VCAM-1 as the dependent variable and HDL-C, LDL-C, 
total cholesterol, TG, ApoA-I, FGP levels, HbA1c, PON1 activity, IgG aHDL, aApoA-I and 
aPON1 antibodies titres as independent variables,  IgG aPON1 antibodies independently 
predicted VCAM-1 levels (t = 3.89, p = 0.001) whereas  HDL-C negatively predicted  VCAM-1 
levels (t = -2.41, p = 0.02). Using the same regression model but with ICAM-1 as a dependent 
variable aApoA-I levels negatively predicted ICAM-1 (t = -2.51, p = 0.02). 
3.2.2.4 Discussion 
This study shows for the first time that antibodies towards HDL and two of its major 
components ApoA-I and PON1 are presented in patients with type 2 diabetes. The absence 
of aApoA-II and aApoC-I antibodies suggests that this is a specific immune response towards 
HDL, indeed the strong correlation between IgG aHDL, aApoA-I and aPON1 suggests that 
ApoA-I and PON1 might be key targets. 
The relationship between HDL-C levels and glucose metabolism has been widely 
studied.642,643 In our cohort the inverse relationship between FPG levels or HbA1c % and 
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HDL-C and ApoA-I levels were confirmed. Moreover titres of IgG aHDL antibodies 
independently predicted increased HbA1c while IgG aPON1 antibodies were independently 
associated with higher FGP levels and consequently with poor glycaemia control suggesting 
that these antibodies may interfere with the protective effect of HDL on glucose 
metabolism. 
Furthermore, the presence of IgG aHDL, aApoA-I and aPON1 antibodies in these subset 
of patients was also associated with a decrease of HDL-C and ApoA-I levels and PON1 activity 
and an increase of adhesion molecules (VCAM-1 and ICAM-1). 
Chronic hyperglycaemia leads to generation of advanced gyration end products (AGEs), 
products from the nonenzymatic glycation of reducing sugars with macromolecules which 
are directly involved in endothelial dysfunction in these patients. The binding of AGEs to its 
receptor (RAGEs) activates intracellular signalling processes triggering AGE-mediated 
pro-inflammatory effects.644,645 AGE modification is known to occur not only with 
hemoglobin (HbA1c), but also with various proteins, thus affecting their functions. In fact, it 
has been reported that nonenzymatic glycation of HDL, ApoA-I and PON1 in vitro affect their 
anti-atherogenic properties, in particularly impairs HDL anti-inflammatory and antioxidant 
functions.329,646,647 Such modifications in proteins and lipids may increase the 
immunogenicity of intracellular antigens, leading to a break in immune tolerance. 
These findings suggest that antibodies towards HDL are associated with an increased 
risk of oxidative stress in these patients and therefore contributing to the accelerated 
atherogenesis present in type 2 diabetes. 
As mentioned previously NO2
- levels seem to reflect changes in eNOS activity and 
endothelial dysfunction whilst NO3
- reflects mainly the “inflammatory” NO• from iNOS.620-622 
It is also known that iNOS, which mediates the pro-apoptotic effects of glucose is down-
regulated by HDL.302  
In this cohort, patients with type 2 diabetes showed increased levels of VCAM-1 and 
ICAM-1 when compared with healthy subjects and a positive association with IgG aHDL, 
aApoA-I and aPON1 antibodies. In particularly IgG aPON1 antibodies which independently 
predict increased VCAM-1 levels, suggesting that this antibodies may interfere with the anti-
inflammatory properties of HDL. 
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This study describes the concurrent presence of IgG aHDL, aApoA-I and aPON1 
antibodies in patients with type 2 diabetes and its association with markers of oxidation, 
nitrative stress and endothelial activation/damage 
These results add to the mounting evidence of greater than expected humoral auto-
immunity in non autoimmune patients with atherosclerotic related clinical events. 
Prospective studies are now required to confirm whether these antibodies are indeed a 
direct cause of the identified immune changes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. BIOLOGIC ACTIVITY AND PATHOGENIC 
POTENTIAL OF ANTIBODIES TOWARDS THE 
HDL COMPLEX 
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4.1 Introduction 
In the previous chapter it was proposed that a humoral response against the HDL 
complex could account for a quantitative and/or qualitative fault of this lipoprotein. 
aHDL antibodies and more particularly aApoA-I (the main apolipoprotein contained in 
HDL) and aPON1 (the main antioxidant enzyme in HDL) antibodies are present in patients 
with autoimmune diseases but also in patients with atherosclerosis-associated clinical 
events outside the context of autoimmune diseases. Furthermore an association was found 
between the titres of these antibodies and several biomarkers of oxidation and endothelial 
dysfunction. However, these findings were reported in cross-sectional clinical studies and 
therefore a causal relationship could not be inferred. Prospective studies would be needed 
to determine the pathogenic effect of these antibodies. Nevertheless, the pathogenicity of 
these antibodies can be assessed in in vitro systems. 
The knowledge that aHDL antibodies purified from patients might interfere with defined 
physiologic mechanisms could provide strong evidence for their pathogenic potential and 
reject their presence as simple bystanders. So far, antibodies against the HDL complex have 
not been previously isolated and therefore proper experiments regarding its biological 
activity are needed. 
4.2 Aim 
The goal of this study is to demonstrate the biologic activity and consequent pathogenic 
capacity of the antibodies towards the HDL complex by isolating them from patient’s serum 
and then studying there in vitro effects on the anti-oxidant and anti-inflammatory properties 
of HDL. 
4.3 Patients and Methods 
Patients 
Patients with SLE and CAD and IS from the cohorts previously studied who had aHDL 
antibodies were selected and the respective serum (already stored) was used. 
Methods 
Antibodies from patients with SLE were isolated using a 96-well microtitre plate as solid 
phase, following the protocol described in methods. The aHDL antibodies from patients with 
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CAD and IS were isolated by immunoaffinity chromatography using a HiTrap NHS- activated 
HP column following the protocol explained in methods. 
Inhibition of PON1 activity by aHDL and aApoA-I antibodies isolated from SLE patients 
was performed as described in previously in 2.3.1.1, whilst inhibition of PON1 activity by 
aHDL antibodies isolated from a pool of patients with CAD and IS was performed as 
described in section 2.3.1.2. 
The effect of the aHDL antibodies isolated from a pool of patients with CAD and IS on 
expression of VCAM-1 and in VEGF levels in HUVECs was studied as described in section 
2.3.2 and 2.1.1.8, respectively. 
The results and discussion of each set of experiment will be presented in separated 
sections 
4.4 Isolation of aHDL and aApoA-I antibodies from patients with 
SLE and in vitro inhibition of PON1 activity 
4.4.1 Results 
The aHDL and aApo A-I antibodies isolated from patients with SLE and incubated with 
human HDL significantly reduced PON1 activity up to a maximum of 70.2% and 78.4% 
respectively, when compared to irrelevant human IgG (Figure 41 A and B). The inhibition of 
PON1 activity was dose-dependent in relation to the concentration of the antibody 
incubated with different known concentrations of HDL. 
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Figure 41. In vitro inhibition of paraoxonase 1 (PON1) activity by aHDL (A) and aApoA-I (B) antibodies 
isolated from serum patients with systemic lupus erythematosus (SLE). Human IgG was used as control and 
correspond to 0% of effect. ***p<0.001; **p<0.01; *p<0.05. 
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4.4.2 Discussion 
The aHDL and aApoA-I antibodies isolated from SLE patients at a constant concentration 
directly inhibited the activity of PON1 in a dose dependent fashion. This complementary set 
of experiments demonstrates that aHDL and aApoA-I interfere with HDL disrupting the 
normal activity of PON1. The negative correlations found in the SLE cohort analysis in the 
previous chapter between the antibodies titres and the PON1 activity were confirmed by this 
in vitro assay. 
The purification protocol allowed only a small recovery volume after isolation and it was 
not possible to determine the concentration of IgG aHDL and aApo A-I antibodies, therefore 
the dose dependency inhibition of PON1 was evaluated by incubating the fixed antibody 
concentration with decreasing concentrations of antigen (HDL). 
4.5 Immunoaffinity chromatography purification of aHDL 
antibodies from patients with IS and CAD 
4.5.1 Results 
The profile of the HDL coupling to the HiTrap NHS activated HP column at 280mn was 
represented in Figure 42. 
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Figure 42. Representative profile of the HDL coupling to the HiTrap NHS activated HP column at 280nm. 
Figure 43 shows the typical profile of serum patients; composed by a bulk of unretained 
proteins that passed directly through the column (fractions from 14-17), a second peak of 
retained proteins that were eluted when the buffer was changed to 0.1 M Glycine pH 2.5 
(fractions from 30-32) and a third peak appeared after washing the column with 20 mM Tris 
pH 8.8 (fractions from 39-41). 
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Figure 43. Representative elution profile of a pool of serum patients with atherosclerosis-associated 
clinical events: coronary artery disease (CAD) and ischemic stroke (IS) and applied to a HDL-HiTrap NHS 
activated HP column at 280nm. Proteins which bound to the column were eluted with 0.1 M Glycine pH 2.5. 
All the collected fractions were tested for the presence of IgG aHDL antibodies (Figure 
44 A) and they were only identified on fractions 31 and 32. 
The IgG aHDL antibodies isolated retained the ability to bind to human HDL (Figure 44 B) 
and the recovery rate in the column was greater than 90%. The fractions 31 and 32 were 
pooled and concentrated to test the biologic activity of the isolated aHDL antibodies. 
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Figure 44. Levels of IgG aHDL antibodies in the fractions collected from the HDL- HiTrap NHS activated HP 
column after patients serum was applied (A). Capacity of recovery of aHDL antibodies from fractions 31 and 32 
in relation to the original patients samples applied to the column (B). Bars show means. 
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4.5.2 Discussion 
The main new finding of this experiment was the development of a methodology for the 
isolation of aHDL antibodies from serum of patients, using immunoaffinity chromatography 
with a HDL - HiTrap NHS activated HP column. 
Immunoaffinity chromatography is a general method for the isolation of antibodies 
found in biologic fluids. The use of a pre-packed column has several advantages over the first 
protocol (Antibodies isolated in a 96-well microtitre as solid phase) since it allows the 
purification of larger amounts and more concentrate antibodies at the same time 
maintaining their specificity and preserving their biological activity. Furthermore, columns 
can be re-used if stored in adequate, though the matrix adsorbed on the column has a 
limited lifetime, and the ligand coupled to the matrix can suffer oxidation (or other biologic 
modification), which may interfere with the isolated antibody. 
This protocol was developed to purify aHDL antibodies from serum of patients with 
atherosclerotic clinical events (IS and CAD). However, it is a method that is generally 
applicable for the purification  of antibodies towards different HDL components (ApoA-I and 
PON1) and also in other pathologies such as SLE. 
4.6 In vitro inhibition of PON1 activity by aHDL antibodies 
4.6.1 Results 
aHDL antibodies isolated from patients with CAD and IS inhibited PON1 activity in a 
dose-dependent fashion from 7% to 52% (Figure 45). The non-specific human IgG used as 
control did not affect PON1 activity when compared to basal conditions (0% effect). 
4.6.2 Discussion 
This experiment showed that aHDL antibodies purified from CAD and IS patients directly 
inhibit PON1 activity, supporting the previous clinical studies where aHDL was associated 
with a pro-oxidant effect and a consequent increase in oxidative stress via a disruption of the 
normal activity of PON1 (sub-chapter 3.2.1). 
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Figure 45. In vitro inhibition of paraoxonase 1 (PON1) activity by IgG aHDL antibodies isolated from serum 
of patients with atherosclerosis-associated clinical events (CAD and IS). Human IgG was used as control and 0% 
effect is the PON1 activity at basal conditions (HDL 100g/mL). 
4.7 In vitro exposure of human umbilical vein endothelial cells 
(HUVECs) to aHDL antibodies 
4.7.1 Results 
Unstimulated HUVECs do not express VCAM-1 (incubation of HUVECs with HDL induced 
a 26.4 ± 11.3 % increase in the expression of VCAM-1 compared to baseline which might be 
likely attributed to an artefactual oxidation of HDL during isolation). VCAM-1 expression can 
be induced by stimulation with TNF-α, in this experiment there was an increase of 
213.7 ± 55.4 % of VCAM-1 expression in comparison to baseline. The pro-inflammatory 
effect of the cytokine was prevented by pre-incubation of HUVECs with HDL which led to a 
marked reduction of 160% in the subsequent expression of VCAM-1 (p=0.0004). In contrast, 
the addition of the aHDL antibodies isolated from patients to the pre-incubation solution 
abrogated the inhibitory effect of HDL on VCAM-1 expression by more than 80%, when 
compared with the non-specific human IgG (Figure 46). The presence of aHDL antibodies 
alone or with TNF-α (without HDL) did not modified the expression of VCAM-1 on HUVECs. 
Additionally the pre-incubation of HUVECs with human monoclonal aApo A-I antibody 
prevented the effect of the pro-inflammatory cytokine by only 65% in comparison to non-
specific human IgG. 
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Figure 46. Effect of aHDL antibodies isolated from patient's serum on the expression of VCAM-1 in 
HUVECs exposed to TNF-α. Confluent cultured HUVECs were incubated in basaline conditions (0% effect), with 
human HDL (1.6mg/mL), TNF-α (10ng/mL), HDL + TNF-α alone or with aHDL antibodies (50μg/mL) isolated from 
serum of patients with atherosclerosis-associated clinical events or a non-specif human IgG (50μg/mL) or 
human monoclonal aApo A-I antibody (30μg/mL). Bars show the means ± SD. Differences between means were 
evaluated using an Bonferroni’s Multiple Comparasion test.  ***P<0.0001 with reference to HDL + TNF-α; NS 
not significant. 
HDL induced a 157% increase in the levels of VEGF produced by HUVECs in comparison 
with baseline. aHDL antibodies isolated from patients decreased HDL-associated VEGF levels 
by 65%, whilst the incubation with human monoclonal aApo A-I antibody did not change the 
VEGF levels (Figure 47). 
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Figure 47. Effect of aHDL antibodies isolated from patients serum on VEGF levels produced by HUVECs. 
Cells were exposed to HDL alone or with aHDL antibodies (50μg/mL) or human monoclonal aApo A-I antibody 
(30μg/mL). Bars show the means ± SD. Differences between means were evaluated using an Bonferroni’s 
Multiple Comparasion test.  
+++
P<0.0001 with reference to HDL. 
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4.7.2 Discussion 
The interaction of leucocytes with the vascular endothelium is pivotal to the 
inflammatory process, and is mediated, amongst others, by adhesion molecules such as 
VCAM-1. They participate in the early events of atherogenesis by promoting monocyte 
adhesion to the endothelium and their subsequent migration through the arterial intima. 
Levels of soluble adhesion molecules have been shown to correlate with various 
cardiovascular risk factors including low HDL-C levels.608 In fact, the ability of HDL as well as 
some of its constituents, to inhibit cytokine-induced upregulation of cell surface adhesion 
molecules expression has been consistently demonstrated in vitro with native HDL213,648 and 
reconstituted HDL.234,235 This inhibition has been documented in endothelial cells activated 
with both TNF- and IL-1. 
However the mechanism by which HDL interacts with the cells to inhibit adhesion 
molecules expression is not fully understood. Some studies suggest that HDL blocks the 
sphingosine kinase (SphK) pathway, an enzyme catalysing a key step in endothelial cell 
activation by TNF-α.649 
In the present study we confirmed the anti-inflammatory property of HDL by inhibiting 
the TNF-α induced expression of VCAM-1 in HUVECs. Furthermore, by adding aHDL 
antibodies isolated from patients to the pre-incubation solution, the inhibitory effect of HDL 
on VCAM-1 expression was blocked, confirming the biologic activity of these antibodies.  
In previous studies (Chapter 3) adhesion molecules levels were directly associated with 
the antibody titres both in SLE patients and in non-autoimmune patients. Although, this 
experiment tested only aHDL antibodies isolated from patients with IS and CAD the 
inhibitory effect of the monoclonal human aApo A-I antibody suggests that aApo A-I 
antibodies isolated from autoimmune or no-autoimmune patients might also exert an 
inhibitory effect on VCAM-1 expression. This pro-inflammatory effect of the aApo A-I 
antibodies is not surprising due to the known anti-inflammatory properties of Apo-I.242,239 In 
fact, the present results suggest that HDL may exert its anti-inflammatory properties via an 
ApoA-I dependent mechanism. 
Angiogenesis  is a critical component of several human diseases, including cancer, auto-
immune diseases, ocular neovascularizing disorders and CVD. VEGF plays a central role in 
this process and in most of these diseases increased levels of VEGF is likely to contribute to 
disease progression. However, in ischemic heart and peripheral vascular disease the problem 
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is one of vascular insufficiency. In fact, autocrine VEGF is required for the homeostasis of 
blood vessels in the adult.650 As matter of fact in animal models non-invasive injection of 
pro-angiogenic compounds such as VEGF has shown promising results in regenerating 
cardiac microvasculature, however these results have failed to translate into successful 
clinical trials, although the motive still unclear.651 
In the present study we also confirmed that HDL-induces angiogenesis652 by increasing 
VEGF levels in HUVECs. The addiction of aHDL antibodies isolated from patients to the pre-
incubation solution abrogated the positive effect on VEGF levels. Unlike what was observed 
on VCAM-1 expression, human aApo A-I antibody did not exert the same effect of the aHDL 
antibodies isolated from patients with IS and CAD. This result suggest that HDL-induced 
angiogenesis by a mechanism independent of ApoA-I and can be due to other components 
of the HDL complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. PHARMACOLOGIC MANIPULATION OF 
HDL-C AND aHDL ANTIBODIES TITRES 
 
 
 
 
 
 
Results 
 
133 
 
This chapter will deal with three blind / randomized clinical trials with different anti-
dyslipidemic drugs in which the primary endpoint was not the evaluation of the effect of the 
drug on the humoral response towards HDL, nevertheless this effect was evaluated in a 
subsequent analysis. None of these studies protocol was written / developed by myself 
however for a better understanding of the study they will be described. All the 
measurements of biochemical and immunological variables presented here in were 
performed by me and included in this thesis with the respective authorization of clinicians 
that developed these clinical trials. 
5.1 Exploratory, double blind placebo controlled, randomized, 
single cross-over study to evaluate the potential anti-oxidant 
activity of Niaspan® (EXPLORE) 
5.1.1 Introduction 
Niacin (nicotinic acid or vitamin B3) is a water soluble vitamin that at physiologic 
concentrations is a substrate for the synthesis of NAD and NADP, which are important 
cofactors in intermediary metabolism (the intracellular process in which nutrient molecules 
are metabolized and converted into cellular components). The pharmacologic effect of 
niacin requires large doses (1.5-3 g/day) and is independent of the use of nicotinic acid to 
produce NAD or NADP. Niacin has been used as a pharmacologic agent to regulate 
abnormalities in plasma lipids and lipoprotein metabolism since 1955.413 
Niacin is the most effective commercially available agent to increase HDL-C levels.416 
Indeed, a meta-analysis of more than 80 clinical trials revealed that niacin (all formulations) 
induced elevation in HDL-C levels to a degree that was 1.6-fold higher than that achieved 
with fibrates.392 Furthermore, niacin not only reduces elevated TG levels by 15 % to 40 % as 
a function of baseline levels, but also reduces LDL-C by up to 25 %; the magnitude of the 
decrement in LDL-C varies with the formulation and dose employed.653 
Niaspan, an extended-release formulation of niacin, reduces the incidence of niacin-
induced major side effects: flush and hepatotoxicity. Although its mechanisms are not fully 
understood, the effects of Niaspan are thought to be due to an increase Apo A-I levels, a 
reduction in the rate of hepatic uptake of HDL particles, a shift in the distribution of the HDL 
subfractions, with and increase of HDL2 when compared to HDL3.422 
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Data regarding the effect of extended-release niacin on ApoA-I metabolism are 
controversial. Niacin has been shown to increase the production rate of ApoA-I both in the 
liver and in the intestinal cells.422,424 In fact, niacin activates both MAP kinase and the PPAR 
transcription factors pathways, which affect ApoA-I production.112 However, in vitro studies 
using hepatic cells and animal experiments with mice reported no effect of niacin on ApoA-I 
production rate, but a decreased in ApoA-I hepatic clerarance.654,655 
Furthermore niacin is the only commercially available agent known to specifically reduce 
circulating levels of Lp(a); this decrement may reach 30% or more in certain instances.656 
Lp(a) is similar to LDL, but contains apo (a) in addition to ApoB-100 in its protein moiety. It 
plays an intricate role in the development of atherothrombosis and premature CHD when 
present at elevated plasma levels (50 mg/dL), and/or when associated with elevated levels 
of LDL-C (130 mg/dL).657 
Despite being proven that extended-release niacin increases HDL-C levels in plasma, 
there are no studies regarding its effect on HDL function. 
5.1.2 Aim 
The aim of this study was to assess qualitative changes in the anti-oxidant activity of 
HDL, as well as in the titres of IgG aHDL and aApoA-I antibodies independently of the plasma 
reduction of the lipoprotein levels or HDL-C increase in patients treated with extended-
release niacin. 
5.1.3 Patients and methods 
Study design 
This exploratory phase II, randomized double blind placebo controlled, single cross-over 
study (EMR 64300-609) was investigator initiated and conducted in one center in Portugal: 
Department of Pharmacology, Faculty of Medical Sciences, Lisbon, Portugal. 
The study was divided in two sequential treatment periods that had the same scheduled 
visits and assessments (Figure 48). The first treatment period started at V1 (week1) and the 
subjects eligible for enrolment had to meet all the protocol inclusion criteria and none of the 
exclusion criteria; in Visit 1 patients were randomized to placebo or Niaspan for a total of 
twelve weeks. The first 7 weeks of each treatment period corresponded to the titration dose 
period, which was followed by a period of 5 weeks on maximum dose (1500mg of Niaspan 
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or placebo). After 4 weeks of wash-out period and cross-over of treatment arms, Niaspan 
or placebo were provided for an equivalent period (second treatment period). After a follow-
up period (4 weeks after last visit of the second treatment period) a final assessment of 
safety and efficacy was performed. 
 
Figure 48. Study design scheme. 
The study had a screening visit up to 4 days before randomization (these two visits could 
be combined in the same evaluation day if all assessments required for the study were 
available). The first period of treatment included scheduled visits at weeks 1, 4, 8 and 13. 
Followed by a wash-out period and cross-over of the treatment groups that was scheduled 
for visit at week 17. The second period of treatment included scheduled visits at weeks 20, 
24 and 29. The follow-up period and final visit were scheduled for week 33. 
Niaspan or placebo was administered orally once a day, at night. Subjects had an initial 
loading dose from weeks 1 till 8 (500 mg and 1000 mg daily), followed by a total of 5 weeks 
with maximum (1500 mg) dose, corresponding to the first period of treatment. After 4 
weeks of wash-out and cross-over of treatment arms, Niaspan or placebo were provided 
for an equivalent period (second period of treatment). 
Study subjects 
Patients were screened in 2009 and men and nonpregnant women who were ≥18 years 
of age and with HDL-C ≤ 40 mg/dL in men or HDL ≤ 50 mg/dL in women and were included in 
this trial. No other dyslipidemic medication besides the study medication was used during 
the study course. 
Exclusion criteria included a history of sensitivity to any of the components of the 
treatment drug; serious or unstable medical or psychological conditions that could 
compromise the patient’s safety or successful trial participation; treatment with statins, 
Results 
 
136 
 
fibrates or anti-oxidant during the 8 weeks prior to enrolment; serum LDL-C > 180 mg/dL and 
TG > 200 mg/dL; clinically relevant CAD, type 2 diabetes or other relevant CVD; a history of 
active peptic ulcer; a history of active arterial hemorrhagic; a history of drug abuse (with the 
exception of alcohol abuse); creatinine clearance > 60 mL/min; total bilirubin  2 times the 
upper limit of normal; AST and ALT  3 times the upper limit of normal; and participation in 
another investigational drug trial within 30 days of trial enrolment. 
All participants gave informed consent before any trial procedure was initiated. The 
relevant institutional review boards approved the trial protocol and any amendments, and 
the trial was performed in accordance with the principles of the Declaration of Helsinki and 
according to Good Clinical Practice guidelines. 
Assessments 
Blood assessments were carried out in the fasting state at baseline (before 
randomization to Niaspan or placebo) and for the safety parameters (hematology and 
clinical chemistry) at week 17 and 33, and for target parameters at week 8, 12, 17, 24, 29 
and 33. The target parameters included PON1 activity, serum nitric oxide metabolites (NO2
- 
and NO3
-), total HDL-C, HDL sub-fractions 2 and 3, ApoA-I levels, IgG aHDL and aApoA-I 
antibodies 
Biochemical parameters 
Serum IgG aHDL and aApoA-I antibodies titters were measured by ELISAs and ApoA-I, 
total HDL-C, HDL2 and HDL3, PON1 activity and nitric oxide metabolites (NO2
- and NO3
-) 
levels were tested as described in methods. 
Statistical analysis 
The primary efficacy end point was the change of PON1 activity in serum and the 
analysis was performed based on the intention-to-treat and per protocol populations. 
Changes of PON1 activity from baseline to the end of the treatment periods were analyzed 
(within and between treatment groups), using Wilcoxon test. Mean changes and 95% 
confidence intervals were presented. 
Secondary efficacy endpoint included changes in serum nitric oxide metabolites, lipid 
profile and IgG aHDL and ApoA-I antibodies, and were analyzed within and between 
treatment groups using Wilcoxon test. The secondary efficacy analysis was performed based 
on the intention-to-treat population. 
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Pearson coefficients were used to analyze the correlation between changes in HDL-C 
and/or ApoA-I levels and the following variables: PON1 activity, serum nitric oxide 
metabolites levels and IgG aHDL and aApoA-I antibodies. 
Sample size was calculated with SD for change in log-transformed PON1 activity values 
of 0.34 from a previous study. With a power of 80% , it was estimated that a total of 30 
patients needed to be randomized. 
Thus, assuming a 15% dropout rate, a minimum of 36 subjects were planned to be 
randomized. 
Quantitative variables were described using mean, SD, median, range and 95% 
confidence interval when applicable. Qualitative variables were summarized by number of 
observations (n) and percentages (%). All statistical tests were two-tailed with a significance 
level of 5%. 
Statistical analysis was performed using SPSS (Version 21.0) software package. 
Safety assessments included recording of treatment-emergent adverse events (adverse 
events that started or worsened during randomized treatment), hematologic and clinical 
chemistry measurements (performed in the same central laboratory), and physical 
examinations. All patients who received any study drug were included in the safety analysis, 
and safety data were summarized descriptively without statistical analysis. 
5.1.4 Results 
Study population and baseline characteristics 
A total of 21 patients were enrolled as the study was interrupted earlier due to a lack of 
efficacy. Of the 21 patients enrolled and randomized, 4 patients discontinued treatment due 
to the occurrence of adverse events (2 from Niaspan group and 2 from the placebo group). 
Since these 4 patients left the study before the occurrence of cross-over, only 17 patients 
completed and were taken into account for the efficacy analysis. 
The baseline characteristics are summarized in Table 14 and were similar in both groups. 
There were 44% and 50% of patients, respectively in group placebo and Niaspan who had a 
prior history of hypertension. The baseline lipid profile was comparable amongst the groups. 
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Table 14. Baseline demographic characteristics and clinical and serological data of two groups 
 
Placebo  
 (n = 9)  
Niaspan 
 (n = 8)  
p 
Age (years)  49 ± 13  47 ± 11  0.57 
Sex: female/male (n)  4 / 7  3 / 7  1.00 
Ethnic origin: black/caucasian (n) 1 / 8  1 / 7 1.00 
Weight (Kg) 78.2 ± 13.8 87.9 ± 17.5 0.22 
Height (m) 1.69 ± 0.09 1.77 ± 0.11 0.12 
BMI (Kg/m
2
) 29.6 ± 4.6 28.6 ± 4.0 0.64 
SBP (mmHg) 124.1 ± 17.1 133.5 ± 17.2 0.27 
DBP (mmHg) 76.4 ± 12.9 79.8 ± 7.5 0.52 
Medical History, N (%)    
Hypertension 4(44) 4 (50) 1.00 
Cerebrovascular disease 0(0) 1 (12) 0.47 
Others 5(56) 7(87) 0.29 
Lipid profile (mg/dL)    
LDL-C  132.5 ± 31.2 141.5 ± 25.4 0.43 
Total cholesterol  199.8 ± 27.6 206.2 ± 28.6 0.51 
TG 127.5 ± 52.7 151.9 ± 67.9 0.25 
VLDL-C 25.5 ± 10.5 30.5 ± 13.6 0.23 
HDL-C 35.3 ± 7.7 34.3 ± 4.6 0.63 
HDL2 7.4 ± 3.0 6.4 ± 1.7 0.23 
HDL3 27.9 ± 5.2 27.9 ± 3.7 0.98 
ApoA-I 135.9 ± 18.2 133.7 ± 11.6 0.69 
Biological variables    
PON1 activity (U/L) 333.1 ± 101.8 331.3 ± 97.9 0.70 
NO2
- 
+ NO3
-
 (M) 58.9 ± 37.0 55.8 ± 38.8 0.82 
IgG aHDL (% p. control) 126.7 ± 67.2 128.3 ± 102.1 0.44 
IgG aApoA-I (µg/mL) 0.37 ± 0.14 0.34 ± 0.10 0.55 
Abbreviations: Body mass index (BMI); systolic blood pressure (SBP), diastolic blood pressure (DBP), Low 
density lipoprotein-cholesterol (LDL-C); Triglycerides (TG); Very low density lipoprotein-cholesterol (VLDL-C); 
High density lipoprotein-cholesterol (HDL-C); Apolipoprotein A-I (ApoA-I); Paraoxonase 1 (PON1); nitric oxide 
metabolites (NO2
- 
+ NO3
-
); anti-HDL antibodies (aHDL) and anti-ApoA-I antibodies (aApoA-I). Data were 
presented as mean ± SD. Differences between means were evaluated using Mann-Whitney t-test. 
Flushing was reported as moderate/mild by 3 (37.5%) subjects in the extended-release 
niacin group and 1 (11.1%) in the placebo group, but none stopped the medication. Others 
adverse events include epigastric pain, dry mouth and headache also occurred at similar 
rates in both groups. 
No significant differences were observed in the safety hematologic and clinical 
chemistry parameters assessed (transaminase, total bilirubin, creatinine, creatine kinase, 
electrolytes and uric acid) between the two study groups. 
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Effect of Niaspan on lipid profile 
Patients treated with extended-release niacin showed a decrease of VLDL-C (p = 0.04), 
TG (p = 0.04) and increase of HDL2 (p = 0.04) levels when compared to placebo at the end of 
treatment (Figure 49 A and B). 
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Figure 49. Effect of treatments on lipid profile. Percentage of change from baseline on low density 
lipoprotein-cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDL-C), total cholesterol (TC) and 
triglycerides (TG) levels at the end of 12 weeks of treatment (A). Percentage of change from baseline on total 
high density lipoprotein-cholesterol (HDL-C), HDL2, HDL3 and apolipoprotein A-I (ApoA-I) levels at the end of 
treatment (B) Bars show the means. Black bars represents placebo group and white bars the Niaspan group. 
Differences between means were evaluated using Mann-Whitney t-test 
Although LDL-C, total cholesterol, HDL-C and HDL3 levels did not differ between 
treatment groups in a statistically significant fashion, the levels of LDL-C, total cholesterol 
decrease and HDL-C and HDL3 increase when compared to placebo at the end of treatment  
Moreover, the levels of total HDL-C and HDL3 subclass were positively associated with 
ApoA-I levels in both groups of study both at baseline and at the end of treatment (r = 0.73, 
p = 0.001 and r = 0.74, p = 0.0009, respectively). The HDL2 subclasses also showed a positive 
association with ApoA-I levels but only in placebo group at baseline and in extended -release 
niacin group at the end of treatment (r = 0.72, p = 0.001 and r = 0.65, p = 0.005, 
respectively). 
Effect of Niaspan on PON1 activity 
PON1 activity of both groups was comparable at the baseline and no significant effect 
on PON1 activity was observed after extended-release niacin treatment in comparison to 
placebo (Figure 50). 
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Figure 50. Paraoxonase 1 (PON1) activity acording treatment groups at baseline and at end of 12 weeks of 
treatment. Bars show the means ± SD. Black bars represents placebo group and white bars the Niaspan group. 
No association was found between PON1 activity and the levels of total HDL-C, HDL2, 
HDL3 subclasses and ApoA-I in both groups at baseline or at the end of treatment. 
Effect of Niaspan® on nitric oxide metabolites 
No significant difference were observed on total nitric oxide metabolites (NO2
- + NO3
-) 
levels between both treatments at the end of study (Figure 51), nor between mean NO2
- and 
NO3
- levels. 
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Figure 51. Serum nitric oxide metabolites (NO2
-
 + NO3
-
) acording treatment groups at baseline and at the 
end of 12 weeks of treatment. Bars show the means ± SD. Black bars represents placebo group and white bars 
the Niaspan group. 
Effect of Niaspan® on titres of IgG aHDL and aApoA-I antibodies 
Baseline IgG aHDL and aApoA-I antibodies titres were non-significantly different in the 
two groups of study. The level of IgG aApoA-I antibody increased 73% after 12 weeks of 
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treatment with extended-release niacin in comparison with placebo (p = 0.001) (Figure 52). 
There was no significant variation regarding IgG aHDL antibodies in either groups. 
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Figure 52. Levels of IgG aHDL (A) and IgG aApoA-I (B) antibodies in both groups of study at baseline and at 
the end of 12 weeks of treatment. Bars show the means ± SD. Black bars represents placebo group and white 
bars the Niaspan group. Differences between means were evaluated using an Mann-Whitney t test. 
***p=0.009 represents the statistical comparison between Niaspan and placebo group at the end of 12 
weeks of treatment. 
Although titres of IgG aHDL antibodies did not differ between treatment groups, there 
was a positive correlation between IgG aHDL and aApoA-I antibodies after 12 weeks of 
treatment with extended-release niacin (p = 0.03) (Figure 53 A). A positive correlation was 
observed between HDL2 and IgG aApoA-I antibodies (p = 0.03) after the 12 weeks of 
treatment with extended-release niacin, that was not observed at baseline, neither in the 
placebo group (Figure 53 B). 
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Figure 53. Correlation (Spearman’s rank test) between IgG aApoA-I and IgG HDL antibodies (A) and HDL2 
levels (B) at the end of treatment in subject taking extended-release niacin. 
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Despite the fact that treatment did not alter PON1 activity a negative correlation was 
observed between PON1 activity and IgG aApoA-I antibody titres at baseline and at the end 
of treatment, in the group of subjects taking extended-release niacin (p = 0.02 and p = 0.01, 
respectively) (Figure 54). 
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Figure 54. Correlation (Spearman’s rank test) between IgGaApoA-I antibodies and PON1 activity at 
baseline (A) and at the end of 12 weeks of treatment (B) in subject taking extended-release niacin. 
5.1.5 Discussion 
In this study levels of VLDL-C, TG decreases and HDL2 subclasses increased after 
treatment with extend release niacin when compared to placebo, however PON1 activity did 
not significantly increased. The main findings of this study was the enhancement of IgG 
aApoA-I antibodies at the end of 12 weeks of treatment with extend release niacin when 
compared with the placebo group. This results suggest that despite the concentration of 
HDL2 increase its protective capacity or functionality does not increase with extend release 
niacin, rather these increases resulted in a enhancement of the production of auto-
antibodies against HDL components. 
Previous studies suggest that bedtime niacin administration diminishes lipolysis and 
release of free fatty acids to the liver; this, in turn, leads to an abolition of the usual diurnal 
increase in plasma TG, which may result in diminished formation and secretion of TG in the 
VLDL fraction.417,418 It has been proposed that alterations in VLDL-C production by the liver 
limits plasma CETP activity which exchanges TGs in VLDL and LDL particles for cholesteryl 
esters in HDL particles, thus a reduction in free fatty acids could explain, at least in some 
part, the effects of niacin on VLDL-C, HDL-C and LDL-C. This study confirms the effect of 
extended-release niacin in reducing the TG, VLDL-C levels and increasing HDL2 subclasses. 
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Although treatment with extended-release niacin did not changed LDL-C, total cholesterol, 
HDL-C and HDL3 levels in a statistically significant fashion, the levels of LDL-C, total 
cholesterol decrease and HDL-C and HDL3 increase when compared to placebo. Moreover 
treatment with extended-release niacin did not change the ApoA-I levels as previously 
descried.422,424 
The lipid-modifying efficacy of niacin requires a minimum dose of 1000 mg/day, with the 
greatest lipid efficacy seen at the 2000 mg/day dose. Progressive increase in the dose of 
Niaspan tablets by 500 mg/day at monthly intervals produced incremental reductions in 
LDL-C and ApoB levels each of approximately 5%, together with incremental increases in 
HDL-C of approximately 5% over the dose range of 500 mg to 2000 mg/day.658 
In the present study the extend release niacin dose was escalated to 1500 mg/day in all 
patients that completed the study. The effect of the doses of 1500 mg, 1000 mg and 
500 mg/day of extend release niacin, when analyzed separately showed that total HDL-C, 
HDL2, HDL3 and ApoA-I elevation were more marked in the lower dose group. Thus, the 
effect on total HDL-C, HDL2, HDL3 or ApoA-I by extend release niacin was found not to be 
dose dependent, in this study. 
A recent study comparing the effect of niacin and ezetimebe on serum paraoxonase and 
arylesterase activity showed a significant reduction in both PON activities with ezetimide, 
but no change was observed in PON or arylesterase activity with niacin.659 Our study had 
similar results with no significant differences on PON1 activity after treatment with 
extended-release niacin or placebo. 
Furthermore, niacin also improves endothelial dysfunction, measured by flow-mediated 
dilation (FMD) of the brachial artery and nitroglycerin-mediated endothelium-independent 
dilation (NMD), in patients with CAD and low HDL-C, but not with normal HDL-C.432 In 
addition, extended-release niacin therapy improved the capacity of HDL to stimulate 
endothelial NO•, to reduce superoxide production, and to promote endothelial progenitor 
cell–mediated endothelial repair in patients with type 2 diabetes.431 The present study did 
not show an increase in NO• production with niacin-treatment. 
The effect of lipid modifying agents on antibodies toward HDL and its constituents had 
never been study. Interestingly, titres of IgG aApoA-I antibodies were significantly higher 
after 12 weeks of treatment with extended-release niacin in comparison with placebo. 
Although titres of IgG aHDL antibodies were not increased, they were positively associated 
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with IgG aApoA-I antibodies. Furthermore, HDL2 was positively associated with IgG aApoA-I 
antibodies and PON1 activity was negatively associated on the group treated with extended-
release niacin. 
All together this data suggest that extended-release niacin may increase the levels of 
HDL2 subclasses but it did not improve the functionality of HDL. In fact, by increasing titers 
of IgG aApoA-I antibodies niacin may be is to increase the dysfunctionality HDL. 
Nonetheless, there are several limitations to this study. First of all, this study had a small 
number of patients, the wash-out period of 4 weeks may not have been sufficient for the 
crossover of the treatments and the duration of treatment of 12 weeks may not have been 
sufficient. Finally, patients included in this study did not have an elevated cardiovascular risk, 
with exception of low HDL-C levels, but normal ApoA-I levels. 
Niacin is the most effective medication in current clinical use for increasing HDL-C, 
however if this increase is translated in a increase of HDL function is not clear. This study 
suggests that the anti-oxidant properties of HDL are not induced by extend release niacin. 
Due to the already referred study limitations, these results should be viewed as hypothesis-
generating and will require replication in other study. 
 
5.2 Prevention of atherosclerosis with atorvastatin in patients with 
systemic lupus erythematosus (SLE): a pilot study 
5.2.1 Introduction 
CVD accounts for a significant morbidity and mortality in patients with SLE594, with a 
frequency of 6.1 to 8.9 (varies with age) fold higher than in the normal population, even 
after correction for the traditional Framingham risk factors.660 Age at first MI occurs almost 
20 years earlier than in the general population.661 
An association of atherosclerosis with disease-specific factors, such as prolonged steroid 
treatment, chronic inflammation and renal disease has been demonstrated in this 
population,595-597 together with an atherogenic lipid profile, characterized by elevated levels 
of VLDL, TG and lower levels of HDL.598 
Statins have been used extensively in clinical practice to reduce cardiovascular-related 
morbidity and mortality. This effect is partly mediated through beneficial effects on the lipid 
profile, in particularly lowering LDL-C, but accumulated evidences suggested that statins 
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exert immunomodulatory and anti-inflammatory actions independently of their lipid-
lowering effects.662,663 These pleiotropic immunomodulatory properties of statins indicate 
that theses might have a therapeutic effect on autoimmunity and atherosclerosis, acting in 
these was on both factors for CVD in patients with SLE. Unfortunately, very few 
observational and interventional trials have evaluated the effect of statins in SLE, which 
makes routine statin therapy inappropriate in these patients 
5.2.2 Aim 
This study aimed at determining the effect of one year placebo controlled pilot trial with 
atorvastatin in some pro-atherogenic oxidant and inflammatory markers, as well as in the 
titres of antibodies towards HDL complex on SLE patients. 
5.2.3 Patients and methods 
Patients and study design 
The study was designed as a pilot, randomised, double blind and placebo controlled. SLE 
patients were stratified by age (age <40 or >40 years) and randomised by computer 
generated numbers in a 1:1 ratio to receive 40 mg of oral atorvastatin daily or placebo. 
Between September 2006 and November 2008, consecutive SLE patients from the Leeds 
Connective Tissue Disease Clinic, who fulfilled the inclusion and exclusion criteria, were 
invited to participate in the study. 
Inclusion criteria were 4 or more the ACR revised criteria587,588 for the classification of 
SLE, being 18 years of age, able to understand and provide informed consent and willingness 
to switch to atorvastatin if already on a different statin, unless contraindicated. 
Exclusion criteria were inability or unwillingness to give informed consent, acute or 
chronic infections, uncontrolled heart failure, uncontrolled endocrine disease, uncontrolled 
hypertension, mal-absorption, acute liver disease, heavy alcohol intake, pregnancy or risk of 
pregnancy (not using appropriate contraception or planning pregnancy over the study 
period), breast feeding and previous statin intolerance. 
The relevant hospital committee granted ethical approval (reference MREC 04/012). 
Patients were seen at baseline and then every 3 months for one year. At baseline case notes 
were reviewed with regards to traditional CVD risk factors, past and current medication, 
history of vascular occlusions (ischemic heart disease with or without MI, IS, peripheral 
vascular disease). At each visit, including baseline, patients underwent a physical 
Results 
 
146 
 
examination and had their weight and blood pressure checked and women had a pregnancy 
test. At each visit routine blood samples were taken for full blood count, clotting screen 
including lupus anticoagulant, renal and liver function tests, lipid profile (TG, total 
cholesterol, LDL-C and HDL-C), IgG aCL. In addition research blood samples were taken in 
baseline and after one year of treatment for, -hsCRP, SAA, oxLDL 2GP1, nitric oxide 
metabolites (NO2
- + NO3
-), plasma 3-NT, TAC, PON1 activity and IgG aHDL and aApoAI 
antibodies. 
Forty four patients were enrolled in the study. Of these 7 were already on a different 
statin and were switched to atorvastatin; therefore 37 SLE patients were randomized, 20 in 
the placebo arm and 17 in the atorvastatin arm. After randomisation 7 patients from the 
placebo arm and 7 from the atorvastatin arm dropped out or simply ceased attending. Final 
pre and post data were available for 17 patients in the atorvastatin arm, of whom 12 were 
statin naïve and 5 were statin pre-treated (simvastatin n=4, pravastatin n=1; switched to 
atorvastatin at study entry) and for 13 patients in the placebo arm. 
Biochemical parameters 
Serum IgG aHDL and aApoA-I antibodies titers were measured by ELISAs and plasma 
levels of 3-NT, hs-CRP and SAA, oxLDL2GPI complex and serum PON1 activity, TAC and 
nitric oxide metabolites (NO2
- + NO3
-) levels were quantified as described in methods. 
Statistical analysis 
For categorical variables, Chi-squared test or Fisher’s exact test were used. Univariate 
comparisons between baseline and one year of atorvastatin treatment for continuous variables 
was carried out by Mann-Whitney t-test paired. Statistical analysis was performed using the 
GraphPad Prism software, version 5 (GraphPad Software Inc., San Diego, USA). 
5.2.4 Results 
Characteristics of the study subjects 
Baseline demographic and clinical characteristics of the placebo and atorvastatin groups 
were matched (Table 15). 
Regarding the biological variables measured all of them were comparable among the 
groups at baseline. 
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Table 15. Demographic characteristics, clinical and laboratory data of patients with systemic lupus 
erythematosus (SLE) randomized to placebo and atorvastatin group. 
 
Placebo 
 (n = 13) 
Atorvastatin 
 (n = 17) 
p 
Age (years) 48 ± 10 55 ± 10 0.08 
Sex: female/male (n) 13/0 17/0 1.00 
Ethnic origin: 
black/caucasian (n) 
3 / 11  0 / 17  
0.07 
Disease duration (years) 15 ± 11 9 ± 8 0.10 
BMI (Kg/m
2
) 26.4 ± 4.0 26.5 ± 5.4 0.93 
SBP (mmHg) 128.0 ± 21.2 125.0 ± 14.4 0.65 
DBP mmHg) 79.0 ± 3.5 82.5 ± 24.8 0.62 
Medical History N (%)    
Hypertension 8 (61.5) 11 (64.7) 1.00 
Type 2 diabetes 0 1 (5.9) 1.00 
Dyslipidemia 3 (23.1) 6 (35.2) 0.69 
Medication N (%)    
Prednisolone 7 (53.8) 11 (64.7) 0.71 
Hydroxycloroquine 7 (53.8) 8 (47.0) 1.00 
Methotrexate 2 (15.4) 3 (17.6) 1.00 
Anti-hypertensive agents 7 (53.8) 9 (52.9) 1.00 
Warfarin 1 (7.7) 4 (23.5) 0.35 
Aspirin 8 (61.5) 4 (23.5) 0.06 
Laboratory features N (%)    
Ig aCL  20GPL 3 (23.1) 1 (5.9) 0.29 
Lupus anticoagulant 2 (15.4) 1 (5.9) 0.56 
Abbreviations: Body mass index (BMI), systolic blood pressure (SBP); diastolic blood pressure (DBP); 
anticardiolipin (aCL); Data were presented as mean ± SD. 
Changes in measured biological variables over 12 months 
After one year of therapy with atorvastatin patients with SLE showed a significant 
decreases in total cholesterol (-22%), LDL-C (-37%), hs-CRP (-75 %) and oxLDL 2GP1 (-18 %) 
levels, in comparison with the placebo group (Table 16). 
No differenced were observed in SAA levels between atorvastatin and placebo group. 3-
NT levels significantly increased in placebo group (+82%) in comparison with atorvastatin 
group. 
Non-significant increases were observed in HDL-C (+0.3%), TAC (+6%) and PON1 activity 
(-6%) even decreased after on year of treatment with atorvastatin. 
No statistical significant differences in the IgG aHDL and aApoA-I antibodies titres were 
observed after on year treatment in comparison with placebo, nevertheless the increase of 
the IgG aApoA-I antibodies in placebo group when compared with baseline was higher than 
in atorvastatin group. 
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Table 16. Biological variables mesuared of patients with systemic lupus erythematosus (SLE) randomized 
to placebo and atorvastatin group. 
 Placebo (n=14) Atorvastatin (n=17) p 
 
Baseline After 1 year % Baseline 
After 
1 year 
% 
 
Total cholesterol 
(mg/dL) 
186.9±66.5 212.7±39.4 +14 174.5± 3.2±0.6 -22 0.0008 
LDL-C (mg/dL)) 96.4±48.9 122.3±20.5 +27 96.4±37.7 60.7±23.12 -37 <0.0001 
HDL-C (mg/dL) 67.5±17.5 69.8±17.7 +3 56.9±26.5 57.1±19.9 +0.3 0.412 
TG (mg/dL) 100.8±59.9 103.3±42.0 -3 103.3±42.0 93.2±47.4 -10 0.419 
hs-CRP (µg/mL) 3.1±2.8 2.8±1.9 -9. 5.1±7.4 1.4±1.0 -75 0.001 
SAA (µg/mL) 19.7±6.7 3.5±2.4 -82 19.5±10.0 4.7±4.3 -76 0.417 
oxLDL2GPI (units/mL) 2.7±0.6 3.1±0.6 +14 2.6±0.6 2.1±0.7 -18 0.003 
NO3
-
 (µM) 32.5±24.5 28.0±18.1 -14 23.9±14.8 21.3±13.9 -16 0.778 
NO2
-
 (µM) 8.9±4.6 9.3±4.8 +5 11.7±5.9 10.9±4.1 -6 0.675 
3-NT (nM) 3.5±8.0 6.6±2.0 +82 4.1±1.9 6.5±4.3 +15 0.005 
TAC – Vit E analogue 
equivalent units (mM) 
9.0±2.0 9.5±1.9 +6 9.1±2.1 9.7±1.7 +6 0.769 
PON1 activity (U/L) 194.2±57.1 186.9±51.8 -4 203.9±45.4 192.8±45.5 -6 0.900 
IgG aHDL antibodies 
(%p. control) 
154.2±80.3 141.0±72.8 -8 110.4±35.8 100.9±51.2 -8 0.933 
IgG aApoA-I 
antibodies (µg/mL) 
1.0±0.3 2.1±1.6 +102 1.6±1.3 2.0±1.6 +23 0.072 
Abbreviations: %: percentage difference; TG: triglycerides; Low density lipoprotein-cholesterol (LDL-C); 
High density lipoprotein-cholesterol (HDL-C); hs-CRP: high sensitive C-reactive protein; SAA: serum amyloid A; 
oxLDL2GPI: oxidised low density lipoprotein-beta 2 glycoprotein-I complex; NO3
-
: nitrate; NO2
-
: nitrite; 3-NT: 
3-nitrotyrosine; TAC: total antioxidant capacity; PON1: paraoxonase 1; anti-HDL antibodies (aHDL) and anti-
ApoA-I (aApoA-I) antibodies. Data are presented as mean ± SD. Differences between % were evaluated using 
an Mann-Whitney t-test. 
5.2.5 Discussion 
In this study, levels of total cholesterol, LDL-C, hs-CRP and oxLDL 2GP1 in SLE patients 
were reduced after one year of atorvastatin treatment. However, no changes were observed 
in HDL-C, PON1 activity and TAC after on year of treatment with atorvastatin. 
The major effect of statins is the reduction of plasma levels of ApoB-containing 
lipoproteins, principally LDL (20-60%), with a modest raise of HDL-C levels (by 3% to 15%) 199, 
371-373. 
Atorvastatin, reduces LDL-C from 35 to 61% over the dose range of 10 to 80 mg, as well 
as total cholesterol (19 to 45%) and TG (12 to 53%).664 The effect of atorvastatin on HDL-C is 
varies between unchanged or increases of approximately 2 to 7%.665 Some studies show that 
the increase of HDL-C is inversely related to the dose of atorvastatin (in the range of 20 to 
80 mg/day), unlike any other statins.374,375 
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Similarly to previous studies, our results show that atorvastatin significantly reduces 
total cholesterol (22%), LDL-C (37%) and triglyceride (10%) levels, however there were no 
changes in HDL-C levels. 
With regards to the two inflammatory markers evaluated in this study, SAA and CRP, 
only the latter showed a significant post treatment changes. Even though the levels of SAA 
have also decreased significantly in relation to the baseline this effect cannot be attributed 
to treatment with statin because the same percentage decrease was observed in the 
placebo group. 
Patients treated with atorvastatin seems to have lesser increase of 3-NT when 
compared to the placebo group (14% vs. 82%). 
Statins seems to enhance the activity of HDL-associated enzymes as demonstrated by 
the increase in PON1 activity (5 to 14%).667-669 In the present study the PON1 activity 
decreased in both groups, probably due to the lack of change of HDL-C. 
PON1 accounts for most of the HDL protective effect against LDL oxidation hence 
against atherosclerosis itself and its activity can be reduced in SLE as showed in previously 
chapters. To counteract this mechanism, 2GPI, binds to oxLDL to form the covalent 
complex oxLDL 2GPI. This complex is elevated in patients with APS, SLE136 and chronic 
nephritis.542 Here we show that atorvastatin treatment induces a reduction of serum 
concentration of the oxLDLβ2GPI complex in keeping with its anti-atherogenic effect. 
Regarding the antibody titres atorvastatin did not have any significant effect, however 
IgG aApoA-I antibodies increased in both groups though this was more pronounced in the 
placebo group that also  had a lower baseline titre. 
 
5.3 Influence of Rosuvastatin on the oxidative modification of LDL 
in type 2 diabetes 
5.3.1 Introduction 
Premature vascular disease is a well-established complication of type 2 diabetes largely 
promoted by oxidative stress.27 There is considerable evidence that hyperglycaemia might 
result directly, or indirectly in the generation of AGEs and/or ROS via the activation of 
diacylglycerol-PKC pathway in vascular cells, and to increased glucose flux through the 
aldose reductase pathway.670 These pathways have been associated with activation of NF-κB 
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and increased release of O2
•- which play a role in glucose-mediated inflammation and 
oxidative stress.671 
Several studies have indicated that patients with type 2 diabetes tend to have more 
oxidative internal environments than those of healthy normal subjects. Therefore, these 
patients show an increased ROS generation and oxidative stress markers, such as elevated 
lipid peroxidation levels with an accompanying decrease in anti-oxidant levels.672-674 
As in other diseases associated with atherosclerotic cardiovascular complications, 
enhanced serum levels of oxLDL and oxLDL 2GP1 complexes have been reported.675,676 In 
addition, the redox imbalance becomes overwhelmed due to an impaired PON1-mediated 
HDL anti-oxidant function also observed in these patients.646,677 
Observations that statins may lower oxLDL 2GP1 complexes675 and increased PON1 
activity678 may suggest that the pleiotropic effects of this class of drugs may prevent or 
decrease the oxidative modification of LDL possibly by an antioxidant mechanism. In this 
study we intended to test this hypothesis; rosuvastatin is a hydrophilic statin with multiple 
sites that form a strong interaction with the enzyme HMG-CoA reductase and therefore 
provide more potent enzyme inhibition than other statins.679 In fact, rosuvastatin has an 
affinity for the HMG-CoA reductase active site that is 104-fold higher than that of HMG-CoA. 
In addition, rosuvastatin has an advantage compared to some other statins (like 
atorvastatin), since it is not metabolized predominantly through CYP3A4, eliminating many 
potential drug-drug interactions. Furthermore, rosuvastatin together with pitavastatin are 
the most potent compounds within this class to increase HDL-C (6-12%).199 
5.3.2 Aim 
This study aimed at determining the effect of rosuvastatin in prevent or decrease the 
oxidative modification of LDL possibly by an antioxidant mechanism mediated by PON1-HDL, 
as well as in the titres of antibodies towards HDL complex in patients with type 2 diabetes. 
5.3.3 Patients and methods 
Patients and study design 
The study was an open label 2:1 assignment of consecutive diabetes patients into a oral 
rosuvastatin (10 mg/day for six weeks) arm or an observational arm respectively. 
Consecutive type 2 diabetes patients attending the endocrinology and diabetes outpatient 
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clinic at the Hospital General de Occidente, Zapopan, Mexico from August 2007 to October 
2008 were invited take part in the study. 
The diagnosis of type 2 diabetes mellitus relied on the presence of abnormal FGP 
(normal range 70–110 mg/dL), abnormal glucose tolerance test, chronic hyperglycaemia and 
metabolic disturbances of lipid, carbohydrate and protein metabolism due to defects in 
insulin production or activity.680 
Exclusion criteria were macroalbuminuria or kidney disease, CVD (MI, angina, peripheral 
arterial disease and stroke), concomitant systemic acute or chronic inflammatory diseases 
(bacterial or viral infections), concomitant acute or chronic autoimmune disorders, 
pregnancy, statin use within 6 months of the study and intolerance to statins. 
Diabetes patients with hypertension, obesity, dyslipidemia and microalbuminuria were 
accepted within the study: hypertension was defined as a systolic blood pressure 
> 130 mmHg or diastolic blood pressure > 85 mmHg and obesity as a BMI > 27 for the 
Mexican population.681 One hundred and twenty five patients were eligible for the study. 
After the 2:1 assignment, 86 patients entered the rosuvastatin arm and 39 the observational 
arm. In the rosuvastatin group 10 patients did not complete the study (4 discontinued 
intervention for minor side effects and 6 did not attend follow-up) and in the observational 
group 4 did not attend follow-up. The final study included 111 patients of whom 76 
completed 6 weeks’ treatment with 10 mg daily of oral rosuvastatin and 35 did not receive 
rosuvastatin and were reviewed at the end of the same time span. 
Patients on rosuvastatin were instructed not to modify other regular medications 
throughout the study. Counselling with a dietician was available to all patients throughout 
the study. 
Physicians involved in the care of the patients were not involved in data analysis and 
interpretation. The study (#141/07) was approved by the ethics committee of the Hospital 
General de Occidente, Zapopan (Mexico), performed in accordance with the Declaration of 
Helsinki and all patients signed informed consent before entering the study. 
Fasting blood samples were obtained from all participants at study entry (baseline 
sample) and from all patients who completed the 6 weeks interventional and observational 
arms. Sera for routine chemistry, lipid profile, oxLDL β2GPI complexes, nitric oxide 
metabolites (NO2
- + NO3
-), 3-NT, ADMA levels, PON1 activity, IgG aHDL and aApoA-I 
antibodies were stored frozen at -70ºC until tested at the end of the study. Routine 
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chemistry and lipid profile investigation were performed at the Hospital General de 
Occidente clinical laboratory in Mexico with standard laboratory methods (Wiener 
Laboratories, Rosario, Argentina). The measurement of HbA1C was determined by the 
NycoCard HbA1C (Axis-Shield PoC AS, Oslo, Norway) (reference range 4.5–6.3%). All other 
parameters were quantified at the Pharmacology Laboratory of Faculty of Medical Sciences 
of Lisbon. 
Biochemical parameters 
Serum IgG aHDL, aApoA-I antibodies titers, 3-NT, oxLDL β2GPI complexes and ADMA 
levels were measured by ELISAs, and serum PON1 activity and nitric oxide metabolites (NO2
- 
and NO3
-) levels were tested as described in methods. 
Statistical analysis 
For categorical variables, Chi-squared test or Fisher’s exact test were used; for 
continuous variables and to analyse the effect of rosuvastatin treatment on study variables, 
paired t-test and Wilcoxon Signed Rank Sum test (when applicable) were used. Statistical 
analysis was performed using the GraphPad Prism software, version 5 (GraphPad Software 
Inc., San Diego, USA). 
5.3.4 Results 
Characteristics of the study subjects 
Demographics, baseline clinical characteristics and serological data of rosuvastatin and 
observational arms were shown in Table 17. Both groups were matched on demographic and 
baseline clinical characteristics. Regarding the serological data all of them were comparable, 
with exception of total cholesterol and LDL-C levels that were higher on the observational 
arm. 
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Table 17. Demographic characteristics, clinical and serological data of patients with type 2 diabetes 
randomized to receive or not rosuvastatin. 
 Type 2 diabetes patients  
 
Without Rosuvastatin 
 (n = 35) 
With rosuvastatin 
 (n = 76) 
p 
Age (years) 56 ± 7 54 ± 12 0.620 
Sex: female/male (n) 27/8 53/23 0.499 
Disease duration (years) 7.6 ± 6.1 7.9 ± 7.0 0.972 
Medical History N (%)    
Hypertension (%) 5 (14.2) 18 (23.7) 0.319 
Obesity (%) 22 (62.8) 33 (43.4) 0.237 
Medication N (%)    
Oral glucose lowering drugs 30 (85.7) 61 (80.2) 0.600 
Insulin 5 (14.3) 13 (17.1) 0.788 
Anti-hypertensive agents 6 (17.1) 7 (9.2)) 0.339 
Serological data    
FGP (mg/dL)  137.1 ± 67.9 160.2 ± 82.8 0.253 
HbA1c (%)  7.5 ± 1.9 7.6 ± 2.8 0.927 
CRP (mg/L)  2.8 ± 0.3 2.5 ± 0.3 0.191 
Total cholesterol (mg/dL)  224.5 ± 22.6 199.5 ± 36.1 0.0002 
TG (mg/dL) 227.7 ± 120.3 222.2 ± 125.5 0.529 
LDL-C (mg/dL) 141.4 ± 26.7 120.1 ± 31.9 0.001 
HDL-C (mg/dL) 45.5 ± 9.3 46.1 ± 9.7 0.717 
Abbreviations: Fasting plasma glucose (FPG); Glycosylated hemoglobin (HbA1c); C-reactive proten (CRP) 
Triglycerides (TG). Data are presented as mean ± SD. Differences between means were evaluated using an 
Mann-Whitney t-test paired. 
Effect of six weeks treatment with rosuvastatin 
After six weeks of therapy with rosuvastatin, patients with type 2 diabetes showed a 
significant decreases in total cholesterol (-25%), TG (-27%) and LDL-C (-37%) in comparison 
with the observational group (Table 18). 
Table 18. Effect of six weeks treatment with rosuvastatin in serological data of patients with type 2 
diabetes 
 Without rosuvastatin 
 (n = 35) 
With rosuvastatin 
 (n = 76) 
 
 After 6 weeks % After 6 weeks % P 
FGP (mg/dL) 147.5 ± 71.4 +5 154.6 ± 76.0 -3 0.415 
HbA1c (%) 7.3 ± 2.0 -3 7.6 ± 2.1 +0.6 0.336 
CRP (mg/L) 2.9 ± 0.3 +5 2.4 ± 0.3 -4 0.502 
Total cholesterol (mg/dL) 212.2 ± 20.4 -6 150.2 ± 34.6 -25 <0.0001 
TG (mg/dL) 210.0 ± 100.2 -8 161.6 ± 78.1 -27 0.021 
LDL-C (mg/dL) 126.1. ± 25.3 -12 76.2 ± 34.7 -37 <0.0001 
HDL-C (mg/dL) 45.2 ± 9.7 +0.5 45.3 ± 8.7 -1.6 0.726 
Abbreviations: %: percentage difference; Fasting plasma glucose (FPG); Glycosylated hemoglobin 
(HbA1c); C-reactive proten (CRP) Triglycerides (TG). Data are presented as mean ± SD. Differences between % 
were evaluated using an Mann-Whitney t-test paired. 
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The rosuvastatin arm showed significant decrements in IgG aApoA-I antibodies (-5.%), 
NO3
- (-33.5%) and NO2
- (-25.5%) levels in comparison with the observational group. 
Nevertheless the decrease of oxLDL β2GPI complexes and 3-NT levels were more 
marked on patients treated with rosuvastatin it was not statistical significant in comparison 
with observation arm. No changes were noted in the others biological variables analyzed 
(Table 19). 
Table 19. Biological variables mesuared after treatment with or without rosuvastatin on patients with 
type 2 diabetes. 
 Without rosuvastatin 
 (n = 35) 
With rosuvastatin 
 (n = 76) 
 
 Baseline 
After 6 
weeks 
% Baseline 
After 6 
weeks 
% P 
oxLDL2GPI 
(units/mL) 
0.83±0.6 0.76±0.8 -8.3 0.79±0.5 0.53±0.3 -32.6 0.248 
PON1 activity (U/L) 205.1±70.6 206.5±78.7 +0.5. 176.4±71.1 176.8±76.9 +0.2 0.880 
IgG aHDL antibodies 
(%p. control) 
130.2±62.3 125.6±47.6 -3.5 132.6±51.1 124.3±43.8 -6.3 0.953 
IgG aApoA-I 
antibodies (µg/mL) 
0.91±0.4 1.3±0.8 +40.5 1.1±0.7 1.0±0.6 -5.0 0.03 
NO3
-
 (µM) 33.8±28.2 32.8±22.7 -3.1 53.7±32.2 35.7±13.9 -33.5 0.006 
NO2
-
 (µM) 20.2±12.2 20.8±14.2 +3.2 23.5±13.8 17.5±10.5 -25.5 0.043 
3-NT (nM) 8.3±10.4 8.5±9.7 +1.8 9.9±10.8 8.1±9.2 -17.9 0.142 
ADMA (µM) 0.56±0.1 0.53±0.1 -4.7 0.59±0.1 0.56±0.1 -4.6 0.422 
Abbreviations: %: percentage difference; oxLDL2GPI: oxidised low density lipoprotein-beta 2 
glycoprotein-I complex; PON1: paraoxonase 1; aHDL: anti-HDL antibodies; aApoA-I: anti-ApoA-I antibodies; 
NO3
-
: nitrate; NO2
-
: nitrite; 3-NT: 3-nitrotyrosine; ADMA: Asymmetric dimethylarginine. Data are presented as 
mean ± SD.  Differences between % were evaluated using an Mann-Whitney t-test. 
5.3.5 Discussion 
The interventional arm of this study showed that 10 mg of oral rosuvastatin daily for 6 
weeks was associated with a significant reduction of the IgG aApoA-I antibodies, nitric oxide 
metabolites levels(NO2
- and NO3
-) as well as with the expected decrease in total cholesterol, 
LDL-C and TG. 
Contrary to what has been shown in previous clinical trials we did not observe an 
increase in HDL-C levels, neither PON1 activity was enhanced by rosuvastatin treatment and 
therefore could not have contributed its specific antioxidant capacity towards the decrease 
of oxLDLβ2GPI; likewise CRP did not show a significant decrease after treatment and 
therefore an anti-inflammatory effect of rosuvastatin seemed less likely. 
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On the other hand a significant decrease of nitric oxide metabolites (NO2
- and NO3
-) may 
represent a beneficial effect of rosuvastatin as it indirectly indicates a reduction in reactive 
nitrogen species contributing to LDL oxidation. 
In the course of inflammation endothelial and mononuclear cells generate more O2
•- as 
well as more NO• that behaves as a pathogenic mediator or as a cytotoxic molecule.625 Most 
of NO• mediated pathogenicity depends on the formation of secondary intermediates such 
as ONOO– and •NO2 that are more reactive and toxic than NO• per se. In fact ONOO
– 
interacts with CO2 to give ONOOCO2
– that will induce nitration of tyrosine residues in 
proteins.623 Measurement of nitrated proteins therefore represents a fingerprint of the 
interaction of O2
•- with NO•.626 Although rosuvastatin appears to reduce the levels of 3-NT, 
this reduction was not statistically significant in comparison with the observational arm 
possibly due to the fact that treatment with rosuvastatin for six weeks was not enough. 
Protein and lipid modifications may increase the immunogenicity of intracellular 
antigens by generations of neo-epitopes, leading to a break in immune tolerance626 This may 
be the cause for the production of antibodies toward HDL complex. Another reason may 
simply be due to an increase in antigen level. Although HDL-C levels did not increased with 
rosuvastatin treatment, it improved the redox imbalance characteristic of these patients, 
which may have contributed the decrease in antibody titres towards ApoA-I, in contrast to 
raise of 40.5% in the observational arm. 
An apparent limitation of this study may have been the exclusion of type 2 diabetes 
patients with cardiovascular, cerebrovascular and peripheral vascular disease and patients 
with abnormal kidney function and macroalbuminuria, thus our population may have a low 
degree of vascular inflammation and therefore marginal or no changes in the markers of 
inflammation (CRP, ADMA and NT). Another limitation of this study could have been the 
short period of treatment and the dosage of rosuvastatin that may have limited the effects 
on HDL. 
Our study could not pointedly show that rosuvastatin prevent the oxidative modification 
of LDL, notably by reducing the oxLDL β2GPI complex concentration and possibly by an 
antioxidant mechanism mediated by PON1-HDL. Nevertheless, the reduction of the oxidative 
internal environments by rosuvastatin may have limited the increase of antibodies toward 
HDL complex demonstrating the benefit of treatment with rosuvastatin. 
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A possible humoral response towards HDL has been put forward with this thesis. We 
first tested this hypothesis in patients with autoimmune disease such SLE, using this disease 
as a clinical model, due to its enhanced atherogenesis and increased immune (including 
humoral) activity. We were able to show the presence of both IgG aHDL and aApoA-I 
antibodies in these patients and showed an association with decreased PON1 activity and 
TAC, increased biomarkers of endothelial dysfunction (NO• metabolites, adhesion 
molecules: VCAM-1 and ICAM-1) and an increase in disease-related damage and activity. 
Another group has recently confirmed this work and its importance has now been 
recognised, with the recent suggestion by the American College of Rheumatology that aHDL 
antibodies could be a new biomarker for vascular disease in the context of systemic 
autoimmune condictions.682 
The recognition that the overall background mechanism could be the same outside the 
spectrum of autoimmune diseases, led us to test whether patients with atherosclerosis-
related clinic events such as CAD, IS and type 2 diabetes, would also have these antibodies. 
Indeed, we found increased titres of IgG aHDL, aApoA-I and aPON1 antibodies in these 
patients. Moreover, the presence of these antibodies was again associated with a pro-
inflammatory and pro-oxidant profile: higher NO•metabolites, VCAM-1, ICAM-1, 3-NT and 
lower PON1 activity. 
Our results suggest that aHDL antibodies were associated with modifications in some 
known anti-oxidant and anti-inflammatory HDL-related functions. However, these findings 
were cross-sectional clinical studies, which cannot explain whether the antibodies were 
causal to the clinical events or whether they were merely an epiphenomenon. 
With the overall goal to demonstrate the biologic activity and consequent pathogenic 
capacity of the antibodies towards the HDL complex we set up a protocol for the antibody 
isolation from serum of different patients. 
These antibodies inhibited PON1 activity in a dose-dependent fashion. Moreover the 
anti-inflammatory effect of HDL on cytokine-induced production of VCAM-1 was abrogated 
in more than 80% by aHDL antibodies isolated from patients in an in vitro experiment. The 
aHDL antibodies also abolished the HDL-induced angiogenesis by reducing VEGF levels in 
65%. These set of experiments provide evidence for a biologic activity and consequent 
possible pathogenic potential of these antibodies. 
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To our knowledge, outside the autoimmune context, only one group has studied aApoA-
I antibodies but in a different clinical context. They showed a higher prevalence of aApoA-I 
antibodies in patients with acute coronary syndrome, which were associated with a decrease 
of ApoA-I plasmatic levels, an increase of oxLDL levels.615 They suggested that these 
antibodies increase the atherosclerotic plaque vulnerability617 and could be used as a 
prognostic marker in MI.616 Their work complemented ours but they have only addressed 
aApoA-I antibodies in a specific group of acute ischemic heart disease patients. 
Finally, we investigated the effect of current available pharmacologic agents for 
increasing HDL-C concentrations on the antibody titres in comparison with placebo in double 
blind randomized trials with extended release niacin and atorvastatin, and an open label 
study with a rosuvastatin arm and an observational arm. It should be noted that none of the 
three trials was designed for the study of a direct effect on the antibodies towards HDL 
complex titres as the primary endpoint (except for the trial with extended release niacin). 
Niacin is the most effective medication in current clinical use for increasing HDL-C, 
however it is not clear that this increase is translated into a raise of HDL functions. Our 
results suggest that the extend release niacin may increase levels of total HDL-C or HDL 
subclasses but it did not induce an enhancement of HDL anti-oxidant properties and 
improvement of endothelial dysfunction mediated by HDL. In fact, by increasing the titres of 
aApoA-I antibodies, niacin may hamper the protective effect of HDL. 
Statins only modestly raise HDL-C levels and even then there are differences between 
their potency to increase HDL-C. 
Our results do not show an increase of HDL-C levels by atorvastatin neither rosuvastatin. 
However both statins were associated with a reduction of serum oxidative modification of 
LDL notably by reducing the oxLDL β2GPI complex concentration. This antioxidant effect was 
not through a PON1-mediated mechanism. Nevertheless, the reduction of the oxidative 
internal environment by atorvastatin and rosuvastatin may have limited the increase of 
aApoA-I antibodies. Even so, our data seems to suggest that rosuvastatin may potential be 
more beneficial that atorvastatin in preventing the increase in antibody production. 
Due to the previously mentioned limitations of our trials some of these results might be 
viewed as hypothesis-generating and will require replication in others studies. 
In clinical trials as well as in the current clinical practice, quantification of total HDL-C is 
still the test of choice because its a simple determination, easily performed and affordable, 
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particularly in the context of such a common condition. Nevertheless levels of HDL-C often 
do not translate HDL functions. 
The presence of biologic active antibodies towards HDL complex might explain why 
many patients have low levels of HDL-C and why others remain at risk for clinical events, 
despite having normal lipid levels. The concept that these antibodies may contribute either 
to the long-term evolution of atherosclerotic lesions or to the triggering of a clinical event 
can also explain the heterogeneity found in individual patients and large cohorts when it 
comes to risk factors and clinical outcomes. Furthermore, recent failures in improving clinical 
outcomes using drugs that increase HDL concentration such as CETP inhibitors may be 
explained through the eventual presence of these antibodies. 
In conclusion, we have established that aHDL antibodies are a newly found family of 
auto-antibodies, directed towards different structures in the HDL complex and with the 
capability to interfere with their biologic functions. Confirmation of the high pathogenic 
potential of these antibodies may lead to the identification of a new biomarker of vascular 
disease risk, whilst presenting itself as a novel target for a different treatment approach. 
 
The “clinical phase” of this line of research allowed us to identify differences in the 
pattern of serum aHDL antibodies according to the different manifestations of patients with 
vascular disease. However these were cross-sectional studies, and we intend to create 
prospective cohorts of patients in order to confirm whether antibodies towards HDL 
components will be in fact a risk factor for atherosclerosis progression and vascular events. 
Whether some or all of the aHDL antibodies, by causing HDL dysfunction, can induce 
atheroma progression or plaque instability in such a way as to have clinical significance will 
be the final, overall aim of this project. 
From the basic research point of view, we intent to investigate what are the structural 
changes (e.g.oxidation, glycation, nitrosilation) or each identified antigen in the HDL complex 
that are responsible for this acquired humoral response. 
Furthermore, we would like to determinate the role of these antibodies in the functional 
maturation and activation of human dendritic cells and macrophages as they represent an 
important part of the immune cellular response in atherogenesis. 
As one of the main challenges in the development of new HDL raising drugs will be to 
insure that any change in HDL metabolism triggered by the new drugs also improves the 
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atheroprotective function of HDL, functional tests for HDL will be critical. The confirmation 
that aHDL antibodies cause HDL dysfunction may prove to be an indirect way of testing HDL 
functionality. 
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